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Temporary vascular access for hemodialysis treatment.
Adapted from: 
Marcel C. Weijmer
Piet M. ter Wee
Dept. of nephrology, Vrije Universiteit Medical Center, Amsterdam
Temporary vascular access for hemodialysis treatment. 
Current guidelines and future directions.  Contrib Nephrol 2004;142:94-111
1 Introduction
12 13
or graft. A third of these patients had to be hospitalized because of the infection. 
In order to prevent the most important catheter-related complications, i.e. infection 
and thrombosis, and to optimize the survival of a catheter, a number of considerations 
have to be taken into account. The duration for which a catheter will be needed is 
the most important. Considerations include decisions on the optimal site and method 
of cannulation, the type of catheter used and whether the catheter should be tunneled or 
not. In addition, the access team must determine what kind of dressing should 
be used and whether antimicrobial ointment and/or antimicrobial locking solutions 
should be applied. A thorough protocol for connecting and disconnecting blood lines 
must be available, as well as a protocol on how to treat catheter-related complications. 
Whether post procedural checks like chest X-rays, often postponing dialysis treatment, 
are really needed is questionable.
Recently the National Kidney Foundation - Dialysis Outcome Quality Initiatives 
(NKF-DOQI) Clinical Practice Guidelines for Vascular Access have been updated and 
published [3]. These guidelines can be of use when making decisions on hemodialysis 
catheter-related procedures and on care-giving protocols. However, new strategies have 
emerged that may prevent catheter-related bacteremia and dysfunction and reduce 
patient morbidity and mortality.
introduc tion
Since Dr. Wilhelm J. Kolff first introduced the artificial kidney in 1943 and started his first 
hemodialysis treatment in the Stadsziekenhuis in Kampen [1], it was clear that proper 
access to the circulation for repetitive dialysis treatment would be the Achilles’ heel 
of chronic dialysis treatment. His first patient died after 34 days of dialysis treatment 
because possibilities for access were exhausted. From this early observation on, 
it has become clear that whatever access device was chosen to obtain access to the 
bloodstream, it should have a number of qualities. The access should be easily available 
for connection to the dialysis machine at least three times a week and should provide 
adequate blood flow of 200-500 ml/min. After treatment, disconnecting should 
be possible relatively rapid. In addition, complication rates like bleeding, thrombosis and 
infection should be low and discomfort for the patient minimal. An arteriovenous fistula 
on the forearm as developed first by Brescia and Cimino in 1966 [2], embodies most 
of these features and is still considered the best option for access to the bloodstream 
for patients on chronic hemodialysis treatment. After a period of maturation of about 
6 weeks, repetitive access to the circulation can be obtained by puncturing the dilated 
veins. Unfortunately, an arteriovenous fistula is not always possible because of insufficient 
diameter or maturation of the veins. The most common alternative is the placement 
of a subcutaneous arteriovenous graft. These have the advantage that maturation is not 
needed and are available for puncturing after 2 to 4 weeks. Arteriovenous grafts have 
a substantially higher risk for thrombosis and infection than arteriovenous fistula 
and are considered second best [3]. 
However, a significant number of patients present with acute renal failure or have 
no adequate arteriovenous access available when they reach end stage renal failure 
and require hemodialysis treatment. Mostly, this is because of slow maturation of their 
fistula. Likewise, patients with failure of previously available renal replacement therapy 
such as transplantation or peritoneal dialysis often do not have a functional arteriovenous 
access. All these patients require a temporary vascular access by means of a hemodialysis 
catheter to achieve immediate access to the circulation for adequate dialysis treatment.
Hemodialysis catheters are available as untunneled catheters (UCs), used when a catheter 
is needed for only a short period of time, and as tunneled cuffed catheters (TCCs) when 
a catheter is needed for longer periods. UCs are relatively small bore (11–13 Fr) catheters 
and have no cuff adhered to the catheter. These can be inserted with relative ease 
by a bed-side procedure under local anesthesia without the formation of a subcutaneous 
tunnel and are usually intended to be used for up to 2-3 weeks. In current practice 
the use of temporary hemodialysis catheters is substantial. From the recent data 
of the Dialysis Outcomes and Practice Patterns Study (DOPPS), it is recognized 
that 15-50% of patients in Europe and 60% of patients in the US start hemodialysis 
treatment with a catheter for vascular access [4]. However, such widespread application 
of catheters exposes patients to an enhanced risk of catheter-related complications. 
Because of these complications, about 50% of all temporary catheters have to be replaced 
which results in substantial patient morbidity as well as additional consumption 
of resources, nursing and nephrologists time [5;6]. Tokars et al. [7] demonstrated 
in a prospective study including hemodialysis patients with a catheter that they had 
a relative risk for infection of 2.07 compared to patients with an arteriovenous fistula 
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c a n n u l at i o n  S i t e S
Once the duration for which a hemodialysis catheter is needed has been estimated, 
the next decision that needs to be made is which cannulation site is best. 
Generally, the femoral, subclavian or internal jugular veins are used. In patients 
with exhausted access due to thrombosed veins or infection, exotic routes 
like translumbar or transhepatic routes may be necessary [12;13]. Even long-term 
arterial cannulation has been used for dialysis [14]. Because these routes are rarely 
necessary, they will not be discussed in detail.
Femoral vein
The femoral vein is preferred when rapid access is needed because of the underlying 
condition of the patient or for logistic reasons.  Insertion is relatively easy, complications 
are rare and treatment can be started without delay. In addition, it is the preferred site 
when patients can not lie flat because of dyspnea and in case of severe coagulation 
disturbances. With modern flexible catheters, patients can even be mobilized [15]. 
According to the NKF-DOQI guidelines, there are data that recommend that untunneled 
femoral catheters should not be left in place for more than 5-7 days because 
of the high risk of infections. Oliver et al. [8] demonstrated in a study in 218 patients 
that the subset of patients with femoral catheters had a high incidence of bacteremia 
(10.7%) when the catheter was left in place for more than 1 week. 
However, occlusive dressings were applied in this study and there was no strict protocol 
for the removal of catheters in case of exit site infection.
Subclavian vein
The NKF-DOQI guidelines recommend that the subclavian vein should not be used 
in patients who need permanent vascular access because of a high risk of subclavian 
vein thrombosis. Schillinger et al. [10] compared in a prospective study the outcome 
of 50 subclavian with that of 50 jugular hemodialysis catheters and found an incidence 
of 42% subclavian stenosis compared to 10% jugular stenosis. Subclavian stenosis and 
occlusion can lead to arm edema and can hamper the development of an adequate 
arteriovenous fistula or graft in the future. This indicates that in all patients with 
chronic renal failure, vascular access through the subclavian vein should be avoided. 
Another disadvantage of subclavian vein cannulation is that it requires more skills of 
the operator and is associated with more severe insertion complications such 
as pneumothorax and hemothorax. Notwithstanding these guidelines it was shown 
in the DOPPS that in the US 46% of all temporary catheters used in patients starting 
hemodialysis treatment were inserted into the subclavian vein. Probably, the reason 
for this widespread use of subclavian catheters is the observation that they have 
a lower risk for infectious complications than untunneled jugular catheters [6]. 
Subclavian catheters are more comfortable for the patient and provide reliable blood flow 
if placed in the right atrial cavity. 
Therefore, the subclavian site should only be used if a catheter is needed in patients 
with acute renal failure when renal replacement therapy is expected to be temporary 
or when the jugular site is not available.
introduc tion
d e t e r m i n at i o n  o F  t H e  t i m e  d u r i n g  W H i c H  a  c at H e t e r  i S  n e e d e d
There are numerous clinical situations in dialysis for which acute vascular access 
is required. The specific clinical situation of the patient usually determines for how 
long a hemodialysis catheter is needed and what the chances for renal recovery are. 
These two factors determine at large the decisions on the cannulation site and 
on the type of catheter that is needed.
Acute renal failure and exchange therapy
In acute renal failure requiring immediate dialysis treatment and in case of plasma 
exchange therapy, vascular access by means of a temporary catheter is the best choice. 
Usually, a femoral catheter will be inserted because treatment can be started without 
delay, which can be essential for example in cases of life-threatening hyperkalemia. 
The cause of renal failure can be analyzed and an approximation can be made of the time 
period during which dialysis is needed. However, femoral catheters should not be left 
in place for more than 1 week because they are associated with an increased risk 
of infection and dysfunction [8]. When recovery of the renal function is unlikely and the 
need for chronic dialysis treatment is expected, the use of the subclavian vein for inserting 
a catheter should be prevented because of the high risk of central vein thrombosis [9;10]. 
This can compromise arteriovenous access in the future. 
NKF- DOQI guidelines recommend that when can be foreseen that a catheter is needed 
for more than 3 weeks, a tunneled cuffed catheter should be used. However, it has been 
recognized that this recommendation is largely opinion based.
In continuous renal replacement therapy in the intensive care unit (ICU) femoral catheters 
are frequently used.  Although there are no data on double-lumen dialysis catheters in 
the ICU patient, it has been shown that femoral catheters that are used for infusion have 
an increased risk of infection [11]. Therefore, subclavian or jugular catheters should 
probably be preferred in ICU patients. 
Chronic renal failure and failure of peritoneal dialysis treatment
Despite the fact that increasing attention is paid to the timely creation of a functional 
arteriovenous fistula or graft in the predialysis care, most commonly, a catheter 
is inserted because hemodialysis treatment is needed for end-stage renal failure resulting 
from known progressive chronic renal failure [4]. In most of these patients creation and 
maturation of a functional arteriovenous access will take at least several weeks. 
It is preferable to start with a jugular catheter that can provide adequate dialysis for 
this period. Whether this should be a tunneled catheter will be discussed in the paragraph 
on tunneled versus untunneled catheters.
The same accounts for failure of peritoneal dialysis. Removal of a peritoneal dialysis 
catheter can be necessary for persistent or relapsing peritonitis. Another common cause 
for interruption of peritoneal dialysis treatment is the failure of ultrafiltration. 
In both cases vascular access catheters often have to remain in place for months. 
In a substantial number of these patients, infection or ultrafiltration failure results 
in a definitive transition to hemodialysis.
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might explain the observation in the DOPPS that untunneled catheters are still 
widely used beyond the recommended 3 week period. In incident hemodialysis patients, 
48% of catheters in the US and 75% of catheters in Europe are untunneled. 
Even in prevalent patients over a third of all catheters are untunneled [4]. 
As was pointed out recently, there are limited data available in the literature 
comparing the outcome of untunneled and tunneled cuffed catheters [21]. 
Reported bacteremia rates vary from 3.8-6.5/1,000 catheter-days for untunneled catheters 
to 1.6-5.5 for tunneled cuffed catheters [5;6;8;22;23]. In these studies, 
catheter care protocols and the definitions of complications differ. In addition, 
because untunneled catheters and tunneled cuffed catheters are used for different 
clinical situations, the higher incidence of complications in untunneled catheters 
may be caused by differences in patient characteristics and risk factors for infection. 
All these factors contribute to the finding that the incidence of catheter-related 
complications can vary widely between the types of catheters used and between 
dialysis facilities [7]. Therefore, a comparison on the outcome of untunneled catheters
in one center with that of another center is not reliable as was recently clearly 
pointed out by Lund et al. [24].
It is not completely clear why tunneled cuffed catheters have a lower risk for infection. 
It is possible that the fixation of tunneled cuffed catheters is  better through 
the use of a subcutaneous cuff adhered to these catheters in the subcutaneous route and 
that bacterial migration from the exit-site to the venous entry site is impeded [25]. 
A recent meta-analysis has clearly demonstrated that cuffing and tunneling of catheters 
reduces the risk for catheter-related bacteremia by 44-77% [26]. However this analysis 
only included non-hemodialysis catheters.
t i p  d e S i g n  a n d  c at H e t e r  l e n g t H
Many different catheter types are available and most catheters are offered in 
multiple lengths. Both untunneled and tunneled cuffed catheters are available in silicon 
and different polymer plastics. However, limited data are available on what catheter type 
and material are best. For characterizing catheters, flow curves are often performed 
in static in vitro models with blood-like substances, not taking into account the possibility 
of coagulation and pulsatile flow. Furthermore, no model is available for the interdialytic 
period when the catheter is locked but remains in the blood stream. So far none of 
the clinical trials has shown a major difference between different catheters [27;28].
Geometry and tip design
The geometry and tip design of catheters have been determined mainly by methods 
of trial and error. Multiple side holes were thought to be necessary to secure sufficient 
inflow in case of obstruction of some side holes or when a catheter was placed close 
to the vessel wall. However, side holes can induce thrombosis because they often have 
an irregular surface [29]. Furthermore, the diameter of the holes is not adapted to actually 
required flow rates. Despite the various types of catheters available, studies on 
the influence of tip construction on fluid dynamics are scarce. 
introduc tion
Internal jugular vein
A hemodialysis catheter in the internal jugular vein is preferred for patients on chronic 
dialysis treatment. Cannulation is easy, especially when inserted with the use 
of ultrasound localization of the vein and the complication rates are low [16]. 
The right jugular site is preferred because of the straight intravascular route 
to the right atrial cavity. Left situated jugular catheters can also be used but are associated 
with more complications and shorter survival compared to right jugular catheters [17;18].
The most important problem of jugular catheters is that they are uncomfortable for 
the patient because neck and head movements are limited. This holds especially true 
for straight, high-inserted, precurved catheters (fig. 1) and jugular catheters with
a curved extension (fig. 2).
These catheters have a higher rate of infectious complications compared to subclavian 
catheters [6]. Probably, this is because adequate fixation is hampered by continuous 
movements of these catheters with movements of the head and by downward pulling 
of dialysis tubes at the extensions when connected to the hemodialysis machine. 
In addition, these catheters have an upward directed exit site which in analogy 
to peritoneal dialysis catheters might be associated with an increased risk for exit 
site infections as has been demonstrated for peritoneal dialysis catheters [19;20]. 
S H o u l d  a  c at H e t e r  b e  t u n n e l e d ?
Using the limited data available on complication rates of straight untunneled jugular 
catheters with curved extensions, the NKF-DOQI guidelines recommend that a tunneled 
cuffed catheter should be inserted when it can be anticipated that a catheter will 
be needed for more than 3 weeks [3]. Even when a catheter is needed for less 
than 3 weeks, inserting a tunneled cuffed catheter is acceptable. However, inserting 
a tunneled cuffed catheter requires prolonged procedure time and special skills 
of the physician. 
In addition, its removal is hampered by growth of subcutaneous tissue into 
the cuff adhered on these catheters. These drawbacks for the use of tunneled catheters 
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Figure 1.
Uncomfortable position and poor fixation of a 
straight jugular catheter.
Figure 2.
Uncomfortable position and poor fixation of 
an untunneled jugular catheter with curved 
extensions.
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The relevance of these findings is supported by the outcomes of two recent clinical trials. 
Oliver et al. [31] compared a 12-french tapered tip, multiple side hole catheter with 
a 13.5-french open shotgun tip catheter. They demonstrated that effective blood flow was 
higher with the shotgun tip catheter and that there was less necessity for reversal 
of the lumen polarity, a well known cause of high recirculation rates. 
Recently, a randomized study comparing 30 consecutively inserted untunneled femoral 
catheters was completed [31].  Patients were randomized either to a 20- or 24- cm 
double-lumen catheter with an open shotgun tip (Niagara®, Bard, Salt Lake City, Utah, 
USA) or to a 20 cm catheter with a tapered tip (Gamcath®). Recirculation rates were 
measured at a blood flow of 200, 250 and 300 ml/min with blood-lines situated normally 
as well as after the reversal of pools.A benefit was demonstrated concerning effective 
blood flow, recirculation rates and early failure rates for the shotgun tip catheter.
For tunneled cuffed catheters, two prospective randomized studies of interest have been 
performed. Trerotola et al. randomized 64 patients to the 14 Fr Ash-split catheter and 
68 to the 14.5 Fr Opti-flow [27]. Although the authors concluded that the 
Ash-split catheter had a better survival, the differences seemed to be caused completely 
by insertion problems (kinking) and manufacturing faults (broken hubs). 
There were no differences in catheter-related bacteremia and late flow problems despite 
large differences in tip construction. Richard et al. compared 38 Ash-split, 39 Opti-flow, 
and 36 Tesio catheters [28]. Tesio catheter mean insertion time (42 min) was significantly 
longer than that of Ash-split (29 min) or Opti-flow (30 min) catheters. There were more 
insertion complications related to Tesio catheters. Mean flow rates and catheter-related 
infections were not significantly different among the catheter groups. From these studies 
in tunneled catheters, it can be concluded that double lumen catheters are preferred over 
two single lumen catheters and that, currently, no double lumen catheter has shown 
to be superior to an other.
In conclusion, for untunneled catheters there are good data to support that 
11-12 Fr catheters with a multiple side hole design should be replaced by a double lumen 
open shotgun tip design with a larger diameter and no more than one side hole. 
For tunneled cuffed catheters, one should probably choose a double lumen catheter for 
ease of insertion. It has not been shown convincingly that one cuffed catheter design 
is superior, provided that they have at least a diameter of 14 Fr. Therefore, 
physicians’ experience and cost should play an important role.
The optimal length of the catheter
The current recommendation of the NKF-DOQI is that a femoral catheter should be 
at least 19 cm long to minimize recirculation [3]. In the aforementioned trial was shown 
that 24 cm shotgun tip catheters have even lower recirculation rates compared 
to 20 cm catheters (0 vs 5%). Also direct dysfunction was lower, probably because longer 
catheters have a better capability to reach the inferior vena cava. Thus, for femoral use 
double lumen open shotgun tip catheters of at least 24 cm are recommended [31].
For untunneled and tunneled subclavian and jugular catheters data are less clear. 
NKF-DOQI guidelines recommend placement of a catheter with the tip adjusted 
to the level of the caval atrial junction or into the right atrium to ensure 
introduc tion
Recently, De Wachter et al. [30] presented a study on the hemodynamics 
of a dual lumen hemodialysis catheter with 5 arterial and 3 venous side holes 
(Gamcath®, Joka Kathetertechnik, Germany). A computer flow model was used simulating 
a blood flow of 300 ml/min through the catheter while placed in a 3 cm wide tube. 
The sequential placement of the arterial holes was demonstrated to be the reason 
why mainly the first available hole is employed to draw the blood into a catheter. 
The distal holes of the arterial side appeared to have a low flow zone, suggesting 
an increased risk of thrombus formation in clinical use (figure 3). Likewise, at the venous 
side the effectiveness of the multiple side hole design was questioned because the 
first two side holes appeared to be greatly underemployed. At the most proximal venous 
side hole (closest to the hub), some of the blood was even drawn into the catheter due 
to the high difference in velocities between the fluid in the catheter and the vein. 
Another disadvantage of multiple side holes is that locking solutions can easily dissolve 
from the tip. The authors concluded that most currently available temporary catheters 
can be improved to optimize hemodynamics and reduce dysfunction by reducing 
the number of side holes. Currently, we are using this computer model to analyze 
different catheter and catheter tip designs to try to determine the optimal tip 
construction. Preliminary data from this model reveal that double lumen open shotgun 
tips are optimal and that a single large side hole is probably sufficient.
Figure 3. 
Computer model for estimation of flow distribution through a catheter with multiple side 
holes. Scale on the left shows flow speed.
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For jugular and subclavian vein cannulation there is also extensive evidence for the use 
of ultrasound localization of the vein before puncture as well as the use of real time 
ultrasound guided cannulation [16;41]. The risk of complications such as pneumothorax, 
arterial puncture and fausse route can be decreased to less then 2% and procedure times 
are shortened. However, long term patency and the risk of infection were not improved 
in these trials. 
It has been demonstrated that patency rates and recirculation are affected by correct 
positioning of the tip of the catheter [42;43]. Preferably, the tip should be at or just below 
the caval-atrial junction. Fluoroscopy during positioning has been advised by radiologists 
but is not always available to nephrologists and has not turned out to be beneficial. 
Using the knowledge from the study of Twardowski et al. on the correlation between BSA 
and large vein sizes as discussed in the paragraph on catheter length, correct placement 
of tunneled catheters is possible without fluoroscopy [32].
After insertion of tunneled cuffed catheters a chest X-ray is mandatory for evaluating 
complications and correct positioning of the tip. However, when untunneled jugular 
catheters are inserted with ultrasound localization, the procedure is uncomplicated and 
straightforward, the blood flow is good, and there are no post procedural complaints 
of the patients, there is convincing evidence that dialysis can be started safely without 
the use of a chest X-ray. This can offer substantial savings [43-45].
d r e S S i n g S ,  a n t i m i c r o b i a l  e x i t - S i t e  a p p l i c at i o n S  a n d  l o c k i n g  S o l u t i o n S
All hemodialysis catheter manipulations should be performed by carefully instructed 
dialysis staff. At every dialysis session, the exit-site should be cleaned with 
a chlorhexidine-containing solution as this can reduce infectious complications 
by 49% compared to the use of povidone iodine [46].  It has clearly been shown 
that non-occlusive dry gauze dressings should be used for covering the exit-site [47]. 
Recently, antimicrobial ointments have been introduced. Mupirocin ointment and 
a polysporin triple antibiotic ointment have been shown to reduce the risk of infectious 
complications by 70 to 80% [48;48-50]. Therefore, mupirocin ointment has been 
advocated in the latest NKF-DOQI guidelines. However, widespread introduction could 
lead to the development of mupirocin resistance which may limit its application 
in the future [51;52]. 
Catheters have to be locked with a solution for the interdialytic period. Traditionally, 
heparin is installed but there are no studies to support this practice. Moreover, 
an increasing number of reports are published showing that leakage of heparin from 
the tip of the catheter can cause unintentional systemic anticoagulation and clinically 
relevant bleeding episodes [53;54]. Antimicrobial locking solutions could be an attractive 
alternative and will emerge into clinical practice in the near future. It is known from 
in vitro studies that solutions containing antibiotics can prevent biofilm formation 
on foreign surfaces [55]. But also the use of antibiotics in solutions for interdialytic locking 
of catheters can result in severe side effects caused by leakage from the tip resulting 
in continuous systemic levels of the antibiotic. Dogra et al. [56]  demonstrated 
in a randomized trial that gentamicin in a lock solution reduced the number of incidents 
of catheter-related bacteremia but also caused irreversible hearing problems because 
introduc tion
optimal blood flow. For untunneled catheters, the catheter length and diameter should 
be adjusted to the size of the patient. Twardowski et al. [32] determined the exact 
distance from 
an insertion site to the right atrium by magnetic resonance imaging of the dimensions 
of the venous system of the chest in 31 adult volunteers and correlated them 
to anthropometrical measurements. The best overall correlations of the lengths and 
diameters of the large upper body veins were with the body surface area. 
A table was made to help with the selection of the total catheter length and diameter 
in relation to the body surface area and insertion site. In general, in patients with a body 
surface area of 1.5 to 2.0 m2 a 12-15 cm catheter should be selected for the jugular vein 
in the low right position and a 15-19 cm catheter for the left jugular vein. 
A 14 to 17 cm catheter should be used for the right subclavian vein and a 17 to 22 cm 
catheter for the left subclavian vein.
For the preferred length of tunneled cuffed catheters no guidelines are available. 
In our experience, for the right jugular position (tip to hub) 28 cm are needed 
for appropriate atrial placement and an adequate tunnel length. For the left jugular vein 
we use a 32 cm catheter.
c at H e t e r  m at e r i a l S  a n d  c o at i n g S
In vitro data on the biocompatibility of polymers used in catheter manufacturing, namely 
silicon and polyurethane, are conflicting [33;34]. Likewise, in small randomized trials 
comparing tunneled cuffed catheters of different materials and construction, 
no clear benefit of one particular material was found [35]. It might be that silicone 
catheters are more prone to construction failures because of the difficult manufacturing 
process necessary [36]. 
Promising progress is made with coating of catheters. In ICU patients catheters coated 
with antibiotics, silver or heparin reduce the number of infections substantially. 
In a recent review, however, only heparin-coated catheters were considered 
to be cost-effective [10]. Studies on hemodialysis catheters have been disappointing 
so far [37]. A problem with bonding of hemodialysis catheters is that they are 
often needed for a longer period of time and the substance impregnated or bonded 
on catheters can disappear over time.
g u i d e l i n e S  F o r  i n S e r t i o n  p r o c e d u r e S  a n d  p o S t  p r o c e d u r a l  c H e c k S
Complications can be minimized when insertion is performed or supervised by 
an experienced physician. Both untunneled and tunneled cuffed catheters can 
be safely inserted under local anesthesia by nephrologists or radiologists [24;38]. 
The procedure should be strictly aseptic. Light sedation can be of benefit in anxious 
patients. Ultrasound-guided cannulation has proven to be superior to landmark-guided 
cannulation and is therefore recommended by the NKF-DOQI [3].Femoral catheters can 
be inserted using a blinded percutaneous Seldinger technique, but for femoral catheters 
it has also been shown in dialysis patients that procedure time can be significantly 
shortened with the use of ultrasound guidance [39]. The first attempt success rate 
increased by 30% and accidental arterial puncture decreased by about 10% [40]. 
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high plasma levels of gentamicin occured. Trisodium citrate (TSC) has been advocated for 
locking because it provides local anticoagulation. Ash et al. [57]  reported their experience 
with a hemodialysis patient cohort of 70 patients with 60% tunneled cuffed catheters. 
After the introduction of TSC 23-47% for catheter locking they observed a decline 
of 4.5 to 0% patients having a bacteremia. The utilization of urokinase for catheter flow 
problems also decreased significantly. Additional advantages of TSC are that it prevents 
unforeseen systemic anticoagulation and is less expensive than heparin. However, 
an important concern has risen over an accident using TSC for catheter locking. 
In this particular case, a large amount (over 10ml) of TSC was accidentally injected 
by a physician not aware of the potency of the solution, which stresses the importance 
of a thorough protocol for these solutions [58].
r e F e r e n c e S
1.  Kolff, W. J., Berk, H. J. T., and ter Welle, M. The artificial kidney: a dialyzer with a great
  area. Acta Med Scand 117, 121-131. 1944. 
2.  Brescia MJ, Cimino JE, Appell K, Hurwich BJ, Scribner B.H. Chronic hemodialysis using  
  venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966; 275: 
  1089-1092 
3.  NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2006. 
  Am J Kidney Dis 2006; 48: Suppl 1:S187-S317 
4.  Pisoni RL, Young EW, Dykstra DM et al. Vascular access use in Europe and the 
  United States: Results from the DOPPS. Kidney Int 2002; 61: 305-316 
5.  Little MA, O’Riordan A, Lucey B et al. A prospective study of complications associated
  with cuffed, tunnelled haemodialysis catheters. Nephrol Dial Transplant 2001; 16:
  2194-2200 
6.  Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis
  catheters. Nephrol Dial Transplant 1999; 14: 1710-1714 
7.  Tokars JI, Light P, Anderson J et al. A prospective study of vascular access infections at  
  seven outpatient hemodialysis centers. Am J Kidney Dis 2001; 37: 1232-1240 
8.  Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia 
  from temporary hemodialysis catheters by site of insertion and duration of use: 
  a prospective study. Kidney Int 2000; 58: 2543-2545 
9.  Cimochowski GE, Worley E, Rutherford WE et al. Superiority of the internal jugular
  over the subclavian access for temporary dialysis. Nephron 1990; 54: 154-161 
10. Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis
  in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal
  jugular accesses. Nephrol Dial Transplant 1991; 6: 722-724 
11.  Merrer J, De Jonghe B, Golliot F et al . Complications of femoral and subclavian
  venous catheterization in critically ill patients: a randomized controlled trial. 
  JAMA 2001; 286: 700-707 
12.  Po CL, Koolpe HA, Allen S, Alvez LD, Raja RM. Transhepatic PermCath for hemodialysis.
  Am J Kidney Dis 1994; 24: 590-591 
13.  Gupta A, Karak PK, Saddekni S. Translumbar inferior vena cava catheter for long-term 
  hemodialysis. J Am Soc Nephrol 1995; 5: 2094-2097 
chapter 1
24 25
47.  Conly JM, Grieves K, Peters B. A prospective, randomized study comparing 
  transparent and dry gauze dressings for central venous catheters. J Infect Dis 1989; 
  159: 310-319 
48.  Lok CE, Stanley KE, Hux JE et al. Hemodialysis infection prevention with polysporin
  ointment. J Am Soc Nephrol 2003; 14: 169-179 
49.  Sesso R, Barbosa D, Leme IL et al. Staphylococcus aureus prophylaxis in hemodialysis 
  patients using central venous catheter: effect of mupirocin ointment. 
  J Am Soc Nephrol 1998; 9: 1085-1092 
50.  Johnson DW, MacGinley R, Kay TD et al. A randomized controlled trial of topical exit
  site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters.
  Nephrol Dial Transplant 2002; 17: 1802-1807 
51.  Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin 
  resistance after long-term use for Staphylococcus aureus colonization in patients 
  undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337-341 
52.  Annigeri R, Conly JM, Vas SI et al. Emergence of mupirocin-resistant staphylococcus
  aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent 
  exit-site infection. Perit Dial Int 2001; 21: 554-559 
53.  Bayes B, Bonal J, Romero R. Sodium citrate for filling haemodialysis catheters.
  Nephrol Dial Transplant 1999; 14: 2532-2533 
54.  Moritz ML, Vats A, Ellis D. Systemic anticoagulation and bleeding in children with 
  hemodialysis catheters. Pediatr Nephrol 2003; 18: 68-70 
55.  Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of 
  persistent infections. Science 1999; 284: 1318-1322 
56.  Dogra GK, Herson H, Hutchison B et al. Prevention of tunneled hemodialysis 
  catheter-related infections using catheter-restricted filling with gentamicin and
  citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13: 2133-2139 
57.  Ash SR, Mankus RA, Sutton JM et al. Concentrated sodium citrate (23%) for catheter 
  lock. Hemodial Int 2000; 4: 22-31 
58.  FDA issues warning on triCitrasol® dialysis catheter anticoagulant. FDA Talk Paper
  T00-16 . 14-4-2000 
introduc tion
 
31.  Weijmer MC, Vervloet MG, ter Wee PM. Long shotgun-tip femoral catheters have
  better immediate function, better actual blood flow and lower recirculation rates.
  Nephrol Dial Transplant 2003; 18: 737 
32.  Twardowski ZJ, Seger RM. Dimensions of central venous structures in humans 
  measured in vivo using magnetic resonance imaging: implications for central-vein 
  catheter dimensions. Int J Artif Organs 2002; 25: 107-123 
33.  Neu TR, Van der Mei HC, Busscher HJ, Dijk F, Verkerke GJ. Biodeterioration of 
  medical-grade silicone rubber used for voice prostheses: a SEM study. Biomaterials 
  1993;14: 459-464 
34.  Solomon DD, Arnold WL, Martin ND, Lentz DJ. An in vivo method for the evaluation of  
  catheter thrombogenicity. J Biomed Mater Res 1987; 21: 43-57 
35.  Sherertz RJ, Carruth WA, Marosok RD et al. Contribution of vascular catheter material 
  to the pathogenesis of infection: the enhanced risk of silicone in vivo. 
  J Biomed Mater Res 1995; 29: 635-645 
36.  Trerotola SO, Kraus M, Shah H et al. Randomized comparison of split tip versus step
  tip high-flow hemodialysis catheters. Kidney Int 2002; 62: 282-289 
37.  Trerotola SO, Johnson MS, Shah H et al . Tunneled hemodialysis catheters: use of
  a silver-coated catheter for prevention of infection--a randomized study. 
  Radiology 1998; 207: 491-496 
38.  Trerotola SO, Johnson MS, Harris VJ et al. Outcome of tunneled hemodialysis
  catheters placed via the right internal jugular vein by interventional radiologists.
  Radiology 1997; 203: 489-495 
39.  Kwon TH, Kim YL, Cho DK. Ultrasound-guided cannulation of the femoral vein for 
  acute haemodialysis access. Nephrol Dial Transplant 1997; 12: 1009-1012 
40.  Farrell J, Gellens M. Ultrasound-guided cannulation versus the landmark-guided
  technique for acute haemodialysis access. Nephrol Dial Transplant 1997;
  12: 1234-1237 
41.  Lin BS, Huang TP, Tang GJ, Tarng DC, Kong CW. Ultrasound-guided cannulation of the
  internal jugular vein for dialysis vascular access in uremic patients. 
  Nephron 1998; 78: 423-428 
42.  Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, 
  but can’t live without them. Kidney Int 1999; 56: 1-17 
43.  Work J. Chronic catheter placement. Seminar Dial 2001; 14: 436-440 
44.  Guth AA. Routine chest X-rays after insertion of implantable long-term venous
  catheters: necessary or not? Am Surg 2001; 67: 26-29 
45.  Farrell J, Walshe J, Gellens M, Martin KJ. Complications associated with insertion of 
  jugular venous catheters for hemodialysis: the value of postprocedural radiograph.
  Am J Kidney Dis 1997; 30: 690-692 
46.  Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with
  povidone-iodine solution for vascular catheter-site care: a meta-analysis. 
  Ann Intern Med 2002; 136: 792-801 
chapter 1
2 Aim and outline of the thesis
2
28 29
l o c k i n g  S o l u t i o n S
Catheters have to be locked with a solution for the interdialytic period. It is well known 
that locking solutions leak out from the tip of the catheter, but the clinical implications 
of this feature are not clear. Traditionally, heparin is installed but there are no studies 
to support this practice. Heparin might be causing clinical problems because 
of unintentional systemic anticoagulation. Local acting antimicrobial locking solutions 
could be an attractive alternative. Low and high concentrations of trisodium citrate (TSC) 
have been advocated as locking solution because it provides local anticoagulation and 
might have antimicrobial properties. Additional advantages of TSC are that it gives 
no unforeseen systemic anticoagulation and is less expensive than heparin. However, 
the optimal concentration of TSC remains to be determined. In Chapter 6 we describe 
the antimicrobial properties of 4 different concentrations of TSC in vitro, using 
two classical antimicrobial susceptibility tests. From this study we derived the optimal 
concentration for a catheter locking solution to be used in a multicenter double blind 
randomised controlled trial. Results of this trial are also described in Chapter 6. 
In this study we also describe the clinical relevant complications of locking solution 
leakage from the catheter tip.
aim and outline of the thesis
The objective of the studies presented in this thesis was to reduce hemodialysis 
catheter-related complications by studying the influence of the following issues.
c a n n u l at i o n  S i t e S  a n d  W H e n  S H o u l d  a  c at H e t e r  b e  t u n n e l e d
In Chapter 3 we address the best cannulation site once the time period a hemodialysis 
catheter is needed has been estimated. According to the NKF-DOQI guidelines, 
untunneled femoral catheters should not be left in place for more than 5-7 days 
because of the high risk of infections. For untunneled jugular catheters the opinion is not 
to use these for more than 3 weeks and use an untunneled jugular catheter for the longer 
time periods. However no clinical studies support these time limitations. We analysed 
the outcome of hemodialysis catheters to address the issue of timing and catheter choice. 
In Chapter 4 we describe the effect of a novel design jugular catheter on catheter-related 
complications and addressed the time recommendations found in the previous study, 
including the question when a hemodialysis catheter should be tunneled.
c at H e t e r  m at e r i a l S ,  c o n S t r u c t i o n  a n d  t i p  d e S i g n
Hemodialysis catheter related complications can be caused by imperfect catheter 
constructions. Especially the construction of untunneled jugular catheters could be 
an important reason because these catheters can not be fixated well and have an upward 
directed exit-site, a well known risk factor for catheter-related infections. 
Recently a for patients more comfortable untunneled jugular catheter with better 
properties concerning fixation and exit-site direction has become available. 
In Chapter 4 we study the influence on infectious complications of using this novel 
design precurved jugular hemodialysis catheter in a clinical study.
It is not clear whether silicone or polymers like polyurethane should be the preferred 
material for hemodialysis catheters. Catheter fractures have been reported, especially 
with silicone catheters. The reason for these fractures is unknown and it is not clear 
whether catheter material is relevant. In Chapter 5 we describe the construction and 
potential flaws in the manufacturing process from a fractured silicone hemodialysis 
catheter by performing an extensive scanning electron microscopy study and using 
energy-dispersive X-ray spectral analysis to determine the components of the catheter.
The geometry and tip design of catheters have been determined mainly by methods 
of trial and error. Multiple side holes were thought to be necessary to secure sufficient 
inflow in the case of obstruction of some side holes or when a catheter was placed close 
to the vessel wall. However, side holes can induce thrombosis because they often have 
an irregular surface. Despite the various types of catheters available, studies 
on the influence of tip construction on fluid dynamics are scarce.
In the second study presented in Chapter 5 we performed an in vitro study on the fluid 
dynamics of four different types of tunneled and untunneled catheters. To determine 
the influence of side holes, catheters were studied with open and closed side holes.
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Compared to tunnelled cuffed haemodialysis catheters, temporary 
untunnelled catheters are associated with more complications al-
ready within 2 weeks of use. 
Weijmer MC, Vervloet MG, ter Wee PM. 
Dept. of nephrology, Vrije Universiteit Medical Center, Amsterdam
Nephrol Dial Transplant 2004;19: 670-677.
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i n t r o d u c t i o n
Vascular access for hemodialysis treatment is best achieved with an arteriovenous fistula 
or arteriovenous graft. Tunneled cuffed hemodialysis catheters (TCC) are used 
for long-term vascular access in a small proportion of patients mostly because 
opportunities for an arteriovenous access are exhausted. However, 
a significant number of patients requires a temporary vascular access because of acute 
renal failure, slow maturation or failure of their permanent arteriovenous access or 
as bridging to transplantation or peritoneal dialysis. In these situations, untunneled 
catheters (UC) are used when a catheter is needed for only a short period of time and 
TCC for longer periods. UC are relatively small bore (11-13 Fr) catheters and have no cuff 
adhered to the catheter. These can be inserted with relative ease by a bed-side procedure 
under local anesthesia without the formation of a subcutaneous tunnel and are usually 
intended for a relatively short period of time. In current practice the use of catheters 
for hemodialysis treatment is substantial. From recent data of the Dialysis Outcome 
and Practice Patterns Study (DOPPS), it is recognized that 15-50% of patients in Europe 
and 60% of patients in the US start hemodialysis treatment with a catheter as primary 
access [1]. This widespread use of catheters implies an enhanced risk for catheter-related 
complications, particularly catheter-related infections. Observational data suggest that 
these risks are higher for temporary  UC compared to TCC and this is also reflected 
in guidelines[2]. Recently, the updated NKF-DOQI guidelines recommended that when 
it can be anticipated that a catheter will be needed for more than three weeks, 
a TCC should be inserted [3]. Inserting TCC, however, requires more experience, prolonged 
procedure time and special skills of the operator. In addition, removal is hampered 
by growth of the subcutaneous tissue into the cuff . These drawbacks for the use of TCC 
might explain the observation in the DOPPS that UC are still widely used. In incident 
hemodialysis patients, 48% of catheters in the US and 75% of catheters in Europe are 
untunneled and even in prevalent patients over a third of all catheters are untunneled [1]. 
As was pointed out recently, there are limited data available in the literature comparing 
the outcome of UC and TCC [4]. 
Reported bacteremia rates vary from 3.8-6.5 per 1000 catheter-days  for UC and 
1.6-5.5 for TCC [5-9]. In these studies, catheter care protocols and the definition 
of complications differ. In addition, because UC and TCC are used for different clinical 
situations, the higher incidence of complications in UC may be caused by differences 
in patient characteristics and risk factors for infection. These factors all contribute to 
the finding that the incidence of catheter-related complications can vary widely between 
types of catheters used and dialysis centers [10]. Therefore, comparison of outcome 
of UC in one center with TCC 
in another center is not reliable as was clearly pointed out by Lund et al [11]..
The aim of the present study was to compare the outcome of TCC with UC limiting 
as much as possible the influence of confounding factors. The second purpose was to 
see whether our results support the time recommendations for maximum use of 
UC outlined in the NKF-DOQI guidelines.
comparison of outcome of temporar y c atheters
a b S t r a c t 
Background. Comparison of outcome of untunneled catheters (UC) and tunneled cuffed 
catheters (TCC) is difficult because they are usually used for different patients and 
conditions. The aim of the present study is to compare the outcome of TCC with 
UC limiting as much as possible the influence of confounding factors. The second purpose 
was to see whether our results support the time recommendations for maximum use 
of UC outlined in the NKF-DOQI guidelines.
Methods. Catheter and patient characteristics, catheter-related complications and 
all cultures taken from  hemodialysis catheters inserted during a three year period 
were collected.
Results. We analyzed the outcome of 272 catheters (149 patients, 11612 catheter days, 
37 TCC and 235 UC). Patients with an UC suffered more often from acute renal failure 
(40% vs 8% for TCC, p<0.001), their hospitalization rates were higher 
(54% vs 14%, p<0.001) and coumarins were used less (11 vs 27%, p<0.01). 
Rates of preliminary removal were 1.8 per 1000 catheter-days for TCC, 35.3 for untunneled 
femoral catheters (UFC) and 17.1 for untunneled jugular catheters (UJC). Infection rates 
were 2.9 per 1000 catheter-days for TCC, 15.6 for UJC and 20.2 for UFC. 
Hospitalization, was an independent risk factor for an adverse outcome and more 
apparent in patients with an UC. After correction for patient differences, 
the strongest risk factor for preliminary removal (RR 9.69, p<0.001) and infection 
(RR 3.76, p<0.001) was having an UC inserted.  Already within two weeks actuarial and 
infection free survival were better for TCC (p<0.05 vs all separate groups). 
Conclusion. According to our results, a TCC should be used whenever it can be foreseen 
that a hemodialysis catheter is needed for more than 14 days. 
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cleansed with a povidone-iodine solution. Before removing the caps, the catheter hubs 
were disinfected with a chlorhexidine solution (2.5%). After dialysis all catheters were 
locked with unfractionated heparin (5000 U/ml) with a volume equivalent to the 
internal volume of the lumen noted on the catheter. Catheters were used for 
hemodialysis exclusively.
Catheter-related bacteremia was defined as fever or cold chills with positive blood 
cultures and no other obvious cause of infection. When a catheter-related bacteremia 
was established, the catheter could be left in place in case of good clinical response 
on initiation of antibiotic treatment. No catheter exchange procedures for 
catheter-related bacteremia were performed. A catheter-related exit-site infection was 
considered to be present on clinical grounds by the caring nephrologist, a culture of 
the exit-site was taken and treatment with antibiotics had been started.
In accordance to national guidelines, the minimal acceptable Qb was 200 ml/min, 
the target was 250 ml/min. The target for dialysis efficiency was a Kt/V of at least 
1.2 per treatment. When the minimal acceptable blood flow was not achieved 
or when the catheter was occluded, urokinase, 10.000U/ml during 15 minutes, was 
installed with a volume equivalent to the internal volume of the lumen. In general, 
when Qb improved but 200 ml/min was not achieved, the procedure could be repeated, 
otherwise the catheter was removed or exchanged over a guide wire. 
Statistical analysis
Statistical analysis was performed with SPSS software 9.0 (SPSS Inc., Chicago, Ill, USA). 
Non parametric tests for two (Mann-Whitney U test) and multiple continuous variables 
(Kruskal-Wallis test) were used.  For comparing binary and categorical variables 
Chi-square and Fisher’s exact tests were applied where appropriate. ANOVA was used 
to compare age and time on dialysis between multiple groups. Kaplan-Meier survival 
curves were constructed to analyze the patency rates and infectious complications. 
Functional catheters at the end of the observation time and catheters removed because 
they were not needed anymore were analyzed as censored values. 
Curves were constructed for all patient and catheter characteristics mentioned 
in table 1. The log rank test was used to compare groups and identify individual risk 
factors associated with a preliminary removal or catheter-related infection. 
At an individual two-sided P value of < 0.1, the factor was included to fit a Cox-regression 
model. We have included male sex, acute renal failure, time on dialysis, hospitalization 
and having an UC inserted in the final model. We used a forward stepwise conditional 
technique to identify the factors independently associated with catheter failure and 
infection. R-square of linear regression was estimated for infection free survival 
and overall patency curves. Actuarial catheter survivals at 14, 21 and 28 days were 
counted with the use of life tables and significance was calculated with the log rank test 
for the individual time periods. Differences were considered statistically significant for 
p less than 0.05.
comparison of outcome of temporar y c atheters
S u b j e c t S  a n d  m e t H o d S
Patients and data collection
We analyzed all hemodialysis catheters inserted at the dialysis department of 
an academical teaching hospital from January 1st 1997 to January 1st 2000. On average, 
60 hemodialysis patients are treated in our unit, 10% are acute patients and 
25% of patients depend on a catheter for vascular access. Follow-up on inserted catheters 
was done from insertion to removal and in case of persistent patency up to July 1st, 
2000. Data on all inserted catheters and catheter-related complications at follow-up were 
entered prospectively in a computerized patient data system by the caring nephrologist 
and dialysis nursing team. The decision on the type of catheter and place of insertion 
was left to the physician responsible for the patients’ care at time of insertion.
Reasons for catheter removal were entered in the database: elective removal, exit-site 
infection or bacteraemia, dysfunction or accidental removal. In case of uncertainty 
the caring nephrologist was consulted. Catheters were evaluated for type, place 
of insertion, time of insertion, duration of use and reason for removal. All cultures of blood 
and exit-sites taken from the patient during the period that a catheter was in place were 
collected from the computerized data system of the department of microbiology. Baseline 
patient characteristics and demographical data were collected at time of insertion. 
In addition, hospitalization for non catheter-related reasons at any time a catheter was 
in place was analyzed as separate risk factor for adverse outcome[10]. Acute renal failure 
was defined as dialysis dependency for less then three months which was not the result 
of slowly progressive renal insufficiency. All other patients where considered having 
chronic renal failure including patients referred because of failing peritoneal dialysis 
treatment. Patients after renal transplantation were only considered having chronic renal 
failure if they needed dialysis treatment because of chronic rejection. 
Data on two catheters (both untunneled jugular catheters) were lost to follow-up because 
of transferal to an other dialysis center. Three catheters (two femoral and one subclavian 
untunneled catheter) were excluded from analysis due to insufficient data. 
These were excluded from the analysis. Catheters, intended to be used only once 
(almost exclusively untunneled femoral catheters) were not included in the analysis.
Catheters, catheter care protocol and catheter outcome assessment
For femoral, we used straight dual-lumen polyurethane catheters of 20 cm, for 
the right subclavian site 15 cm and  for the left subclavian position 20 cm (Quinton 
(Seattle, WA, USA); n=18 and Gamcath (Gambro, Hechingen, Germany); n=113). 
For the internal jugular position we used the same catheters with curved extensions 
(Quinton n=15, Gamcath n=89). For TCC we used  Neostar Circle-C (Horizon Medical 
Products, Atlanta, GA, USA; n=24), PermCath (Quinton Instruments, Bothell, WA, 
USA; n=5), Tesio twin-cath (n=3) and Ash-split (Medcomp, Medical Components Inc., 
Harleysville, PA, USA; n=5). 
All catheters were inserted under local anesthesia and strict asepsis, and sutured 
to the skin. Catheters were only used by experienced dialysis nurses or nephrology staff, 
using sterile gloves and masks. The semi-occlusive transparent dressings we used, were 
inspected every dialysis session and changed at least once a week, the exit-site being 
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Table 1.  Catheter and patient characteristics
Catheter characteristics Untunneled catheters TCC
femoral jugular subclavian total
No. of catheters 83 104 48 235 37
No. of catheter-days 793 3209 1492 5494 6118
Right sided insertion (%) 53 84 63 69 87
Guide wire exchanges (%) 5 9* 21 10* 27*
Patient characteristics
Age (mean ± SD) 60.3 ± 15.9 61.0 ± 13.8 62.9 ± 15.6 61.1 ± 16.0 62.5 ± 13.0
Gender male (%) 55 66 60 61 51
Race (%)
        caucasian 70 71 83 73 70
        black 19 18 15 18 22
        other 11 11 2 9 8
Cause of ESRD (%)
        diabetes 18 24 13 20 30
        renovascular 16 20 29 20 11
        polycystic disease 2 8 4 5 16
        glomerulonephritis 16 13 13 14 8
        HIV 2 1 2 2 0
        other 41 24 31 31 27
        unknown 5 10 8 8 8
Acute renal failure (%) 42 38** 44 40** 8**
Diabetes mellitus (%) 23 32 25 27 35
Hospitalization at all (%) 68 42 † 52 54 † 14 †
        general ward 43 31 29 35 14
        intensive care 25 11 23 19 0
       
Time on dialysis (mo ± SD) 15.8 ± 24.9 13.8 ± 25.1 15.6 ± 25.9 14.9 ± 25.1 23.5 ± 29.7
Immunosuppressive drugs 15 14 6 12 11
Coumarines (%) 12 8 ‡ 15 11 ‡ 27 ‡
Sau nasal carrier (%) 45 48 49 48 32
Malignancy (%) 15 9 8 11 3
Abbreviations: TCC, tunneled cuffed catheters; SD, standard deviation; ESRD, end-stage
renal disease; Sau, Staphylococcus aureus
 *  P<0.01
** P<0.001
†   P<0.001
‡   P<0.01
comparison of outcome of temporar y c atheters
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A total of 272 catheters (11612 catheter days) in 149 patients (82 male, 57 female) 
were included in the final analysis. There were 83 untunneled femoral catheters (UFC) 
inserted, 104 jugular (UJC) and 48 subclavian (USC). Of 37 TCC, 35 were jugular and 
2 were femoral. There were no significant differences in outcome between left and 
right-sided catheters and between the different types of catheters. Patients with more 
than one catheter inserted were more likely to be chronic patients and on dialysis for a 
longer period of time and less likely to be hospitalized during the period they had 
a catheter placed.
In our study the risk for an adverse outcome or infection for second or more insertions 
was not increased (RR 1.10, 95% CI 0.75-1.62 P=0.62) and therefore these catheters were 
not analyzed separately. Patient and catheter characteristics are given in table 1. 
Of patients who had a TCC inserted, 92% was on chronic haemodialysis treatment 
in contrast to patients with an UJC (62%, p<0.001) and to the group of all UC combined 
(60%, p<0.001). Patients with UC were characterized by higher hospitalization rates for 
non catheter-related reasons compared to TCC (54% vs 14%, p<0.001). Also, patients 
with UC concerned patients admitted to the intensive care more often (p<0.01). 
Furthermore, 27% of TCC were inserted with the use of a guide wire exchange procedure 
(p<0.01) and more patients with a TCC were on coumarin treatment (11 vs 27%, p<0.01). 
Other differences in patient characteristics were not significant.
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Figure 1a. Kaplan-Meier  curves of total survival of tunneled cuffed catheters 
(TCC) (—) compared to untunneled jugular (UJC) (—) (p<0.001 by log rank statistics), 
untunneled femoral (UFC) (—) (p<0.001) and untunneled subclavian catheters 
(USC) (—) (p<0.001. Tick marks indicate censored catheters.
The survival for UFC was significantly lower for any time point compared to TCC 
(42% at 14 days, 37% at 21 days and 32% at 28 days, p<0.001 for all periods) and UJC 
(75% at 14 days, 69% at 21 days and 58% at 28 days, p<0.05 for all periods). Importantly, 
TCC had also better survival rates at all time periods compared to UJC 
(p<0.01 for all periods by log rank testing) (figure 2a).
As patient characteristics differed between the catheter groups, risk factors for adverse 
outcome were analyzed. After univariate analysis, male sex (RR 1.73), acute renal failure 
(RR 1.75), hospitalization (RR 2.48) and having an UC inserted (RR 9.44) were significant 
associated with preliminary removal. The strongest factor predicting an adverse outcome 
was having an UC inserted (RR 9.69; 95% CI 4.25-22.08 P<0.001, after correction
 for hospitalization). When only jugular catheters were compared, the risk of preliminary 
removal for UC remained almost tenfold increased (RR 9.39; 95% CI 3.96-22.28 p<0.001, 
after correction for hospitalization). Hospitalization was the only other independent factor 
(RR 2.41; 95% CI 1.60-3.61 p<0.001).
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c at H e t e r  o u t c o m e S
Of 235 UC inserted, 128 (54%) were removed because they were not needed anymore 
compared to 26 (70%) of TCC. In contrast, 107 (46%) UC had to be removed 
for a complication compared to 11 (30%) TCC (p<0.001 by log rank analysis).  
Catheter and patient characteristics are shown in table 2. 
NOTE. Values expressed as number (percent) unless noted otherwise.
Abbreviations: TCC, tunneled cuffed catheters
* P<0.05 for comparison between untunneled subclavian and untunneled jugular and TCC 
The rate for preliminary removal per 1000 catheter-days was lowest for TCC (1.8) 
and highest for UFC (35.3). UJC and USC had similar rates (17.1 and 16.1 per 
1000 catheter-days) but were also higher than TCC. Reasons for premature removal 
differed slightly but not significantly between UC and TCC. Infection was the primary 
reason (49% for UC and 55% for TCC). Considering untunneled catheters only, USC were 
removed less because of infection but more for persistent flow problems or mechanical 
complications, compared to both UFC (p<0.05) and UJC (p<0.01) catheters. Log rank 
analysis of survival curves showed better patency rates for TCC compared to any of 
the untunneled groups  (p<0.001) adjusted for hospitalization. Of UC, outcome of UFC 
was significantly worse compared to USC (p<0.05) and UJC (p<0.01) (figure 1a). 
Cumulative hazard-ratio analysis of adverse outcome showed a linear appearance for 
all catheter groups suggesting a risk of adverse outcome constant over time 
(test for linearity R2 > 0.8 for all groups).
To relate the results to the time recommendations in the NKF-DOQI guidelines, 
we calculated the patency rates at 14, 21 and 28 days. Actuarial catheter survival was best 
for TCC, 95% at 14 days, 95% at 21 days and 95% at 28 days.  
Table 2.  Characteristics of premature catheter removal
Untunneled catheters TCC
femoral jugular subclavian total
No. of Catheters 83 104 48 235 37
Removal for all complications 28 (34%) 55 (53%) 24 (50%) 107 (46%) 11 (30%)
        per 1000 catheter-days 35.3 17.1 16.1 19.5 1.8
Reason for premature removal
        infection 12 (43%) 37 (67%)* 3 (13%)* 52 (49%) 6 (55%)*
        flow problem 13 (46%) 16 (29%) 19 (79%) 48 (45%) 3 (27%)
        mechanical / fracture 3 (11%) 2 (4%) 2 (8%) 7 (7%) 2 (18%)
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Infection rates for TCC (2.9 per 1000 catheter-days) were significantly lower compared 
to UC (12.8 per 1000 catheter-days, p<0.001 by log-rank testing), especially to UJC 
(15.6 per 1000 catheter-days, p<0.001) and UFC (20.2 per 1000 catheter-days, p<0.01). 
CRB rates per 1000 catheter-days showed analogous results (table 3). 
The probability of infection free survival was best for USC and TCC (91% at 14 days, 89% 
at 21 days and 89% at 28 days) (figure 1b). 
Figure 1b. Kaplan-Meier  curves of infection free survival of tunneled cuffed catheters(TCC) 
(—) compared to untunneled jugular (UJC) (—) (p<0.01 by log rank statistics), untunneled 
femoral (UFC) (—) (p<0.01) and untunneled subclavian catheters (USC) (—). Tick marks 
indicate censored catheters.
For UJC the probability of infection free survival was significantly lower for any time point 
compared to TCC (UJC; 73% at 14 days, 64% at 21 days and 56% at 28 days; p<0.05 for all 
periods, figure 2b). The rates for CRB free survival were also significantly better for TCC.
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Figure 2a. Patency rates at 14, 21 and 28 days of tunneled cuffed catheters compared to 
untunneled jugular catheters. 
i n F e c t i o u S  c o m p l i c at i o n S
A total of 35 episodes of catheter-related bacteremia (CRB) occurred in 31 catheters 
in 27 patients; in 8 patients an exit-site infection preceded CRB. There were 45 episodes 
of solitary exit-site infections. Differences in CRB and exit-site infection rates within 
the catheter groups are presented in table 3.
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Table 3. Characteristics of catheter-related infections
Infection rates per 1000 catheters-days
Exit-site infection CRB Total
TCC 1.3 1.6 2.9
All untunneled 8.2 4.6 12.8
        femoral 12.6 7.6 20.2
        jugular 10.0 5.6 15.6
        subclavian 2.0 0.7 2.7
Abbreviations: TCC, tunneled cuffed catheters; CRB, catheter-related bacteremia
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characteristics. Kairaitis et al found in their prospective study on 105, mainly subclavian, 
UC that 59% of catheters had to be removed prematurely because of a complication. 
A total of 6.5 periods with CRB per 1000 catheter days were observed [5]. However, only 
few patient characteristics (age, gender and diabetes) were reported. Furthermore, 
75% of catheters were inserted in the subclavian vein and no data are available on 
the number of right and left sided catheters. In contrast, Oliver et al recently reported 
a much lower rate of CRB of 3.8 per 1000 catheter-days for UC even including femoral 
catheters [7]. Patients’ characteristics, however, were not described but only analyzed 
as risk factor for CRB and no data were given concerning patency rates. 
In a large prospective study analyzing vascular access infection in 111.383 dialysis 
sessions, Stevenson et al found a relative risk for CRB of 1.9 for UC compared to TCC [2]. 
However, the major limitation, already recognized by the authors in their discussion, 
was that no data were available on patient characteristics and sites of insertion and 
no corrections could be made for these potential confounding factors. Moreover, 
only 1.6% of all dialysis treatments were performed with the use of an UC suggesting that 
these catheters were used only in a very specific patient group. In studies investigating 
TCC only, the incidence of CRB generally is lower (1.3-5.5 episodes per 1000 
catheter-days) [5] compared to our results. It is, however, striking to observe the four-fold 
higher incidence of CRB found in the study by Saad (5.5 periods of CRB per 1000 
catheter-days) compared to the study of Little et al (1.3 periods of CRB per 1000 
catheter-days) while their study design and definition of CRB seemed comparable [6;8]. 
These differences between catheter studies could well be caused by differences 
in patients’ characteristics or catheter management protocols. From these observations 
it is obvious that the reported complication rates for UC and TCC in these studies differ 
widely and can not be used for individual comparison.
In the present study we could demonstrate multiple differences between patients who 
had an UC or a TCC inserted. In particular, we observed more hospitalizations, 
an established risk factor for infections, for non catheter-related reasons in patients with 
an UC.  This observation concerning hospitalization as risk factor for adverse outcome 
confirms the findings of Tokar et al [10].
Another important factor influencing the outcome of catheters is the catheter care 
protocol. It has been shown in randomized studies and recommended in the NKF-DOQI 
guidelines that the risk for CRB can be reduced with a thorough protocol [3;12]. 
Even the level of education of the dialysis nurses concerning catheter handling influences 
the outcome [13].  Studies on catheter-related complications differ widely in 
these practices and could be an important confounder when comparing patency rates 
and CRB. In the present study we have tried to exclude these possible confounding 
factors by using a similar catheter care protocol for all catheters. 
To relate our results to the NKF-DOQI guidelines, we focused on the survival and infection 
rates for the time period of four weeks as UC, especially UJC could be a reasonable 
alternative to TCC for this period of time [7]. We could demonstrate that even when 
a catheter is needed for only 14 days, the best survival and lowest infection rates were 
for TCC. Within two weeks, 25% of UJC had to be removed for a complication and in 27% 
an exit-site infection or CRB had occurred. Of all TCC only 5% had to be removed for 
comparison of outcome of temporar y c atheters
Figure 2b. Infection free survival rates at 14, 21 and 28 days of tunneled cuffed catheters 
compared to untunneled jugular catheters. 
Risk factors for infection differed only slightly from risk factors for preliminary removal. 
Again, the only independent risk factors for infection were having an UC 
(RR 3.03, 95% CI 1.54–5.94, P=0.001) and hospitalization in the week before the infection 
occurred (RR 2.72, 95% CI 1.75–4.22, P<0.001). Untunneled and tunneled jugular catheters 
were compared after correction for differences in patient characteristics. 
The strongest risk factor for infection (RR 3.76, 95% CI 1.88-7.51 P<0.001) or CRB 
(RR 3.07, 95% CI 1.08-8.74, P<0.05) was having an untunneled jugular catheter.
In 48% of cases cultures yielded gram-positive microorganisms, predominantly 
Staphylococcus aureus or Staphylococcus epidermidis, in 36% it concerned gram-negative 
microorganisms. The remaining cultures revealed multiple microorganisms or yeasts.
d i S c u S S i o n
Our study demonstrates that TCC had significant better survival and lower risk 
for infection compared to UC as early as two weeks after insertion. We have shown that 
the risk for an adverse outcome increases linearly over time. This implicates that almost 
all catheters for hemodialysis treatment should be tunneled. The unique feature of 
our study is that we performed a single center study and used a similar catheter care 
protocol by the nursing staff for all catheters. Furthermore, we corrected for differences 
in patient characteristics that might have interfered with the better outcome of patients 
with a TCC. This results in a more reliable comparison between catheter groups, compared 
to previous reports. So far, the current evidence for time recommendations on 
the use of catheters is from uncontrolled studies not correcting for differences in patient 
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dysfunctional UC because the latter can be exchanged more easily. 
However, it is unlikely that dysfunctional catheters regain flow when one or two sessions 
of intraluminal thrombolytic therapy are unsuccessful [18]. In addition, the acceptance 
of a blood flow of 200-250 ml/min has probably favored the results for untunneled 
catheters. Finally, culture results were not collected prospectively. As every exit-site 
culture and blood culture send from one of our hemodialysis patients to the department 
of microbiology was reviewed, it is not likely we missed infectious periods or introduced 
systemic errors favoring one of the catheter groups.
In conclusion, the present study shows that femoral, subclavian and jugular untunneled 
hemodialysis catheters are associated with a high rate of premature removals and 
infectious complications compared to TCC. According to our results, a TCC should 
be used whenever it can be foreseen that a hemodialysis catheter is needed for at least 
14 days which is earlier than currently recommended by the NKF-DOQI. This indicates 
that almost no UC should be used in daily practice. However, when new strategies 
to reduce catheter-related complications like better designed untunneled jugular 
catheters and antimicrobial locking solutions [19 [20], are introduced in clinical practice, 
the outcome of UC may improve and new prospective randomized studies will be needed 
to estimate the time period  untunneled catheters can be used safely.
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a complication within two weeks and 9% of catheters were infected. This conclusion 
is also supported by the observation that the patency curves and the infection free 
survival curves are close to linear (R-square > 0.8 for all curves). Linearity means that 
the risk is independent of time, that episodes of infection per 1000 catheter-days can 
be compared proportional and are valid for every time period [11]. However, earlier use 
of TCC must be weighted against the more time consuming and difficult insertion and 
removal of TCC and the higher costs.
It is not completely clear why TCC have a lower risk for infection. One explanation could 
be that the fixation of TCC can be achieved better by the use of a subcutaneous cuff and 
that bacterial migration from the exit-site to the venous entry site is impeded [14]. 
A recent meta-analysis has clearly demonstrated that cuffing and tunneling of catheters 
reduces the risk for CRB by 44-77%, however this analysis only included non-hemodialysis 
catheters [15]. UJC are more difficult to fixate properly. Furthermore, they have an upward 
directed exit-site, an established risk factor for infection in peritoneal catheters [16]. This 
is probably because debris can accumulate, colonization is promoted and pus can 
not drain in case of local infection. In addition, preliminary reports on precurved UJC with 
better possibility for fixation and a downward directed exit-site suggest they can 
be left in place for a longer period of time with an equivalent risk for infection compared 
to TCC [17]. USC mostly have a downward directed exit-site and can be fixated more 
easily. This could explain the lower risk for infection for USC we found compared to UJC, 
as was already shown in the study on UC by Kairaitis et al [5]. 
An other point that influences the function of catheters is their construction. 
As TCC have a 2 to 3 Fr larger diameter and Poiseuille’s equation dictates that the flow rate 
is inverse proportional to the diameter to the fourth power, it is clear that there 
is more reserve in case of partial obstruction for TCC compared to UC. Our study 
has several limitations. First, the present study represents observational and prospectively 
stored data and the allocation to any type of catheter was not randomized. 
Guidelines should ideally be based on results from prospective randomized studies. 
However, the need of a large randomized controlled trial could be questioned if 
our results had supported the time recommendations on the safe use of UC. In the light 
of current recommendations it is very difficult to conduct a randomized trial comparing 
TCC and UC and no such trial reports have appeared in the literature so far despite 
the great number of catheters used worldwide. . Second, like in almost all other catheter 
studies we included all catheters inserted in patients and not only first episodes. 
This could lead to repeated tabulation of patients and dependency of catheter episodes. 
However, in temporary catheters, Oliver et al recently showed that multiple insertions and 
even guide wire exchanges are not 
a risk factor for an adverse outcome [7]. For TCC, Little et al could only find an increased 
risk for an adverse outcome when three or more TCC were inserted [8]. In our study only 
3 patients had two TCC inserted and no patient had more then two inserted. Furthermore, 
the risk for an adverse outcome or infection for second or more insertions in our study 
was not increased (RR 1.10, 95% CI 0.75-1.62 P=0.62). Third, despite similar protocols 
for TCC and UC in our center, there is a possibility that more often thrombolytic treatment 
was used for a dysfunctional TCC and that dysfunctional TCC were left in place longer than 
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4 Prospective follow-up of a novel design 
hemodialysis catheter; lower infection rates and 
improved survival
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i n t r o d u c t i o n
Temporary uncuffed haemodialysis catheters for vascular access are regularly used 
in haemodialysis practice. Today, the preferred site for a temporary catheter is 
the jugular vein. Uncuffed catheters are often left in place for a prolonged period 
of time despite the recommendation in the recently updated NKF-DOQI guidelines 
to use tunneled cuffed catheters (TCC) whenever it can be anticipated that a catheter will 
be needed for more than three weeks [1]. This is probably because inserting TCC requires 
more experience, prolonged procedure time and special skills of the operator.
In incident haemodialysis patients, 48% of catheters in the United States and 75% 
of catheters in Europe are untunneled and even in prevalent patients over a third 
of all catheters are untunneled [2]. It has been shown that catheter-related complications 
are higher for temporary untunneled jugular catheters compared to tunneled catheters 
[3;4]. The reasons for these increased rates are not clear. It is suggested that poor fixation 
could be important. Current models of untunneled straight jugular vein catheters (USC) 
are placed in the external or internal jugular vein pointing upward from the place 
of insertion. They are fixated cranial from the point of insertion and have either curved 
extensions (figure 1a) or are curved laterally. These catheters are uncomfortable for 
the patient and can easily dislocate. In addition, on connection to the haemodialysis 
machine, pulling lines can kink the catheter or cause laceration of the exit site, 
a known risk factor for infection [5;6].
Recently, a novel designed untunneled precurved temporary jugular catheter (UPC) 
model has become available (Duoflow®, Medcomp, Harleysville, USA). Inserted close 
to the upper border of the clavicle with the catheter bending over the clavicle and 
fixated to the chest wall, this catheter is more comfortable for patients (figure 1b). During 
haemodialysis treatment, movement of this catheter is minimal.
The primary aim of this study was to compare the patency and catheter-related 
complications of this precurved untunneled jugular catheter with untunneled straight 
catheters. We also related the results to the outcome of tunneled cuffed catheters during 
this study.
prospec tive follow up of a novel design hemodialysis c atheter
a b S t r a c t
Background. Untunneled straight jugular catheters (USC) are uncomfortable for patients 
and can not be fixated well. This could be a reason for the high incidence 
of catheter-related complications.
Methods. We prospectively analysed the outcome of an untunneled precurved catheter 
(UPC), bending forward over the clavicle and fixated to the chest wall and compared 
it with the outcome of USC and tunneled cuffed catheters (TCC). 
Results. The outcome of USC was documented over a 32 month period. 
Thereafter, we switched to an UPC. The same catheter care protocol was used and not 
changed over time. A total of 104 USC were inserted, 65 UPC and 64 TCC. Compared 
to USC, less UPC had to be removed for a complication (53 vs 15%; p<0.001) and 
less periods of catheter-related bacteraemia were observed in UPC compared to USC 
(0 vs 5.6 per 1,000 catheterdays; p<0.01 by log rank analysis). Removal for flow problems 
was similar. Compared to TCC, UPC were removed more often for flow problems (4.3 vs 1.0 
per 1,000 cd; p=0.024), other outcomes and complication rates were similar. Complication 
rates for TCC inserted before and after the switch from USC to UPC were equal.
Conclusions. UPC have better patency rates and a lower risk for bacteraemia and exit-site 
infection compared to USC. Infection rates are similar to rates found in tunneled cuffed 
catheters.
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Catheter were inserted in the internal jugular vein about one cm above the clavicle 
(black line), low in the sternocleidomastoid triangle. A standard Seldinger guidewire 
procedure was used to introduce the catheter. Care was given to insert the catheter 
including the first half of the curve. After insertion, the exit site should point forward 
to downward. Catheters were only handled by experienced dialysis nurses or nephrology 
prospec tive follow up of a novel design hemodialysis c atheter
S u b j e c t S  a n d  m e t H o d S
Patients and data collection
We analyzed all untunneled temporary jugular and tunneled cuffed haemodialysis 
catheters inserted in the jugular vein at the dialysis department of an academical 
teaching hospital over a 4 year period. On average, 60 haemodialysis patients are 
treated in our unit, 10% are patients with acute renal failure and 25% of patients depend 
on a catheter for vascular access. Data on all inserted catheters and catheter-related 
complications at follow up were entered prospectively in a computerized patient data 
system by the caring nephrologist and dialysis nursing team. 
The decision on the type of catheter and place of insertion was left to the physician 
responsible for the patients care at time of insertion. In general, tunneled cuffed were 
more likely to be chosen whenever it could be foreseen that a catheter was needed 
for more than four to six weeks. When this could not be determined or the need for 
a catheter was expected to be shorter, a untunneled jugular catheter could be inserted.
Reasons for catheter removal were entered in the database: elective removal, 
exit-site infection, catheter-related bacteraemia, flow problems, accidental removal or 
catheter fracture. Catheters were evaluated for type, place of insertion, time of insertion, 
duration of use and reason for removal. Femoral catheters were excluded. All cultures 
of blood and exit-sites taken from the patient during the period that a catheter was in 
place were collected from the computerized data system of the department 
of microbiology. Baseline patient characteristics and demographical data were collected 
at time of insertion. In addition, hospitalization for non catheter-related reasons at 
any time a catheter was in place and nasal staphylococcal aureus carrier was documented. 
Data on two catheters (both untunneled straight jugular catheters) were lost to 
follow-up shortly after insertion because of transferral of the patient to another 
dialysis center. These were excluded from the analysis. 
Catheters, catheter care protocol and catheter outcome assessment
During the first 32 months of the study we used an untunneled dual lumen 
11 Fr polyurethane catheter with curved extensions (Gamcath®, Hechingen, Germany 
(n=89)) and dual lumen 11.5 Fr polyurethane catheter with curved extensions 
(Mahurkar, Tyco, Mansfield, MA, USA (n=15)) for the jugular site (figure 1a). After 
this period, we switched to a novel design untunneled dual lumen polyurethane catheter 
(11.5 Fr; Duo-Flow® IJ, Medcomp, Harleysville, USA) (figure 1b). For TCC we used Neostar 
Circle-C® (cuffed silicon, Horizon Medical Products, Atlanta, GA, USA; n=48), PermCath® 
cuffed silicon (Tyco, Mansfield, MA, USA; n=5), Tesio twin-cath® cuffed silicon (n=3) and 
Ash-split® cuffed polyurethane (both Medcomp; n=8). All catheters were inserted under 
local anaesthesia and strict asepsis, and sutured to the skin. All untunneled and tunneled 
cuffed catheters were inserted after cannulation of the internal jugular vein close to 
(about one cm above) the clavicle, low in the sternocleidomastoid triangle in accordance 
to the puncture technique described by Rao et al [7]. A standard Seldinger guidewire 
procedure was used to introduce the catheter. Care was given to insert the catheter 
including the first half of the curve. After insertion, the exit site should point forward to 
downward. Ultrasound guidance was used whenever considered necessary.
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Figure 1. Straight untunneled jugular catheter (a) and the novel precurved untunneled 
catheter (b). 
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Functional catheters at the end of the observation time and catheters removed because 
they were not needed anymore were analyzed as censored values. The log rank test 
was used to compare groups and identify individual risk factors associated with
 a premature removal or catheter-related infection. At an individual two-sided P value 
of < 0.1, the factor was included to fit a Cox-regression model. 
We used a forward stepwise conditional technique to identify the factors independently 
associated with catheter failure and infection. Differences were considered statistically 
significant for p less than 0.05.
Table 1.  Base line characteristics of the patients and catheters
Characteristic          Untunneled catheters Tunneled cuffed
Straight Precurved catheters
(n=104) (n=65) (n=64)
Catheter days (no.) 3209 2101 9124
Time left in place (mean (range))
        All catheters 31 (2-162) 35 (5-232) 142 (7-604)
        Uncomplicated catheters 30 (2-132) 32 (5-232) 146 (13-568)
        More than three months (%) 6 3 52
Right sided insertion (%) 84 91 88
Age (mean ± SD) 61.0 ± 13.8 58.7 ± 16.4 58.7 ± 14.7
Race
        Caucasian (%) 71 72 72
        Black (%) 18 20 19
        Other (%) 11 8 9
Male sex (%) 66 59 53
Yr of dialysis (mean ± SD) 1.2 ± 2.1* 1.3 ± 2.2 2.1 ± 2.5*
Cause of end stage renal disease
        Diabetes (%) 24* 11* 27*
        Renovascular (%) 20 11 11
        Polycystics disease (%) 8 11 14
        Glomerulonephritis (%) 13 22 17
        HIV (%) 1 2 1
        Other (%) 24 28 24
        Unknown (%) 10 15 6
Acute renal failure (%) 38** 29** 9**
Diabetes mellitus (%) 27 19 30
Cardiovascular disease (%)
Coumarin use (%) 8 ‡ 17 23 ‡
Immune suppression (%) 14 17 9
Malignancy (%) 9 3 5
Staphylococcus Aureus carrier (%) 48 45 44
Abbreviations: SD, standard deviation
*   P<0.05
** P<0.01
‡   P<0.01
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staff, using sterile gloves and masks. The semi-occlusive dressings we used for exit-site 
care, were inspected at every dialysis session and changed at least once a week, 
the exit-site being cleansed with a povidone-iodine solution. Before removing the caps, 
the catheter hubs were disinfected with a chlorhexidine solution (2.5%). After dialysis 
treatment, catheters were locked with unfractionated heparin (5000 U/ml) with a volume 
equivalent to the internal volume of the lumen noted on the catheter. Catheters were 
used for haemodialysis exclusively. Catheter-related bacteraemia (CRB) was defined 
as fever (temperature > 38ºC) or cold chills not during a dialysis treatment with at least 
one positive blood culture and no other obvious cause of infection. In patients who 
developed signs of bacteraemia without symptoms of an alternative source other than 
the catheter, at least two blood cultures either from the catheter or from a peripheral vein 
were taken. Subsequently, antibiotics for suspected catheter related bacteraemia were 
given. When a catheter-related bacteraemia was established, the catheter was left 
in place in stable patients in whom fever disappeared after initiation of antibiotic 
treatment. In patients not improving within 48 hours or with recurrent bacteraemia within 
three weeks after stopping antibiotic treatment, the catheter was removed. 
The policy was not different between untunneled catheters and tunneled cuffed catheters 
at our institution in the study period. In case of recurrent bacteraemia, only 
the first period was counted for the analysis.
Exit site infection was defined as the development of a purulent exudate or redness 
around the site not resulting from residual stitches. After culturing, antibiotic treatment 
was recommended for at least two weeks. In case of no improvement, the catheter had 
to be removed. 
Flow problems
In accordance to national guidelines, the minimal acceptable Qb was 200 ml/min, 
the target was 250 ml/min. More important, the minimal acceptable dialysis dose was 
a urea Kt/V of at least 1.2 per treatment. When this could not be reached, the flow 
or dialysis duration could be increased.  When a persistent inability to run a blood flow 
of more than 200 ml/min occurred despite positional changes of the patient and/or 
additional flushing, urokinase 10,000 IU/ml was installed in both pools with 
a volume equivalent to the internal volume of the lumen. After 15 minutes the urokinase 
was withdrawn. If a blood flow of more then 200 ml/min was not achieved after this 
procedure, 100,000-250,000 IU of urokinase could be infused in three hours during 
dialysis according to the protocol of Twardowski [8]. When this was not successful, 
the catheter was removed or exchanged.
Statistical analysis
Statistical analysis was performed with SPSS software 11.2 (SPSS Inc., Chicago, Ill, USA). 
Non parametric tests for two (Mann-Whitney U test) and multiple continuous variables 
(Kruskal-Wallis test) were used.  For comparing binary and categorical variables 
Chi-square and Fisher’s exact tests were applied where appropriate. ANOVA was used 
to compare age and time on dialysis between multiple groups. Kaplan-Meier survival 
curves were constructed to analyze the patency rates and infectious complications. 
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Of 65 UPC inserted, 55 (85%) could be used until they were not needed anymore 
compared to only 49 (47%) of 104 USC (relative risk for premature removal 
0.22; 95% CI 0.11-0.44; p<0.001). The rate of premature removal was reduced from 
17.1 to 4.3 per 1,000 catheter days after switching from USC to UPC.  Although 
not statistically different, premature removal rates were higher with UPC compared 
to TCC (2.4 vs 4.8 per 1,000 catheter days; p=0.11). Characteristics of premature removals 
are shown in table 2.There was a reduction of 11.5 to 0 removals for catheter-related 
infections per 1,000 catheter days after switching from USC to UPC (p<0.01). However, 
removals for flow problems were similar (5.0 vs 4.3 per 1,000 catheter days; p=0.27). TCC 
were characterized by less removals for infection (1.0 per 1,000 catheter days; p<0.001) 
compared to USC and less removals for flow problems compared to both untunneled 
catheter groups (1.0 per 1,000 catheter days; p<0.05) Log rank analysis of survival curves 
showed better rates for UPC compared to the USC group (p<0.0001) and similar rates 
compared to TCC (p=0.24, corrected for years on dialysis and acute renal failure) 
(figure 2). The risk for premature removal of TCC inserted before and after the switch from 
USC to UPC was not statistically different (relative risk 1.33; 95% CI 0.55-3.26; p=0.52).
Table 2b.  Summary of premature removals and catheter-related complications
Cox-regression analysis of outcome and
complications
UPC vs USC UPC vs TCC
Variable relative risk (95 percent confidence interval)
Premature removal
for any complication 0.22 (0.11-0.44); p<0.0001 1.48 (0.92-2.37); p=0.11
no. per 1000 cath. days
For any infection 0.02 (0.01-0.33); p=0.006 0.15 (0.01-5.80); p=0.08
no. per 1000 cath. days
For flow problems
no. per 1000 cath. days
For fracture / accidental /
removal / other
Catheter-rel. bacteremia 0.02 (0.01-0.97); p=0.048 0.16 (0.01-3.13); p=0.23
no. per 1000 cath. days
Exit-site infection 0.04 (0.01-0.29); p=0.002 0.36 (0.13-1.01); p=0.053
no. per 1000 cath. days
UPC denotes untunneled precurved catheters, USC denotes untunneled straight
catheters and TCC denotes tunneled cuffed catheters. Comparison between UPC and TCC
was corrected for years on dialysis and acute renal failure.
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A total of 233 haemodialysis catheters (14,434 catheter days) were included in 
the final analysis. There were 104 untunneled straight jugular catheters (USC) inserted, 
65 untunneled precurved jugular catheters (UPC) and 64 tunneled cuffed catheters 
(TCC). Patient and catheter characteristics are given in table 1. 
Of patients who had a TCC inserted, 91% was on chronic haemodialysis treatment 
in contrast to patients with an USC (62%, p<0.01) and to the group with an UPC 
(71%, p<0.01). Patients with an UPC had higher hospitalization rates for other 
than catheter-related reasons compared to TCC (54% vs 34%, p<0.05). Also, patients 
with UPC were less likely to have diabetes diagnosed as primary cause for end stage 
renal disease compared to TCC (p<0.05). Furthermore, patients with a TCC were 
on coumarin treatment more often (8 vs 23%, p<0.01). Other differences in patient 
characteristics were not statistically significant. Patient and catheter characteristics of TCC 
inserted before (n=31) and after (n=33) the switch from USC to UPC, were similar. Most 
catheters were right sided (87%). Since there was no significant difference in outcome 
between catheters inserted in the right or left jugular vein, they were not separated in 
the definite analysis. 
Table 2a.  Summary of premature removals and catheter-related complications
Untunneled Tunneled
catheters cuffed
catheters
Straight Precurved
n (=104) n (=65) n (=64)
Variable no. of events (%)
Premature removal
for any complication 55 (53) 10 (15) 22 (34)
no. per 1000 cath. days 17.1 4.3 2.4
For any infection 37 (36) 0 9 (14)
no. per 1000 cath. days 11.5 0 1.0
For flow problems 16 (15) 9 (14) 9 (14)
no. per 1000 cath. days 5.0 4.3 1.0
For fracture / accidental /
removal / other 2 (2) 1 (2) 0.4
Catheter-rel. bacteremia 18 (17) 0 16 (25)
no. per 1000 cath. days 5.6 0 1.8
Exit-site infection 32 (31) 0 14 (22)
no. per 1000 cath. days 10.0 0 1.5
UPC denotes untunneled precurved catheters, USC denotes untunneled straight
catheters and TCC denotes tunneled cuffed catheters. Comparison between UPC and TCC
was corrected for years on dialysis and acute renal failure.
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Figure 3a. Kaplan-Meier curves of probability of infection free survival for untunneled pre-
curved jugular catheters (UPC) (—) compared to untunneled straight jugular catheters (USC) 
(—) (p<0.001 by log rank statistics) and tunneled cuffed catheters 
(TCC)  (—) (p=0.006 by log rank statistics, corrected for years on dialysis and acute renal 
failure). Tick marks indicate censored catheters.
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Figure 2. Kaplan-Meier curves of cumulative catheter patency for untunneled precurved 
jugular catheters (UPC) (—) compared to untunneled straight jugular catheters 
(USC) (—) (p<0.001 by log rank statistics) and tunneled cuffed catheters 
(TCC) (—) (p=0.24 by log rank statistics, , corrected for years on dialysis and acute renal 
failure). Tick marks indicate censored catheters.
i n F e c t i o u S  c o m p l i c at i o n S
In patients with an UPC inserted, no episodes of catheter-related bacteraemia (CRB) 
occurred. One catheter was instantly removed in an immune compromised patient 
who presented with fever. However, an alternative diagnosis was made during follow up. 
There was a reduction of CRB episodes after switching from USC to UPC 
(5.6 to 0 per 1,000 catheter days; p<0.001 by log rank testing) (figure 3a). CRB rates of UPC 
were also lower compared to TCC (0 vs 1.8 per 1,000 catheter days; p=0.04 by log rank 
testing) (figure 3b). 
Exit-site infection rates were also lower after introduction of UPC compared to both USC 
and TCC. Differences in CRB and exit-site infection rates within the catheter groups are 
presented in table 2. The risk for CRB and exit-site infection in the TCC group during both 
periods was equal (relative risk 1.01; 95% CI 0.47-2.17; p=0.97).
In 42% of cases cultures yielded gram-positive micro organisms, predominantly 
Staphylococcus aureus or Staphylococcus epidermidis, in 34% it concerned 
gram-negative micro organisms. The remaining cultures revealed multiple 
micro organisms or yeasts. 
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exit-site, adequate drainage of debris is prohibited and colonization of the catheter 
exit-site promoted which can cause local infection and subsequent systemic infection. 
Therefore, in peritoneal dialysis catheter management a downward directed exit-site 
is recommended.
Exit-site colonization can also lead to catheter hub colonization and subsequent 
bacteraemia. This could also be an explanation for the differences found in this study, but 
as regular cultures of the hub were not performed, this remains speculative. 
The same reduction of colonization and infections in exit-sites that permit an adequate 
drainage could also be the reason that in recent studies untunneled temporary straight 
jugular catheter had higher rates of infectious complications compared to untunneled 
subclavian catheters [3;4]. The precurved untunneled catheter used in this study has 
the advantage of a forward to downward directed exit-site that makes adequate drainage 
of debris possible. The improved fixation properties and exit-site direction are likely 
the most important explanation for the reduction of infection rates in untunneled 
precurved catheters compared to untunneled straight catheters. As overall outcome 
between UPC and TCC was not different, UPC can be an attractive alternative for 
the time period studied. Possibly infectious data might have differed slightly because
the mean time UPC were left in place was shorter than for TCC and infectious rates 
can rise over time.
There are limitations to our study. The prospective sequential cohort analysis of the USC 
and UPC respectively, instead of a randomized design, could have led to bias due 
to unnoticed differences in time, not accounted for by baseline characteristics. 
Furthermore, the propensity for inserting a TCC instead of an uncuffed catheter might 
have changed over time. However, since outcome in TCC in the two time periods did 
not change, this probably did not influence the results. Also, the analysis between 
the uncuffed catheters on the one hand and the TCC on the other might be biased due 
to lack of randomisation and differences in indication.
There were observed differences in baseline characteristics, like the presence of diabetes 
and the incidence of acute renal failure. However, in contrast to many other studies, we 
corrected for these differences in the outcome analysis.
Previous studies in tunnelled catheters have suggested that catheter-related 
complications, especially infections, are constant over time or tend to decrease [3;11;12]. 
Furthermore, as shown in the Choice study, few patients will need a catheter for more 
than three months [13]. Considering catheter-related infections as major drawback 
for catheter use, our results show that an untunneled precurved catheter for the period 
of three months could be a safe option, more convenient for the patient and physician 
during insertion and probably cost-saving. Compared to TCC, these catheters are six 
to eightfold less expensive. This is in contrast with the NKF-DOQI guidelines which state 
that a tunnelized catheter should be used whenever it can be foreseen that a catheter 
is needed for more than 2 to 4 weeks [1]. However, these guidelines are predominantly 
expert based or supported by studies with untunneled straight catheters including 
our own [3;4].
Compared to tunneled cuffed catheters, more untunneled precurved catheters had to be 
removed for flow problems. This was probably caused by the fact that 
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Figure 3b. Kaplan-Meier curves of probability of catheter-related bacteremia free survival for 
untunneled precurved jugular catheters (UPC) (—) compared to untunneled straight jugular 
catheters (USC) (—) (p<0.001 by log rank statistics) and tunneled cuffed catheters (TCC)  
(—) (p=0.042 by log rank statistics, corrected for years on dialysis 
and acute renal failure). Tick marks indicate censored catheters.
d i S c u S S i o n
Our study demonstrates that a novel design forward bended precurved haemodialysis 
catheter inserted in the low jugular site has a better survival and lower risk for infection 
compared to a straight jugular catheter. 
There are some possible explanations for these findings. In the present study 
the reduction of exit-site infections for UPC (0 per 1,000 catheter days) compared 
to USC (10 per 1,000 catheter days) was remarkable and this probably partially explained 
the reduction in catheter-related bacteraemia. An important problem of USC is that 
an adequate fixation is difficult and that they are uncomfortable for the patient because 
neck and head movements are limited.  Inadequate fixation and discomfort leads to 
more manipulation, sliding of the catheter through its port and can easily give laceration 
and secondary infection of the exit-site. These are well known risk factors for subsequent 
catheter-related bacteraemia [9;10]. In addition, straight jugular catheters have 
an upward directed exit site. In peritoneal dialysis catheters, this is a well established risk 
factor for exit-site infections and peritonitis [5;6]. Probably, with an upward directed 
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tunnelled cuffed catheters have a 2–3 Fr larger diameter and the flow resistance is related 
proportional to the diameter of a catheter to the fourth power. Therefore, it is clear 
that flow characteristics are better in tunneled cuffed catheters and that there 
is more flow reserve in the case of partial obstruction. Probably, the function 
of untunneled precurved catheters can be improved by increasing its diameter and 
tip construction [14].
Another confounding factor in catheter studies influencing the outcome of catheters 
is the catheter care protocol. It has been shown in randomized studies that the risk 
for CRB can be reduced with a thorough protocol [15;16]. In our study, catheter care 
protocol was not changed over the entire observation period and the incidence 
of catheter-related infections of tunneled cuffed catheters in the time periods untunneled 
straight catheters (first period) or untunneled precurved catheters (second period) were 
used, were not statistically different making a time bias and differences in catheter care 
as explanation for our findings unlikely. 
In conclusion, our study demonstrates that in addition to improved patient comfort, 
an untunneled precurved jugular haemodialysis catheter has better patency rates and 
a lower risk for infection compared to a straight jugular catheter with curved extensions. 
The risk for bacteraemia and exit-site infection is comparable to tunneled cuffed catheters 
for the first three months these catheters are left in place.
This novel design precurved catheter placed in the lower jugular position should 
be preferred as untunneled jugular catheter model over straight models with curved 
extensions and can be used safely when it can be foreseen that a catheter is needed 
for up to three months. Our results make a prospective randomized trial comparing TCC 
to UPC with wider inner diameter an important issue for the future.
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c a S e
A 50-year old woman was referred to our hemodialysis department in August 1999 
because of end stage renal failure due to diabetic nephropathy. Because of late referral 
an AV-fistula had not been formed in the patient. Therefore, a tunneled double-lumen 
silicone hemodialysis catheter (AC 230C, Neostar Circle C, 13,5 F, length 23 cm, 
Horizon Medical Products, Atlanta, GA) was placed in the right jugular vein under local 
anesthesia. Subcutaneous tunneling was performed according to the instructions 
provided by the manufacturer. The procedure was uneventful and a chest X-ray (anterior-
posterior and lateral view) after the procedure disclosed an intact catheter with 
the tip in the right atrium. The catheter was used for hemodialysis treatment two times a 
week aiming at a bloodflow of 250 ml/min and low molecular weight heparin 
for anticoagulation. At the end of each dialysis session unfractionated heparin 
(5000 IU/ml) was instilled for locking. After nine months the catheter could be removed 
because a functioning AV-graft was available. Monthly measured Kt/V and urea-reduction 
rates had remained stable over the period of insertion and venous return pressures had 
not exceeded 170 mmHg. Three periods of intraluminal catheter thrombosis had 
been successfully treated with a fifteen-minute installation of urokinase (10.000 U/ml). 
Catheter stripping or intraluminal manipulations with guidewires or brushes had 
not been performed and no infections were observed. Removal of the catheter took place 
without any difficulties. No excessive pulling was needed. The procedure was uneventful 
and the patient mentioned no complaints. After removal, the catheter-tip appeared to 
be broken of (Figure 1). 
Figure 1. Tip of the broken and an intact catheter.
analysis of a spontaneous hemodialysis c atheter frac ture
a b S t r a c t
Central venous catheters have become increasingly important in hemodialysis treatment. 
With their increased use catheter-related problems will be seen more frequently and 
more rare complications may be observed. We describe the first case of an asymptomatic 
spontaneous breakdown of a tunneled cuffed silicone catheter used for long-term 
hemodialysis treatment. This was discovered on removal of the catheter, leaving behind 
a catheter fragment in the left lower pulmonary lobe. An extensive scanning electron 
microscopy study showed accumulation of lumps of non-silicone material at the place 
of the fracture leading to severe disruption of the original cross-linked elastomer 
structure. Utilizing energy dispersive X-ray spectral analysis, that reveals all elements 
with atomic number of eleven and up in a material, we found the lumps to be aggregates 
of bariumsulphate particles used to visualize the catheter on fluoroscopy. We suggest that 
the use of too small or too much bariumsulphate particles has led to high viscosity of 
the raw silicone before polymerization, causing improper mixing of bariumsulphate 
particles in the silicone matrix. This resulted in insufficient removal of admixed airbubbles 
and unequal dispersion of bariumsulphate with the potential for weak spots after 
extrusion of the silicone into its definitive shape. With the increasing use of hemodialysis 
catheters for prolonged times, catheter-related complications, related to materials 
or manufacturing errors can be expected to occur more often.
i n t r o d u c t i o n
Hemodialysis treatment requires reliable access to the circulation. An arteriovenous (AV) 
fistula or an AV-graft is recommended for chronic treatment.¹ In a recent survey³ however, 
only 34% of hemodialysis patients had a functional permanent AV access at the start of 
treatment. At present tunneled cuffed hemodialysis catheters have come 
to play an increasingly important role in the delivery of hemodialysis treatment.² 
Currently, approximately 19% of all hemodialysis patients in the United States have 
a catheter as access for chronic hemodialysis treatment. The two major complications of 
hemodialysis catheters are thrombosis and catheter-related infections. With its growing 
use it can be anticipated that material and manufacturing problems will be observed 
increasingly. We report a spontaneous fracture of a silicone hemodialysis catheter leaving 
behind a fragment in the lung. Scanning electron microscopy revealed the cause of 
the fracture. 
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Figure 3. Scanning electron microscopy analysis.
A. Overview of the fracture. In the circle the abnormal surface and structure is visible
 including a tear (arrow) where the fracture started. The oval shows a part of the catheter 
 with a very irregular surface. In the rectangle the normal surface structure is apparent. 
B. Detail from the white circle in A.
C. Further magnification of B, showing a lumpy texture full of voids lacking internal 
 cohesion and beginning ruptures.
D. A bariumsulphate lump with backscatter technic clearly shows entrapped air, causing 
 a weakness zone in the silicone matrix.
E. Normal smooth inner surface of the catheter.
F. Porous surface in the rupture zone (C) showing aggregates of bariumsulphate with 
 admixed air without the normal continuous phase of cross-linked elastomer 
 recognizable.
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Figure 2. Fragment of the catheter in the left lower pulmonary lobe. 
On the left side the posterior border of the heart is visible.
A chest X-ray showed the tip of the catheter in the lower lobe of the left lung 
(Figure 2). No clinical or radiographical signs of inflammation or pulmonary embolism 
have developed until now.
Scanning electron microscopy of the catheter showed multiple spots with aggregates 
of particles causing irregular cavities in the solid structure of the silicone rubber 
(Figure 3f ). At the place of the fracture these aggregates had formed a large lump. 
The original cross-linked elastomer structure of the silicone was not recognizable 
anymore and the tear that started the rupture was visible (Figure 3a,b). 
Energy dispersive X-ray spectral analysis showed the particles to be bariumsulphate 
grains used to visualize the catheter on X-ray.
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Fortunately, until now the patient experiences no complaints of the fragment in 
the left lung. Percutaneous transvenous snare technique is the therapy of choice 
to retrieve dislocated fragments. However, due to the peripheral position of the fragment 
in our patient the only possible way to remove it would be a segmental resection of 
the pulmonary lobe. Since catheter fragments have been left in place for a long time 
without complications4 and our patient has no complaints, we decided to leave 
the fragment in place.
In the aforementioned two reports of hemodialysis catheter breakdown a clear reason 
was not found9.10, suggesting the possibility of a catheter construction problem also. 
However, electron microscopy had not been performed. With the increasing use 
of hemodialysis catheters for prolonged times, catheter-related complications, related 
to materials or manufacturing errors can be expected to occur more often.
We would like to acknowledge W.J. Lustenhouwer, Microanalytical Laboratory, and Faculty 
of earth sciences, for the interpretation of the scanning electron microscopy analysis.
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d i S c u S S i o n
To our knowledge this is the first report of a ruptured hemodialysis catheter leaving 
behind an intravascular fragment. Spontaneous catheter fractures with fragments 
remaining intravascular have been reported mainly in patients with not used for 
hemodialysis.4-5 The exact incidence of catheter rupture is unknown. Recently 
Biffi et al reported an incidence of 0,68% in 1320 subclavian port placements.6 
Mainly such fragmentation concerned catheters inserted in the subclavian vein with 
the fracture at the place of passage under the clavicle, the so called “pinch-off” syndrome.7 
Catheter fragments may cause severe complications like cardiac arrest, vascular 
perforation and pulmonary embolism.8 Recently two cases of spontaneous breakdown of 
a hemodialysis catheter have been reported one causing extensive recirculation9, 
the other leakage10 but no free fragment developed. In both cases the exact cause was 
not unraveled.
In our case it is not likely that the rupture was caused by accidental damage to 
the catheter at insertion or removal. On insertion no problems were encountered and 
no manipulations with the tip of the catheter had been performed. The initial chest X-ray 
showed an intact catheter with the tip in a normal position. During the period of insertion 
no guidewires or brushes had been used. Urokinase, installed three times, is a proteolytic 
enzyme that is not known to degradate polymer structures. Therefore, it seems unlikely 
that its administration affected the structure of the silicone.
In the present case the most likely cause is an error in the manufacturing process. 
By extensive scanning electron microscopy and energy dispersive X-ray spectral analysis 
(that reveals all elements with atomic numbers of eleven and up in a material) we could 
demonstrate that the bariumsulphate particles, used to visualize a catheter 
on fluoroscopy, were not properly mixed in the silicone rubber matrix. 
Ideally all powder particles should be separately dispersed in the raw silicone material 
before polymerization to preserve tensile strength as much as possible.11 In the studied 
catheter, however, bariumsulphate particles formed aggregates of variable size. 
The larger bariumsulphate powder lumps have trapped airbubbles that formed elongated 
cavities on extrusion. These cavities are clearly visible, both as irregular disruption of 
the surface (Figure 3b) and as voids within the silicone matrix (Figure 3f ). The presence of 
these powder lumps points to insufficient mixing, probably caused by the particle size 
of the bariumsulphate powder. For a given amount of powder, the size of bariumsulphate 
particles defines the number. The bigger the number is, the greater the total surface 
of the powder resulting in a higher viscosity of the silicone paste after mixing. 
This hampers removal of admixed airbubbles from the suspension before extrusion 
to its final shape. Because the amount of bariumsulphate is defined by the grade of X-ray 
contrast needed for fluoroscopy, the only way to lower the total surface of the powder 
and lower the viscosity of the suspension is using a coarser particle size.
Biodegradation and breakdown of silicone caused by chronic inflammation 
in a biofilm and production of strong oxidants by bacteria have been described.12 
Neu et al showed that microorganisms can grow into silicone material, causing 
deterioration of the material.13 However, on scanning electron microscopy we could not 
detect microorganisms in the rupture, nor in the cavities with bariumsulphate particles.
chapter 5a
72 73
analysis of a spontaneous hemodialysis c atheter frac ture
r e F e r e n c e S
1.   NKF-DOQI clinical practice guidelines for vascular access. National Kidney 
  Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30:S150-S191, 1997
2.  Schwab SJ, Buller GL, McCann RL, Bollinger RR, Stickel DL: Prospective evaluation of 
  a Dacron cuffed hemodialysis catheter for prolonged use. 
  Am J Kidney Dis 11:166-169, 1988
3.  Stehman-Breen CO, Sherrard DJ, Gillen D, Caps M: Determinants of type and timing of 
  initial permanent hemodialysis vascular access. Kidney Int 57:639-645, 2000
4.  Richardson JD, Grover FL, Trinkle JK: Intravenous catheter emboli. Experience with 
  twenty cases and collective review. Am J Surg 128:722-727, 1974
5.  Biffi R, Corrado F, de Braud F, de Lucia F, Scarpa D, Testori A, Orsi F, Bellomi M, 
  Mauri S, Aapro M, Andreoni B: Long-term, totally implantable central venous access
  ports connected to a Groshong catheter for chemotherapy of solid tumours: 
  experience from 178 cases using a single type of device. 
  Eur J Cancer 33:1190-1194, 1997
6.  Biffi R, Pozzi S, Orsi F, Grasso F, De Braud F, Cenciarelli S, Andreoni B: Catheter rupture 
  and distal embolisation: a rare complication of central venous ports. 
  J Vasc Access 1:19-22, 2000
7.  Aitken DR, Minton JP: The “pinch-off sign”: a warning of impending problems with 
  permanent subclavian catheters. Am J Surg 148:633-636, 1984
8.  Uflacker R, Lima S, Melichar AC: Intravascular foreign bodies: percutaneous retrieval. 
  Radiology 160:731-735, 1986
9.  Sarnak MJ, Halin N, King AJ: Severe access recirculation secondary to free flow 
  between the lumens of a dual-lumen dialysis catheter. 
  Am J Kidney Dis 33:1168-1170, 1999
10. Verhage AH, van Bommel EF: Catheter fracture-an underrecognized and serious
  condition in haemodialysis. Nephrol Dial Transplant 15:901-903, 2000
11. Silver FH, Christiansen DL: Biomaterials Science and Biocompatibility (ed 1). 
  New York, NY, Springer-Verlag, 1999, pp 89-106
12.  Williams DF, Zhong S.P.: Are free radicals involved in biodegradation of implanted
  polymers. Adv Mater 3:623-626, 1991
13.  Neu TR, Van der Mei HC, Busscher HJ, Dijk F, Verkerke GJ: Biodeterioration 
  of medical-grade silicone rubber used for voice prostheses: a SEM study. 
  Biomaterials 14:459-464, 1993
chapter 5a
Do catheter side holes provide better blood flows? 
Dirk S de Wachter, Marcel C Weijmer, Mantas Kausylas, Pascal M Verdonk. 
Hydraulics Laboratory, Institute Biomedical Technology, Ghent University, Gent, Belgium
Dept. of nephrology, Vrije Universiteit Medical Center, Amsterdam
Hemodialysis International 2002;6:40-46
5b   Clinical implications of hemodialysis 
catheter construction
5
76 77
i n t r o d u c t i o n
Central venous catheters have earned their place among the different methods of 
vascular access for hemodialysis (HD). Apart from their use in situations where immediate 
access to the blood is required [1, 2], catheters are increasingly employed for the delivery 
of dialysis to patients with end-stage renal disease [3]. This has increased interest in 
the performance of catheters to provide adequate dialysis and, consequently guidelines 
have been set forth [4]. The National Kidney Foundation-Dialysis Outcomes Quality 
Initiative (NKF-DOQI) guidelines [5] set the lower limit to 300 ml/min for extracorporeal 
blood flow to be able to treat the patient without need for lengthening the duration of 
the procedure. Yet, due to frequent infection and thrombosis, catheters show the lowest 
patency rate of all current methods of HD access [6]. Thrombus formation in most cases is 
easily remedied by means of a thrombolytic agent [7,8]. However, infection is 
a more severe problem, the rate of which depends not only on the catheter handling 
[9,10] in the dialysis unit and by the patient, but also on the biocompatibility of 
the catheter material [11-13]. The same accounts for thrombogenesis on the inner
or outer surface of the catheter [14], although local hemodynamics also play a role 
in this process [15].
Catheters serve a simple purpose: to guide the venous blood towards the HD machine 
and bring it back into the venous system in a safe ane reliable way. Therefore, 
it is remarkable that the geometrical designs of their blood conduits and tips differ 
substantially [16,17]. Different catheters are equipped with a number of side-holes 
of various sizes and positions on the catheter wall. The common belief is that multiple side 
holes are needed to provide backup in case the apical or some of the side holes become 
obstructed by venous wall suction or a fibrin sleeve [14,17]. However, it has never been 
thoroughly investigated whether these side holes are able to allow the required blood 
flow rate. In addition, the absence of any adverse effects through the presence of these 
holes has not been well studied. Schwarzmann and Sefrin [18] concluded that a catheter 
with multiple holes does not show any advantage as far as thrombogenicity is concerned. 
Twardowski and Moore [19] suggested that side-holes predispose to the formation 
of thrombi, as they observed, using scanning electron microscopy, rough edges of holes 
and clots firmly anchored to the holes of removed catheters.
The goal of the present study was to measure the performance of dual-lumen catheters in 
an in vitro setup by studying their pressure-flow relationships. We also investigated 
the influence of closing off some of the side-holes to see if that would impact 
the performance.
m at e r i a l S  a n d  m e t H o d S
To obtain reproducible pressure-flow relationships under standardized conditions, 
a dedicated in vitro measurement setup was built. The setup consisted of two reservoirs 
connected by two recirculation loops (Fig.1). The upper reservoir’s fluid level was kept 
constant by continuous recirculation from the bottom reservoir and an overflow tube. 
This ensured that a constant pressure of about 2 mmHg is present at the catheter tip. 
The second recirculation loop was made up partly of the catheter circuit; the other part 
was shared with the first recirculation loop. The catheter circuit either ran from the lower 
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a b S t r a c t
Four catheters (Ash Split Cath, Tesio, Duo-Split and DuoFlow; Medcomp, Harleysville, PA, 
U.S.A.) were  tested in a temperature-controlled in vitro setup filled with 50% aqueous 
glycerine solution, to determine hydraulic resistance at different flow rates. 
All these catheters have side holes; hydraulic resistance was determined with these holes 
open or closed. Due to extra pressure losses near the catheter tip, the pressure-flow 
relationship deviates from Poiseuillian theory and is generally quadratic in nature. 
An equivalent diameter was derived from the data. This equivalent diameter can be used 
to evaluate performance using a single number.
Permanent catheters can easily deliver 300 ml/min under optimal circumstances, 
but acute catheters are, In practice, limited to 200 ml/min and even somewhat less in 
the coaxial Duo-Flow type. Permanent catheters have larger equivalent internal diameters 
(1.8 vs. 1.45 mm). Covering the side holes does not influence the hydraulic resistance 
to a great degree, except in the arterial limb of acute catheters. These results indicate 
that, especially in acute catheters, obstruction of the side holes or fibrinsleeve/thrombus 
formation over the inlet holes may severely impact the available blood flow rate during 
dialysis. On the other hand, side holes in permanent catheters or venous limbs seem 
to be superfluous for performance reasons.
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pressure differences were obtained by taking the average of an even number of periods. 
All averaged points were used  to fit a parabolic equation through the origin [Eq. (1)], 
stating the pressure drop (ΔP)-flow rate (Q) relationship of the catheter lumen. 
The parabolic equation was obtained by polynomial regression 
(Sigmaplot, SPSS Inc., Erkrath, Germany);
            ΔP = aQ + bQ2.      (1)
Care was taken to ensure both parameters (a and b) of the fit-equation were statistically 
significant (p<0.05) to describe the data set. Performance can also be characterized by 
the hydraulic resistance (R), which is not constant as the Poiseuille equation suggests, but 
a linear function of the flow rate [Eq. (2)]:
            R = ΔP/Q = a + bQ.     (2)
To compare the different catheters in a standard manner, the concept of equivalent 
diameter (De) was used. The De is determined from the effective diameter (Deff). The Deff is 
defined as the internal diameter that a circular tube with the same length (L) as 
the catheter lumen should have, to exhibit the same pressure drop as the catheter under 
study at a particular flow rate. For laminar flow it is derived from the well-known Poiseuille 
equation and is defined by Eq. (3):
            Deff = (128µLQ/πΔP)¼.  (3)
Deff should be independent on the fluid’s dynamic viscosity (µ), as its effect is cancelled by 
the flow/pressure drop ratio. However, Deff depends on the flow rate because of special 
pressure losses in the catheter that are not linearly proportional to the flow rate. 
For a As a reasonable approximation, it can be assumed that Deff varies quadratically with 
the Reynolds number (Re). Therefore, the actual De is obtained in an iterative fashion as 
the Deff at Re=1000 on the polynomial regression line that is fitted through all Deff in 
the laminar range. Reynolds number (Re) is defined as:
            Re = 4ρQ/πDeμ      (4)
Where Deff  is the density of the glycerin solution (1128 kg/m³). Since the most correct 
results are obtained at equal Re numbers for blood and test fluid [21], and since 
the ratio of the viscosity to density determines the Re number, a slightly elevated viscosity 
was used for the test fluid to correct for the higher density of the glycerin mixture with 
respect to whole blood. The higher the pressure drop is at Re=1000, the lower 
the Deff  becomes. At Re=1000, a flow rate of about 350 ml/minute was attained in 
this set-up for the permanent catheters, and about 250 ml/minute for the acute catheters.
In this study, four catheters with side holes were tested: two permanent 
(Ash Split Cath 14Fr, 28cm; Tesio 10Fr, 30cm (Medcomp, Harleyville, PA, U.S.A.) and 
two acute (Duo-Flow 11.5Fr, 20cm; Duo-Split 12.5Fr, 20cm (Medcomp)). 
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reservoir and through a dialysis roller pump to the venous lumen of the catheter, or 
it starts at the upper reservoir and pased through the arterial lumen of the catheter and 
the dialysis roller pump to the lower reservoir. The circuit is filled with a 50/50% aqueous 
solution of water and glycerine and kept at a constant temperature of 30°C using 
a controlled coil heater. This ensured that the viscosity remained constant at 4.8 mPa 
(or cP), slightly elevated to actual blood viscosity at normal hematocrits (40-45%) 
for reasons explained later. Dialysis patients have a similar blood viscosity due 
to elevated plasma viscosity, increased red blood cell (RBC) aggregation, and decreased 
RBC deformability [20].
Figure 1. Overview of the measurement set-up. The catheter tip is in the constant level 
reservoir. The dialysis pump either pumps the fluid into the venous lumen or draws it from the 
arterial lumen.
Flow rate was determined by an ultrasound transit-time clamp-on flow meter 
(Transonic, Ithaca, NY, U.S.A.), 10-point calibrated for the glycerine solution by 
a gravimetric method over the total measurement range of 0 - 500 ml/minute. 
The pressure drop over the catheter was measured with a differential pressure transmitter 
(Fuji electric, Erlangen, Germany) set to full scale (300 mmHg or 40 kPa). 
The pressure inputs of the transmitter were connected to the Luer lock of the lumen and 
to the constant level reservoir for reference. Both electronic devices were connected to
a computer data-acquisition system (National Instruments, Zaventem, Belgium) for data 
processing. 
The roller pump speed was gradually adjusted to increase the flow rate through 
the catheter. To determine a single data point, flow rate and pressures were recorded 
during a finite time, with a sampling rate of 200/second. Due to roller pump operation, 
these curves exhibit a periodical pattern. To level out the pulsatility of the roller pump  
and the eventual unequal occlusivity of the two rollers, mean levels of flow rates and 
Constant level reservoir
Catheter under test
arterial lumen
venous lumen
Flow
meterMain reservoir,
temperature controlled
Dialysis rollerpump
Differential
Pressure
Transmitter
2 mmHG
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Figure 3. Hydraulic resistance in Tesio twin catheters (arterial: triangle; venous: circle) is 
a linear function of the flow rate. At higher flow rates higher resistances are found. 
Closing of the side holes (hollow) shifts the regression lines obtained with open side holes 
(filled) upwards, but does not alter the slope.
The arterial curves (triangles) initially lie below the venous curves, perhaps due to 
their shorter length; however,  due to extra pressure losses, the arterial curves are 
more quadratic and overtake the venous curves at around 400 ml/min. As an example 
of hydraulic resistance, the results for the Tesio twin catheters are plotted in Fig. 3. 
In this measurement, the hydraulic resistance of arterial limbs is lowest at low flow rates, 
and highest at moderate to high flow rates. It should be noted that the effect of closing 
the side holes is expressed in the upward shift of the curves, which the greatest effect in 
the arterial limb. This signifies that the y-intercept (constant a, Eq. (2)) has been increased 
by about 15% - 20%. As the quadratic content (influence of parameter b) in this catheter is 
small for the usual range of flow rates, this limited increase in intercept has only 
a mild effect on pressure drop (Eq. (1)).
The calculated De‘s are listed in Table1. 
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These catheters differ not only in number and position of side holes, but also in 
basic geometry. The Ash Split Cath and Duo-Split are both double-D catheters [17]. 
The difference between these two catheters lies in the number of larger side holes: 
2 in Ash Split Cath and 6 in Duo-Split. They both have a circular tip lumen with smaller 
diameter, but the Ash Split Cath has 6 small side holes and the Duo-Split has none. 
Twin Tesio catheters come with identical single-lumen pairs, each with 6 side-holes laid 
out in a spiral pattern. The Duo-Flow is a coaxial catheter with tapered venous tip and 
4 side holes for each lumen.
Different test runs were performed for each catheter: once with the actual catheter and 
then with some side holes masked with tape, thus effectively preventing any flow through 
them. For both Ash Split Cath and the Tesio catheters, all side holes were closed; for 
Duo-Split and Duo-Flow catheters, only two side holes in each lumen were masked 
because, otherwise, the flow rate would become too restricted in the Duo-Split and 
impossible for the Duo-Flow.
r e S u lt S
As an example, in Fig. 2 the fitted parabolic equations for Ash Split  Cath measurements 
are shown, together with averaged data points. The fit lines follow the data points closely, 
with good correlation indices and small standard errors on the fit line parameters (a,b). 
Black symbols signify open side holes and white symbols closed holes. All curves lie 
close together; pressures are somewhat elevated with side holes closed. 
Figure 2. Measured and fitted quadratic pressure-flow relationships in both limbs (arterial: 
triangle; venous: circle) of the Ash Split catheter with (filled) and without 
side-holes (hollow).
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Again, a distinction can be made between acute and permanent catheters: in the latter, 
the pressure difference is usually below 200 mmHg, except when side holes are closed. 
However, even in this case, the increase in pressure difference is minor. 
In acute catheters, pressure differences greater than 300 mmHg are needed to maintain 
flows. We measured the flow rates that can be obtained with a reasonable pressure drop 
of 200 mmHg over the catheter length (Table III). In the permanent catheters, a flow rate 
of over 300 ml/min is easily attained, but becomes slightly lower when the side holes 
are occluded. Contrary to what Table I may suggest, there is a performance difference 
between the coaxial catheter (Duo-Flow) and the double-D shaped design (Duo-Split).  
Without occlusion of the side holes, the former attains a 10% (venous limb) 
to 25% (arterial limb) lower flow rate than the latter.
d i S c u S S i o n
Our in vitro study comparing the performance of double-lumen HD catheters 
demonstrates that the De derived from the pressure-flow relationship in permanent 
catheters is larger than the diameter of acute catheters. Generally, in medical 
and dialysis-related literature, the pressure-flow relationship is described by Poiseuille’s 
equation [22], which states that the pressure difference varies linearly with the flow rate 
and is inversely proportional to diameter to the fourth power. While this is true for 
the ideal case of a Newtonian fluid flowing through a circular tube, and neglecting 
end effects, this is not the true for catheters. Although double-D shaped lumens also 
render a linear relationship as described by Poiseuille. The deviation from linearity 
in catheters is related to the extra pressure losses that occur at the entrance and exit 
of the catheter. Inflow through, or outflow from, side holes and tapered tips creates 
local velocity changes both in direction and magnitude. Hence, the pressure-flow 
relationship is a quadratic, as shown for the Ash Split Cath in Fig. 2. The De‘s (Table I) may 
seem rather small compared to actual diameters (e.g. Tesio 8.5 Fr versus 10 Fr advertised). 
The reason for this phenomenon relates to the fact that De is based on performance 
characteristics, which include the effect of extra in- and outflow pressure losses.  
Table 3.  The flow rate (ml/min) through the cannula at a pressure drop of 200 mmHg.
Catheter Holes Arterial Venous
Ash Split Open 337 322
14Frx28cm All Closed 330 (-2%) 286 (-11%)
Tesio Open 290 303
2x10FRx30cm All Closed 250 (-14%) 274 (-10%)
Duo Split Open 209 198
12.5Frx20cm Two Closed 99 (-53%) 196 (-1%)
Duo Flow Open 155 178
11.5Frx20cm Two Closed 92 (-41%) 169 (-5%)
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A clear distinction can be made between the larger and longer permanent catheters and 
the shorter and smaller acute catheters. The permanent catheter group has an De of 
about 1.8 mm (internal diameter). A tube with this size and an assumed typical wall 
thickness of 0.5 mm would correspond to about 8.5 Fr (outer diameter). The acute group 
has much lower De ‘s, about 1.45 mm. (about 7.5 Fr OD).  Closing the side holes has nearly 
no effect in permanent catheters (maximum decrease of 5%) or in the venous limb 
of acute catheters. However, for the arterial limb of acute catheters, De decreases 
significantly (about 20%) when two holes are closed. Since in all catheters except 
the  Duo-Flow, the tip geometry of both limbs is equal, and since this tip geometry has  
a major impact on the performance, the same De is expected in each of these catheters.
A small difference of 1% - 3% in favor of the venous limb is observed as outflow produces 
no or smaller special pressure losses compared to inflow. The absolute value of 
the pressure drop over the length of catheters at a test fluid rate of 300 ml/min 
is listed in Table II.
Table 1.  The equivalent diameters of the catheters for both limbs (in millimetres)
Catheter Holes Arterial Venous
Ash Split Open 1.79 1.83
14Frx28cm All Closed 1.77 (-1%) 1.77 (-3%)
Tesio Open 1.79 1.81
2x10FRx30cm All Closed 1.70 (-5%) 1.76 (-3%)
Duo Split Open 1.42 1.47
12.5Frx20cm Two Closed 1.10 (-23%) 1.47 (0%)
Duo Flow Open 1.38 1.45
11.5Frx20cm Two Closed 1.15 (-17%) 1.45 (0%)
Table 2.  The pressure drop (mmHg) over the catheter at 300ml/min.
Catheter Holes Arterial Venous
Ash Split Open 1.79 1.83
14Frx28cm All Closed 1.77 (-1%) 1.77 (-3%)
Tesio Open 1.79 1.81
2x10FRx30cm All Closed 1.70 (-5%) 1.76 (-3%)
Duo Split Open 1.42 1.47
12.5Frx20cm Two Closed 1.10 (-23%) 1.47 (0%)
Duo Flow Open 1.38 1.45
11.5Frx20cm Two Closed 1.15 (-17%) 1.45 (0%)
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The findings in this study imply that side holes can be eliminated from permanent 
catheters, and that the number of side holes may be decreased in the venous limbs of 
acute catheters. Use of side holes may provoke other problems as well. It has 
been reported that the vein intima may be sucked into the lumen of the catheter through 
the side holes, especially when the tip hole is obstructed [19]. Side holes may enhance 
recirculation between the limbs of dual-lumen catheters, which triggers the manufacturers 
to separate the lumen tips or to position the side holes on opposite sides [17]. Leaching of 
locking solutions may enhance the formation of blood cloths as is frequently observed at 
the tip and side holes of catheters [19]. When vein intima is sucked, the pre-pump pressure 
and, consequently, blood flow through the dialysis machine decrease significantly. 
As recirculation is a dynamic process that depends not only on the geometrical design of 
the catheter, but also on its position in the vicinity of the right atrium and on cardiac input 
flow [23], it currently cannot be determined in our model. For similar reasons, it is difficult 
to use these data to comment on the leaching of anticoagulants between treatments [19], 
as this process depends on catheter tip movement and position in the right atrium [24] 
and density differences between blood and locking solution. One last disadvantage of 
catheter side holes is the formation of blood clots. Clots may be firmly anchored to 
the walls around side holes [18,19]. As some of these holes have a small diameter and 
therefore a much greater wall surface-to-flow area ratio, only limited force can be applied 
to remove the clots in situ. The clinical importance of potential problems caused by side 
holes is not clear. It should be noted that performance might not be the only reason to 
use side holes in catheters. No information about their use and performance as a backup 
for (partial) occluded or malpositioned of catheters is known to us. However in our view, 
occluded tips should always be opened, for a cloth or fibrin sleeve may be the cause 
of hemolysis [25]. Tips that are stuck against the wall can be freed by applying positive 
pressure on the limb. Malpositioned catheters tips will always have less than optimal 
performance. Preliminary studies comparing permanent catheters, with limited 
patient-catheter days, did not show an important advantage with different tip designs 
[26]. For permanent catheters, where the side holes do not increase the performance and 
therefore have limited blood flows through them, with zones of low shear, clot attachment 
may possibly be enhanced [15].
c o n c l u S i o n
Our analysis of different catheters for hemodialysis treatment demonstrates that 
multiple side holes, generally and under the ideal circumstances of the presented in vitro 
setup, do not improve catheter performance, except for inflow in acute catheters. 
The equivalent diameter derived from the pressure-flow relationship of permanent 
catheters is larger than the diameter of acute catheters, and double-D catheters perform 
better than coaxial designs. These findings should be taken into account when developing 
new catheters. More clinical studies are needed to confirm the implications of our findings 
in the practice hemodialysis.
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The total pressure difference is the sum of the Poiseuillian flow resistance, which increases 
linearly with the flow rate and the effect of the extra resistance at the infow or outflow, 
which is proportional to the flow rate squared. According to Eq. (3), an increased pressure 
difference renders a lower De.
The concept of De is an interesting one, as it is a single parameter that allows 
to comparison of pressure-flow data of different catheters independently from 
the test fluid used (and thus also independently of hematocrit and viscosity) and 
the length of the catheter. Longer catheters evidently require a higher pressure difference 
for equal flow rates. Therefore, the De is a direct measure of the performance of 
a catheter’s design. This is especially useful for dual-lumen catheters as, for some designs 
(co-axial, double-D shaped), there exists no clear definition for the diameters of 
the individual limbs, which makes it harder to compare their geometrical data 
with two independent single-lumen catheters, such as, for example, the Tesio twin set. 
Catheters with the same lumen diameter and the same length but with a different De 
differ by the level of their specific pressure losses at in- and outflow. This may also be 
an indication for elevated shear stresses in these zones, which may affect the survival 
of blood cells.
For HD, 300 ml/min is recommended as the minimum value for effective treatment [5]. 
Therefore, we tabulated (Table II) the required pressure differences over the catheter 
length (some extra pressure drop is generated in the dialysis circuit towards the blood 
pump). If patients have a lower  Hct due to anemia, this pressure difference decreases 
proportionally with the actual blood viscosity. In the acute catheters, pressure differences 
greater than 300 mmHg are required. These are not easily attained, even in modern 
dialysis equipment. It is very difficult, especially in the arterial limb, to attain 300 ml/min, 
as the very low pre-pump pressures that are needed would severely limit the actual blood 
flow rate [22]. The pressures required to draw 300 ml/min through acute catheters with 
a reduced number of side holes are completely out of range. This indicates the weak 
point of these catheters: development of a fibrin sleeve over catheter’s tip or thrombus 
formation near the side holes would severely limit the flow rate through these holes and 
consequently through the catheter as a whole.
As already indicated in Fig. 2, the results in Tables I-III clearly show that closing the side 
holes of permanent catheters, or the venous limbs of the tested acute catheters, has only 
a very minor effect on the performance of the catheter. Side holes are required, however, 
at the inflow tip of acute catheters. The decrease in flow rates shown in Table III, especially 
in the arterial limbs of the tested acute catheters, may be due partly to the difference 
in actual diameters (11.5 Fr Duo-Flow and 12.5 Fr Duo-Split result in 3% difference 
in De), but the much larger difference in flow rate (-25%) for the arterial lumens between 
these two catheters is by design. Coaxial catheters generally have poor performance of 
the arterial (outside) lumens. The effect on the pressure differences, listed in Table II, 
may seem somewhat higher than the differences showed in the Tables I and III, but this 
is merely an indication that a small diameter change has a much greater effect 
on pressure difference due to the fact that pressure difference is inversely proportional 
to diameter to the fourth power. For example, a 2.5% decrease in diameter will cause 
a 10% increase in pressure difference.
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i n t r o d u c t i o n
Vascular access is a major factor of concern for patients on hemodialysis treatment. 
Despite the recommendations of the National Kidney Foundation – Dialysis Outcome 
Quality Initiative Clinical Practice Guidelines for Vascular Access that recommends 
placement of an arteriovenous access before initiation of chronic hemodialysis treatment, 
the use of catheters for hemodialysis access is substantial [1]. Stehman-Breen reported 
from the United States Renal Data System 1996 that 66% of patients with end stage renal 
disease started hemodialysis treatment with a catheter for access to the blood stream [2]. 
Twardowski reported that 24.3% of almost 30,000 hemodialysis treatments 
in his outpatient facility in the period 1995 to 1997 were performed with a tunneled 
cuffed catheter [3]. The use of hemodialysis catheters, however, is associated with 
an important risk for catheter-related infection and insufficient dialysis due to flow 
problems with or without intraluminal thrombosis [4]. Especially vascular access-related 
infections, mostly associated with hemodialysis catheters, have emerged as an important 
cause of morbidity and mortality in hemodialysis patients. From a prospective study 
in 796 hemodialysis patients performed in seven outpatient hemodialysis centers 
in 1998, Tokar et al. calculated that over 92,000 episodes of vascular access infection 
occur annually among 220,000 prevalent hemodialysis patients in the US. A third of 
these patients had to be treated by hospitalization because of the infection. 
In addition, patients with a catheter had a relative risk for infection of 2.07 compared 
to patients with an arteriovenous fistula of graft [5]. 
It is recognized that microorganisms can adhere to the surface of a catheter. 
Contamination of the catheter hub, subsequent colonization of catheters with microbes 
and formation of a biofilm produced by bacteria are thought to be major riskfactors 
for both catheter-related infections and intraluminal thrombosis [6]. It is, however, 
not elucidated whether the most important mechanism of catheter related bacteremia 
is extraluminal or intraluminal colonization. If catheter-related blood stream infections 
are mainly secondary to intraluminal colonization, interdialytic locking using a solution 
with extensive antimicrobial effects can provide an important reduction of 
these complications. Traditionally heparin 5000-10.000 IU/ml is used for interdialytic 
locking of hemodialysis catheters. Recently, however, trisodium citrate (TSC) has 
been proposed for catheter locking [7] and TSC 30% is already used in clinical practice [8]. 
TSC provides local anticoagulation by binding Ca2+. It can have important advantages 
over heparin, such as prevention of heparin-induced side-effects and unintentional 
systemic heparinisation that can lead to bleeding complications, as was recently shown 
by Kaaraslan et al. [9]. An additional factor in favor of TSC is its potential antimicrobial 
property. For these reasons TSC has been advocated for hemodialysis catheter locking 
and distributed temporarily by a hemodialysis catheter manufacturer 
(Medcomp, Medical Components Inc., Harleysville, PA, USA). The level of hyperosmolality 
of the solution was considered the main explanation responsible for antimicrobial activity 
although binding of divalent cations was also mentioned [7].
However, very limited in vitro data on the antimicrobial properties of TSC as hemodialysis 
catheter locking solution are presently available. It is also not clear whether antimicrobial 
potency of a solution depends on the level of hyperosmolality or not. 
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a b S t r a c t
Background. Haemodialysis catheters used for vascular access are frequently complicated 
by infection and catheter-related thrombosis. Improvement of interdialytic locking 
solutions could reduce these problems. Trisodium citrate (TSC) has been advocated 
in recent years because it might have antimicrobial qualities. 
Methods. Antimicrobial efficacy of four concentrations of TSC (2.2, 7.5, 15 and 30%) 
was compared with three equi-osmolal sodium chloride (NaCl) concentrations, 
unfractionated heparin 5000 IU/ml and a solution of gentamicin 1 mg/ml in TSC 7.5%. 
We analysed antimicrobial properties by two classical in vitro susceptibility tests. 
All tests were performed in triplicate by incubation of test fluids with Staphylococcus 
aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and 
Candida albicans. 
Results. Increasing TSC concentrations effectively killed the staphylococcal strains 
in both assays. For E.coli and P.aeruginosa complete killing was achieved only with 
TSC 30%. TSC 30% was also the only solution that significantly inhibited growth 
of C.albicans. Heparin manifested no antimicrobial effect of any significance. 
Adding gentamicin to TSC provided superior bacterial growth inhibition but had no effect 
on yeast growth. TSC solutions manifested superior antimicrobial activity compared 
with iso-osmolal NaCl solutions in both assays.
Conclusion. This in vitro study demonstrates superior antimicrobial activity of TSC, 
especially in higher concentrations, in contrast to heparin. The mechanism seems to differ 
from hyperosmolality. Ca 2+ and Mg 2+ chelating effects are probably more important. 
Adding gentamicin provided the most potent antimicrobial solution. 
However, for reasons concerning development of bacterial resistance and sensitization of 
the patient, continuous exposition to aminoglycosides seems not advisable.
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Plates were incubated at 370 C for 24 hours. Afterwards zones of inhibition around 
the well were measured. All tests were done in triplicate with BA and TSB plates.
Statistical analysis was performed with SPSS software package 9.0 
(SPSS Inc., Chicago, Ill, USA) with repeated-measurements analysis of variance for 
time-kill curves. Chi-square analysis was performed for means of bacterial colony forming 
units at t=24 hours and for zones of inhibition achieved from the agar diffusion test. 
Significance of test results was based on p<0.05 on a two-tailed test.
r e S u lt S
Antimicrobial properties of different locking solutions
Time-kill studies
The time-kill curves for heparin, all concentrations of TSC and the combination of TSC 
with gentamicin are presented in figure 1. Heparin showed some growth inhibition 
of S. aureus and S. epidermidis compared to control (NaCl 0.9%). However, after 24 hours 
all strains showed increasing growth (upward directed slope) when incubated 
with heparin. Heparin had no significant effect on growth of gram-negative bacteria 
and C. albicans compared to control.
TSC 15% and TSC 30% reduced the number of cfu/ml of all strains over 24 hours 
compared to the concentration at start of the experiment except for the yeast C. albicans 
and except for P. aeruginosa with TSC 15%. The citrate solutions inhibited growth of 
all strains compared to control (NaCl 0.9%), including Candida. The gram-negative strains 
E. coli and P. aeruginosa were only adequately affected by the highest concentrations 
of TSC (15% and 30%)(p<0.05 for T=24 hours). There were no statistically significant 
differences between TSC 30% and TSC 15%. TSC 30% was more effective 
in growth reduction of E. coli, P. aeruginosa and C. albicans than heparin. 
(p<0.05 for T=24 hours)
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The purpose of this study is to evaluate the in vitro antimicrobial activity of different 
concentrations TSC and to compare them with heparin and isoosmolal sodium chloride 
(NaCl) solutions. We employed two classical in vitro antimicrobial susceptibility tests 
and used four bacterial strains and one yeast strain commonly found in catheter-related 
bacteremia.
m e t H o d S
Antimicrobial efficacy of four concentrations of trisodium citrate (TSC), 
2.2% (300 mosmol/kg H2O), 7.5% (1020 mosmol/kg H2O), 15% (2040 mosmol/kg H2O) and 
30% (4080 mosmol/kg H2O) was compared with sodium heparin 5000 IU/ml 
(300 mosmol/kg H2O). TSC 7.5% with gentamicin 1 mg/ml (1030 mosmol/kg H2O) was 
used to analyze the influence of adding an antibiotic to the solution. As control we 
used NaCl 0.9%. In Addition we also compared the TSC solutions with isoosmolal 
solutions of NaCl 0.9% (300 mosmol/kg H2O), NaCl 6.1% (2040 mosmol/kg H2O) and 
NaCl 12.2% (4080 mosmol/kg H2O). All solutions were manufactured from raw base 
by the department of Pharmacy of the Vrije Universiteit Medical Center, Amsterdam, 
the Netherlands. The solutions were heat sterilized for 16 min at 1210C and the pH was 
controlled between 6.4 and 7.5. Gentamicin sulphate was obtained from commercially 
available vials (Gentamicin CF, Centrafarm Services, Etten-Leur, the Netherlands). 
All tests were performed with five standardized reference strains from the American 
Type Culture Collection (ATCC, Manassas, VA, USA); Staphylococcus aureus (ATCC 25923) 
Staphylococcus epidermidis (ATCC 12228), Pseudomonas aeruginosa (ATCC 25922), 
Escherichia coli (ATCC 27853) and Candida albicans (ATCC 90028).
The antimicrobial activity of the solutions was investigated by time-kill and agar 
diffusion methods, essentially performed according to National Committee for Clinical 
Laboratory Standards guidelines [10]. Briefly, logarithmic-phase bacterial and yeast 
cultures were used for the final inoculum of 105 colony-forming units per ml (cfu/ml).  
Twenty μl of the microbial suspension was added to 2000 μl of a suspension containing 
a 10:1 dilution of the test solution in trypticase soy base (TSB) broth (Difco Laboratories, 
Sparks, MD, USA) to achieve a final bacterial concentration of 103 cfu/ml. At 
this initial concentration, the comparison with time-kill curves of control solution was 
best feasible. Tubes were incubated at 370 Celsius (C). At the start of the experiment (t=0) 
and at 1, 2, 4 and 24 hours 50μl of this suspension was plated on blood agar plates (BA) 
(Oxoid, Basingstoke, Hampshire, UK) supplemented with 7% sheep blood 
(Bio Trading, Mijdrecht, the Netherlands). Subsequently, plates were incubated 
for 24 hours at 370 C. Afterwards colonies were counted and time-kill curves constructed 
from calculated cfu/ml. All tests and cultures were done in triplicate.
The agar diffusion susceptibility test was done analogous to the disk diffusion test 
(Kirby-Bauer) [10]. BA and TSB plates were seeded with a bacterial solution with 
a final inoculum of 105 cfu/ml. Separate plates were used for each of the five microbial 
strains. Instead of using disks impregnated with test solution, one well with a diameter 
of 8 mm was punched out of the agar at the center of the plate. The well was filled with 
test solution and this was repeated every two hours for the first 6 hours of incubation. 
A total of 0.45 ml of test solution had to be added to the well to keep it filled. 
chapter 6a
94 95
Figure 2. Agar diffusion susceptibility test. Bloodagar plates seeded with Staphylococcus 
aureus and wells filled with heparin (A), trisodium citrate (TSC) 7.5% (B) and trisodium citrate 
30% (C) after 24 hours at 37OC showing larger zones of bacterial killing 
for TSC solutions.
Figure 3. Zones of inhibition for the agar diffusion susceptibility test for heparin, trisodium 
citrate and isoosmolal NaCl solutions and the combination of trisodium citrate 7.5% with 
gentamicin. Values are means + SD. Tested microbial strains are Staphylococcus aureus (ATCC 
25923), Staphylococcus epidermidis (ATCC 12228), Pseudomonas aeruginosa (ATCC 25922), 
Escherichia coli (ATCC 27853) and Candida albicans (ATCC 90028).
In general, higher concentrations of TSC demonstrated increasing inhibitory effect 
on all strains (figure 3). TSC 30% was the only solution to inhibit growth of all tested 
microbes including C. albicans. The inhibition zone was significantly larger for all strains 
compared to control (NaCl 0.9%) and heparin (p<0.01 for all comparisons). 
Addition of gentamicin to TSC potentiated the effect of TSC on all bacterial strains in both 
the dilution and the diffusion test. Growth of C. albicans, however, was not influenced.
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Figure 1. Time-kill curves for heparin, trisodium citrate and isoosmolal NaCl solutions and the 
combination of trisodium citrate 7.5% with gentamicin. Tested microbial strains are Staphy-
lococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), Pseudomonas 
aeruginosa (ATCC 25922), Escherichia coli (ATCC 27853) and 
Candida albicans (ATCC 90028).
Agar diffusion susceptibility test (figure 2)
Studies using TSB plates and BA plates revealed similar results. The results for the zones 
of inhibition were therefore pooled for further analysis. Zones of inhibition are given 
in figure 3. For all microbial strains no growth inhibition by the control solution 
(NaCl 0.9%) was found. Heparin also showed no effect at all.
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the past, seldom tests were performed using validated techniques with more then one 
microorganism and mainly established antibiotics were added to solutions for locking 
[11;12]. The methods we applied for this study consisted of two widely validated and 
recommended antimicrobial susceptibility tests . The tests were performed 
as recommended by the National Committee for Clinical Laboratory Standards [10;13]. 
Dilution tests are employed to provide more exact information on the concentrations 
of the antimicrobial solution that cause growth reduction and killing. However, 
the standardized disk diffusion test is the initial susceptibility test used in most 
laboratories because of its ease of performance, reproducibility, and proven value as 
a guide to antimicrobial therapy [14]. This test demonstrated the pronounced 
antimicrobial properties of TSC 30% most distinctly.
For the present study we selected both gram-positive and gram-negative bacteria 
frequently involved in catheter-related bacteremia. S. aureus and S. epidermidis are 
the most common bacteria found in catheter-related bacteremia. However, 
gram-negative bacteria can be isolated in up to 45% of cultures and up to 21% of cultures 
reveal a polymicrobial infection [15]. We used reference microbial strains from the ATCC 
to minimize the variable microbial properties that may affect the results. Microorganisms 
were seeded on bloodagar and trypticase soy based plates to investigate the influence 
of the growth medium. The results were very similar for both plates. Yeasts are 
not commonly involved in catheter related infections. Nevertheless we included 
a Candida albicans strain in our study because of the high mortality of systemic yeast 
infection. Inhibition of growth of Candida spp. by a locking solution could therefore 
be of importance. 
Both susceptibility tests showed clear differences in antimicrobial properties 
for isoosmolal solutions. In 18 of 30 comparisons that could be made between isoosmolal 
TSC and NaCl solutions, TSC exhibited significant greater inhibitory effects on microbial 
growth. Therefore, the anti-microbial properties of higher concentrations of TSC can not 
be attributed to hyperosmolality. It is likely that other effects of TSC like chelation of 
the divalent cations Ca2+ and Mg2+ are more important. From dentistry research it 
is known that Ca2+ and Mg2+ chelating agents like disodium-ethylenediaminetetraacetate 
(EDTA) and sodium citrate exhibit similar inhibition of growth and coaggregation of 
microorganisms. Root et al. showed in an in vitro model with catheter segments incubated 
with 103 S. epidermidis that EDTA provided total killing of bacteria [16]. They suggested 
that especially chelation of Mg2+ can interfere with cellular integrity by degradation of 
the bacterial cell wall membrane. Lipopolysaccharides in the bacterial cell wall 
are crossed-linked with divalent cations, providing stability. Lowering the concentration 
of these cations can lead to disruption of the cell wall and increase permeability [14;17]. 
Consistent with these findings is the observation that sodium citrate proved to be 
a potent permeabilizer of the cell wall at millimolar concentrations in a model used 
for permeability changes in gram-negative bacteria. The effect was partly 
(P. aeruginosa, S. typhimurium) or almost totally (E. coli O157) abolished by MgCl2, 
suggesting that part of the action occurs by chelation [17].
Apart from Mg2+- -binding, removal of Ca2+ from the surrounding milieu can be 
an explanation for the antimicrobial properties of TSC. Ca2+ may regulate several genes 
locking solutions: microbiologic al study
a n t i m i c r o b i a l  p r o p e r t i e S  o F  i S o o S m o l a l  S o l u t i o n S
Time-kill studies
Comparing the results of the time-kill curves of isoosmolal solutions, it is clear that 
there are major differences (figure 1). For the isoosmolal solutions NaCl 0.9% and 
TSC 2.2%, TSC 2.2% provided stronger growth inhibition in S. epidermidis, S. aureus 
and C. albicans (p<0.05). The growth at 24 hours was inhibited significantly better for 
S. epidermidis and S. aureus by TSC 15% compared to NaCl 6.1% and for S. epidermidis 
and S. aureus by TSC 30% compared to NaCl 12.2%. For the other strains the time-kill 
curves were not significantly different.
Agar diffusion susceptibility test
The agar diffusion test also showed larger zones of inhibition for TSC compared 
to isoosmolal NaCl solutions, especially when osmolality increased (figure 3).  
NaCl 6.1% and NaCl 12.2% exhibited no significant effect on microbial growth 
over NaCl 0.9%.  NaCl 0.9% did not inhibit growth of any microbial strain. In contrast, 
isoosmolal TSC 2.2% inhibited growth of S. aureus significantly. TSC 15% showed 
more antimicrobial effect compared to isoosmolal NaCl 6.1% in all strains except 
for P. aeruginosa (p<0.05). For the isoosmolal solutions with the highest osmolality, 
NaCl 12.2% and TSC 30%, superior growth inhibition of TSC 30% was found 
in all strains (p<0.01). 
d i S c u S S i o n
In the present study we investigated the antimicrobial activity of TSC against five different 
microorganisms frequently encountered in catheter-related infections in hemodialysis 
patients using two standardized antimicrobial susceptibility tests. The antimicrobial 
activity was dose dependent with the highest efficacy for TSC 30%. In both tests 
the antimicrobial activity of TSC exceeded that of isoosmolal NaCl concentrations, 
whereas heparin manifested only minimal antimicrobial activity. Thus it can be concluded 
that the use of high concentrations of TSC for catheter locking could have an advantage 
over heparin. Adding gentamicin to TSC provided the most potent antibacterial solution. 
Lynn (Lynn, J Am Soc Nephrol 2000; 10:1006A), however, showed that locking with 
a mixture containing an antibiotic results in low systemic concentrations of 
the antibiotic resulting from diffusion from the tip of the catheter. The development 
of bacterial resistance and sensitization of the patient can be the consequence. 
Addition of aminoglycosides or other antibiotics to locking solutions for long-term use 
is therefore not advisable. Heparin revealed no relevant anti-microbial activity. 
This was recently also reported by Capdevila et al. in vitro by means of the time-kill curves 
method and in vivo by implanting catheters in rabbits and inducing secondary infection 
but they only used one strain of S. aureus [11].
To investigate whether a locking solution can reduce complications, only a clinical study 
with large numbers of patients can provide definitive answers. The present study only 
provides in vitro data, but these studies have to be performed to give direction to which 
locking solution is most likely to reduce complications before conducting 
a clinical trial. No standardized methods are available for testing antimicrobial activity 
of catheter locking solutions. Although other in vitro methods have been advocated in 
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accident [24]. In this particular case, however, a large amount of TSC was injected in 
a previously unstable patient with severe electrolyte disturbances. It is clear that the use 
of these solutions should be restricted to authorized and skilled health care professionals.
We conclude that in our in vitro study using standardized antimicrobial susceptibility tests 
we demonstrated that trisodium citrate 30% was the most potent antimicrobial locking 
solution and that its hyperosmolality was of minor importance to explain the inhibitory 
effects of TSC on microbial growth. However before introduction in practice, randomized 
clinical trials should confirm the benefit.
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responsible for growth and survival of microbes. Holland et al. demonstrated that 
cell division in E. coli in particular appears to be very sensitive to the level of cellular Ca2+, 
with the frequency of division clearly reduced by incubation with EDTA and by verapamil, 
a Ca2+-channel inhibitor. The effect of EDTA was clearly correlated with depletion of 
cellular Ca2+ [18].  Biofilm formation, thought to be a key factor in catheter colonization 
and ultimately bacteremia, is probably dependent on Ca2+. A biofilm consists of bacteria 
that attach to surfaces and aggregate in a hydrated polymeric glycocalyx matrix of 
their own synthesis. Formation of these sessile communities and their inherent resistance 
to antimicrobial agents allows microbes to survive in a hostile environment. 
Even in individuals with excellent cellular and humoral immune reactions, biofilm 
infections are rarely resolved by the host defense mechanisms. In addition antibiotics are 
not very useful because they have been shown to penetrate poorly into a biofilm [19]. 
Furthermore at least some of the microbial cells in a biofilm experience nutrient limitation 
and therefore exist in a slow-growing state. Slow-growing or non-growing microbial cells 
are not very susceptible to antimicrobial agents. Until recently, the bacterial glycocalyx 
was regarded as being homogeneous in construction and static in its structure. It is now 
recognized that glycocalyces are not structurally static, but rather responsive to 
the chemical composition of the surrounding milieu. An increasing environmental 
Ca2+-concentration dramatically enhanced the survival of P. aeruginosa in biofilms upon 
a 12-hour exposure to tobramycine in an in vitro experiment [20]. It was suggested that 
Ca2+-induced crystallization of the glycocalyx resulted in decreased permeability of 
the biofilm for small molecules like aminoglycosides. In summary, chelation of Ca2+ and 
Mg2+ by TSC may prevent the formation of a biofilm that consists of microbes in a firm 
glycocalyx. Reduction of the incidence of catheter-related bacteremia by the intraluminal 
route could be the result. This hypothesis was tested in some in vitro models with catheter 
segments but the constructions with catheters or fragments trying to imitate the clinical 
situation are artificial [21;22].
As stated before, this study only provides data from in vitro antimicrobial susceptibility 
tests. It is not clear if the results can be translated to general practice as numerous factors 
have been implicated in the pathogenesis of catheter-related bacteremia. For that reason, 
locking solutions must be compared in a clinical study to confirm their benefit. So far, 
only few comparative studies have been published showing no clear differences between 
TSC and heparin [8;23]. These studies, though, only accounted about 5000 catheter-days 
pooled data and mostly used lower concentrations TSC. With a rate of 3-5 infections 
per 1000 catheter-days it is obvious that larger studies are needed to find a significant 
difference.
Ash et al. reported their experience in a hemodialysis patient cohort of 70 patients with 
60% tunneled cuffed catheters [7]. After introduction of TSC 23-47% for catheter locking 
they observed an average decline of 4.5% of all patients per month having a bacteremia 
to zero percent. Recently, Stas et al. reported a study comparing heparin 5000 IU/ml and 
TSC 30%. Thrombus formation in the catheter was evaluated after 201 interdialytic locking 
periods; no significant differences could be demonstrated [8]. In both studies no clinically 
relevant side effects occurred during instillation of hemodialysis catheters with TSC. 
This is important, as concern has risen of using TSC for locking catheters after a fatal 
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i n t r o d u c t i o n
In 2001, approximately 900 per 1 million population in the United States were treated 
with hemodialysis for ESRD, and an annual increase of 7.1% is expected until 2010 (1,2). 
For chronic hemodialysis treatment, an arteriovenous fistula or graft is preferred for 
vascular access. However, in current practice, the use of hemodialysis catheters 
is substantial. From recent data of the Dialysis Outcomes and Practice Patterns Study, 
it is recognized that 60% of incident and 17% of  prevalent patients in the United States 
depend on a catheter for vascular access (3). Such widespread application of  catheters 
exposes patients to an enhanced risk for catheter-related complications such as infection 
and insufficient  dialysis as a result of flow problems (4). Because of these complications, 
approximately 50% of all catheters have to be removed and/or replaced, resulting 
in substantial patient morbidity as well as consumption of resources (5). Hemodialysis 
catheter-related bacteremia (CRB) is the most serious complication, with an average 
incidence of 3.4 to 6.5 periods per 1,000 catheter-days (5–9). Recently, it was estimated 
from the United States Renal Data System and the Medicare reimbursement data that 
in the United States, there are 22,000 to 100,000 cases of CRB annually in the hemodialysis 
population and that the costs probably exceed $500 million (2,10,11). Catheter-related 
infections are thought to arise by several different mechanisms. Contamination of 
the catheter hub and subsequent colonization of catheters by microbes as well as 
formation of a bacterial biofilm on the external and internal surface are thought to be 
the major routes for both catheter-related infections and intraluminal thrombosis (12–14). 
Usually, concentrated heparin is used for catheter locking. However, its efficacy 
is uncertain, and its use is seldom discussed in guidelines. The recently updated and 
widely accepted Dialysis Outcome Quality Initiative guidelines of the National Kidney 
Foundation, for example, do not mention heparin for catheter locking (15). 
Also, the safety of heparin locking has never been disputed, although it has been 
demonstrated that heparin causes unintentional systemic anticoagulation and bleeding 
episodes (16 –18). Antimicrobial locking solutions could be an attractive alternative. 
It is known from in vitro studies that solutions that contain antibiotics can prevent biofilm 
formation on foreign surfaces (13). However, solutions that contain high concentrations 
of antibiotics cannot be used in clinical practice for prevention because of side effects 
(19,20). High-concentration trisodium citrate (TSC) has been advocated for hemodialysis 
catheter locking because it provides local anticoagulation. In contrast to heparin, 
it exposes a broad antimicrobial and anti-yeast effect (21). TSC chelates of Ca2+ and 
Mg2+ by which it may prevent biofilm formation and colonization (22,23). Currently, there 
is limited experience with high concentrations of TSC in clinical practice, and 
the efficacy and the safety of these solutions for improving catheter outcome have yet to 
be established (24,25). We conducted a multicenter, double-blind, randomized, controlled 
trial comparing unfractionated heparin 5,000 U/ml with TSC 30% for interdialytic catheter 
locking.The aim was to determine whether locking with TSC 30% could increase overall 
catheter patency and reduce catheter-related infections. The secondary aim was 
to establish the safety and whether a difference in major bleeding episodes could 
be demonstrated.
a b S t r a c t
Background. Interdialytic hemodialysis catheter-locking solutions could contribute to 
a reduction of catheter-related complications, especially infections. 
However, they can cause side effects because of leakage from the tip of the catheter. 
Recently, trisodiumcitrate (TSC) has been advocated because of its antimicrobial 
properties and local anticoagulation.
Methods. In a multicenter, doubleblind, randomized, controlled trial, TSC 30% 
was compared with unfractionated heparin 5000 U/ml for prevention of catheter-related 
infections, thrombosis, and bleeding complications. 
Results. The study was stopped prematurely because of a difference in catheter-related 
bacteremia (CRB; P < 0.01). Of 363 eligible patients, 291 could be randomized. 
The study included 98 tunneled cuffed catheters and 193 untunneled. There were 
no significant differences in patient and catheter characteristics on inclusion. 
In the heparin group, 46% of catheters had to be removed because of any complication 
compared with 28% in the TSC group (P = 0.005). CRB rates were 1.1 per 
1000 catheter-days for TSC versus 4.1 in the heparin group (P < 0.001). For tunneled cuffed 
catheters, the risk reduction for CRB was 87% (P < 0.001) and for untunneled catheters 
was 64% (P = 0.05). Fewer patients died from CRB in the TSC group (0 versus 5; P = 0.028). 
There were no differences in catheter flow problems and thrombosis (P = 0.75). 
No serious adverse events were encountered. Major bleeding episodes were significantly 
lower in the TSC group (P = 0.010). 
Conclusion. TSC 30% improves overall patency rates and reduces catheter-related 
infections and major bleeding episodes for both tunneled and untunneled hemodialysis 
catheters. Flow problems are not reduced.
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solution necessary to lock one lumen of the catheter. Catheter care protocols were 
according to national guidelines for hemodialysis treatment and included insertion 
of catheters under strict asepsis by an experienced operator. In addition, these guidelines 
included catheter exit-site dressing changes after each treatment and catheter 
manipulations only to be performed by trained dialysis staff wearing masks and 
sterile gloves. Use of dry gauze dressings and povidone-iodine ointment at 
the catheter exit site was recommended. 
Patients were examined for nasal carriage of Staphylococcus aureus on inclusion, 
and carriers were treated with intranasal 2% mupirocin ointment for 5 d every month. 
Hemodialysis treatment was performed according to national guidelines with any form 
of regional anticoagulation being permitted.
Assessment of Outcome
Overall premature catheter removal was defined as any removal needed for 
a complication such as infection, thrombosis, and catheter breakdown or leakage and 
unintentional and accidental removals. 
Infection
CRB was defined as fever (temperature > 38°C) or cold chills not during a dialysis 
treatment and at least one positive blood culture and no other obvious cause of infection. 
In patients who developed signs of bacteremia without symptoms of an alternative 
source other than the catheter after careful clinical examination by a physician, 
at least two blood cultures either from the catheter or from a peripheral vein were taken. 
Subsequently, antibiotics for suspected CRB were given. When a CRB was established, 
the catheter could be left in place in case of disappearance of fever and clinical recovery 
on initiation of antibiotic treatment. In patients who did not improve within 48 h or 
with recurrent bacteremia within 3 wk after stopping antibiotic treatment and without 
an alternative source, the catheter had to be removed. In case of recurrent bacteremia, 
only the first period was counted for the analysis.
Exit-site infection was defined as the development of a purulent exudate or redness 
around the site not resulting from residual stitches. After culturing, antibiotic treatment 
was recommended for at least 2 wk. In case of no improvement, the catheter had to 
be removed. CRB-related admissions, defined as admissions solely caused by a CRB, 
were counted. 
Thrombosis
Thrombosis was defined as a persistent inability to run a blood flow of > 200 ml/min 
despite positional changes of the patient and/or additional flushing. Thrombosis was 
treated with instillation of urokinase (5000 to 10,000 IU/ml) in both pools with a volume 
equivalent to the internal volume of the lumen noted on the catheter. After 15 min, 
the urokinase was withdrawn and the dialysis was continued. When a blood flow 
of >200 ml/min  was not achieved after this procedure, 100,000 to 250,000 IU of urokinase 
could be infused in 3 h during dialysis according to the protocol of  Twardowski (26). 
In case of total occlusion of the lumen (i.e., no flow when connected to the dialysis 
m at e r i a l S  a n d  m e t H o d S
Selection of Patients
The study was conducted from April 2001 until September 2002 in nine dialysis units from 
the Netherlands and one from Belgium. Two units were situated in an academic center, 
seven were in a teaching hospital, and one was a private clinic. In the units, 
the overall average percentage of patients who relied on a catheter for vascular access 
was 14%. Patients were eligible for enrollment in the study when they were older than 
18 yr, were not admitted to the intensive care ward, and experienced chronic or acute 
renal failure that required hemodialysis treatment by means of a hemodialysis catheter. 
Only patients with a newly inserted, well-positioned hemodialysis catheter that was 
expected to be needed for > 1 wk could be included. Catheters were used 
for hemodialysis treatment only. The specific type and the diameter used were left to 
the discretion of the interventional physician. The application of national guidelines 
for dialysis treatment, which state that a femoral catheter should not be used for > 1 wk, 
that subclavian catheters should be avoided, and that a tunneled cuffed catheter should 
be used whenever it is foreseen that a catheter would be needed for > 4 to 6 wk, were 
recommended. Exclusion criteria were suspected heparin-induced thrombocytopenia 
or heparin-induced thrombosis, systemic bacterial infection, localized infection requiring 
systemic antibiotics, proven or suspected allergy to heparin or TSC, and pregnancy. 
Hospitalization was defined as admission for non–catheter-related reasons at any time 
a catheter was in place. 
The study protocol was approved by the institutional review board of each of 
the 10 participating institutions, with adherence to the Declaration of Helsinki. 
Written informed consent was obtained from all patients before enrollment.
Study Design
Patients were randomly assigned to have both lumens of their catheter locked with either 
unfractionated sodium heparin 5000 U/ml or TSC 30%. Inclusion and randomization was 
performed immediately after insertion by means of a computer-generated list 
of random numbers in blocks of six and stratified according to the dialysis center and to 
the type of catheter inserted (tunneled cuffed or untunneled). Patients and investigators 
were unaware of the treatment assignments. The locking solutions were manufactured 
from raw base according to standardized pharmaceutical protocols in conjunction with 
European Pharmacopoeia Guidelines and delivered as 5-ml vials (A.J. Wilhelm, Pharmacist, 
Department of Pharmacy, VU University Medical Center, Amsterdam, The Netherlands). 
The solutions were heat-sterilized for 16 min at 121°C, and the pH was controlled between 
6.4 and 7.5. There were no external recognizable differences in the solutions except for 
randomization codes. The randomization codes were kept by the central department of 
pharmacy; all others involved in the study were blinded.
After the hemodialysis treatment had been completed, each lumen of the catheter was 
flushed with 10 ml of 0.9% sodium chloride and locked with the locking solution using 
a volume exactly equivalent to the internal volume of the lumen noted on the catheter. 
For preventing accidental infusion of the locking solution, the maximum size of 
the syringes used was 2.5 ml. The syringe had to be filled with the amount of locking 
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Baseline Characteristics of Patients
Of 363 eligible patients during the study period, 291 could be randomized: 143 to heparin 
and 148 to TSC. Thirty-nine patients were unable or unwilling to give informed consent, 
in 19 patients the catheter had already been flushed or locked with heparin before 
consent could be obtained, four patients were admitted at the intensive care unit 
at the time of catheter insertion, three patients were excluded because of age, 
Table 1.  Base line characteristics of the patients and catheters
Characteristic TSC Group Heparin Group
(n = 148) (n = 143)
Age (yr; mean ± SD) 61.6 ± 14.8 61.3 ± 16.0
Race
        white (%) 73 71
        black (%) 8 11
        other (%) 19 18
Male gender (%) 61 56
Years on dialysis (mean ± SD) 1.1 ± 1.2 1.4 ± 1.3
Weekly dialysis frequency
        two (%) 30 30
        three (%) 69 70
        four (%) 1 0
Cause of ESRD 19 21
        diabetes (%) 19 21
        glomerulonephritis (%) 24 18
        polycystic kidney disease (%) 7 9
        other / unknown (%) 50 54
Acute renal failure (%) 26 25
Diabetes (%) 28 31
Cardiovascular disease (%) 53 55
Coumarin use (%) 31 28
Hospitalization (%) 63 64
Immune suppression (%) 16 14
Malignancy (%) 9 6
Staphylococcus aureus carrier (%) 23 23
Catheter days (n) 8431 8116
Tunneled cuffed catheters (n) 50 48
        catheter-days (n) 4857 4522
        jugular (n) 49 48
        right-sided (%) 92 90
        femoral (n) 0 0
        subclavian (n) 1 0
Untunneled catheters (n) 98 95
        catheter-days (n) 3574 3594
        jugular (n) 77 69
        right-sided (%) 95 91
        femoral (n) 20 24
        subclavian (n) 1 2
There were no significant differences (at P <0.05) between the two groups in any of the summarized characteristics.
machine), 40,000 IU/h urokinase during 3 h could be infused in the lumen of the catheter. 
When this was not successful, the catheter was removed or exchanged. Patients could be 
re-randomized. In accordance with national guidelines, the minimal acceptable 
blood flow was 200 ml/min; the target was 250 ml/min. The target for dialysis efficacy was 
a single-pool Kt/V of at least 1.2 per treatment and a urea reduction rate of 65%.
Safety, Tolerability, and Bleeding Episodes
All noxious and unintended reactions to the locking solution were recorded. 
Patients were asked to report symptoms after each catheter lock procedure. 
Persistent bleeding from the place of insertion after catheter placement was considered 
to be apparent when the patient had to stay on the dialysis unit longer than 3 h or when 
an intervention with intravenous coagulation promoters was needed. Major bleeding 
episodes were defined as a clinical evident bleeding episode that included a decrease of 
the hemoglobin level of 3.6 g/dl (2.0 mmol/L) or more or when a blood transfusion 
was needed. In case of mortality, the cause was recorded and analyzed. All infectious and 
thrombotic complications and all catheter removals and adverse events reported by 
the local investigators were re-evaluated by the study coordinators.
Statistical Analyses
Primary analysis was a Cox regression analysis of catheter survival and CRB from 
the time of randomization (27). Calculation of the required sample size was based on 
the assumption that TSC would reduce the premature catheter removal rate from 40 to 
30%. With a two-sided test, an < level of 0.05, and a power of 80%, the analysis required 
200 catheters per group. With this number of catheters, the power to find a 25% decrease 
in premature catheter removals is 90%, assuming a rate of 20 per 1000 catheter-days and 
a mean catheter survival of 40 d (28). The analysis of outcomes was performed on 
an intention-to-treat basis. A three-member data-monitoring committee judged 
an interim analysis after inclusion of 200 catheters.  The study was stopped because 
a greater than predefined (P < 0.01) significant reduction of the bacteremia rate was 
found by Cox regression analysis with a statistical difference of P < 0.009.
The effect of the treatment assignment on catheter survival and bacteremia was 
determined with stratification according to clinical center and type of catheter and 
was adjusted for the following prespecified baseline factors: Age, gender, race, years 
of dialysis, presence or absence of diabetes, malignancy, cardiovascular disease, acute 
renal failure, hospitalization, use of coumarin, nasal carriage of S. aureus. Kaplan-Meier 
survival curves were constructed (29). Well-functioning catheters at the end of the study 
observation time as well as catheters that were removed because they were not needed 
anymore because patients had a functional arteriovenous access, renal recovery, transfer 
to peritoneal dialysis, or transplantation were analyzed as censored values. 
Secondary outcomes, adverse and bleeding events were analyzed by Cox regressions 
similar to that used in the primary analysis. In case of concurrent CRB and exit-site 
infection, they were counted as both. We did not add these infections at any time point. 
All reported P values are two-sided.
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The effect of the treatment assignment on catheter survival and bacteremia was determined 
with stratification according to clinical center and type of catheter and was adjusted for 
the following prespecified baseline factors: Age, gender, race, years of dialysis, presence or 
absence of diabetes, malignancy, cardiovascular disease, acute renal failure,  hospitalization, 
use of coumarin, and nasal carriage of Staphylococcus aureus. TSC, trisodium citrate; RR, 
relative risk; CI, confidence interval; CRB, catheter-related bacteremia.
Table 2.  Summary of the primary and secondary end points.
Trisodium Citrate Heparin Relative Risk P
Group Group (95% CI)* Value
(N=148) (N=143)
No. of events %
Primary end points
Catheter-related bacteremia
        All Catheters 9 (6) 33 (23) 0.25 (0.12-0.52) <0.001
        No. per 1,000 catheters days 1.1 4.1
        Tunneled cuffed catheters 4 (8) 19 (40) 0.13 (0.04-0.39) <0.001
        No. per 1,000 catheters days 0.8 4.2
        Untunneled uncuffed catheters 5 (5) 14 (15) 0.36 (0.13-1.00) 0.05
        No. per 1,000 catheters days 1.4 3.9
Removal for any complication
        All Catheters 42 (28) 66 (46) 0.57 (0.38-0.85) 0.005
        No. per 1,000 catheters days 5.0 8.1
        Tunneled cuffed catheters 10 (20) 20 (42) 0.38 (0.17-0.83) 0.015
        No. per 1,000 catheters days 2.1 4.4
        Untunneled uncuffed catheters 32 (33) 46 (48) 0.69 (0.44-1.08) 0.11
        No. per 1,000 catheters days 9.0 12.8
Secondary end points
Exit-site infection
        All Catheters 11 (7) 32 (22) 0.41 (0.20-0.81) 0.012
        No. per 1,000 catheters days 1.3 3.9
        Tunneled cuffed catheters 5 (10) 13 (27) 0.47 (0.17-1.34) 0.16
        No. per 1,000 catheters days 1.0 2.9
        Untunneled uncuffed catheters 6 (6) 19 (20) 0.25 (0.08-0.73) 0.012
        No. per 1,000 catheters days 1.7 5.3
Removal for flow problems
        All Catheters 27 (18) 29 (20) 0.92 (0.54-1.55) 0.75
        No. per 1,000 catheters days 3.2 3.6
        Tunneled cuffed catheters 4 (8) 3 (6) 1.23 (0.27-5.48) 0.79
        No. per 1,000 catheters days 0.8 0.7
        Untunneled uncuffed catheters 23 (24) 26 (27) 0.87 (0.49-1.54) 0.64
        No. per 1,000 catheters days 6.4 7.2
Catheters treated with urokinase
        All catheters 69 (47) 63 (44) 1.11 (0.70-1.75) 0.72
        Tunneled cuffed catheters 20 (40) 22 (46) 0.79 (0.35-1.76) 0.56
        Untunneled uncuffed catheters 49 (50) 41 (43) 1.32 (0.75-2.32) 0.34
Admissions for CR-infection (no.) 6 21 0.25 (0.09-0.63) 0.002
        No. per 1,000 catheters days 0.7 2.7
Death from any cause 13 18 0.67 (0.31-1.43) 0.20
Death from catheter-related
bacteremia 0 5 0.96 (0.93-0.99) 0.028
three patients were expected to leave to a nonparticipating hospital within 1 wk, 
one patient had a  contraindication to heparin, in one patient the randomization code 
was lost, one patient had a catheter inserted with another one left in place, and 
one patient was considered to need a catheter for  < 1 wk after inclusion and 
was withdrawn before the first locking  procedure by the caring physician.
The baseline characteristics of the patients were similar in the two treatment groups 
(Table 1). A total of 16,547 catheter-days could be analyzed, 9,379 catheter-days 
in 98 tunneled catheters and 7,168 catheter-days in 193 untunneled catheters. 
Because of the stratification method, the groups did not differ significantly with respect 
to the number of tunneled and untunneled catheters. Both tunneled (97 of 98; 99%) 
and untunneled catheters (146 of 193; 76%) were situated mainly in the jugular position. 
Subclavian catheters were almost completely absent, and only a limited number 
of femoral catheters (44 of 291; 15%) were used in this study. A variety of double-lumen 
silicone and polyurethane tunneled and untunneled catheters were used. 
Tunneled cuffed catheter types included Ash-split (n = 44), Hemo-Cath (n = 24), 
Tesio (n = 5; all Medcomp, Medical Components, Inc., Harleysville, PA), and Neostar 
Circle-C (n = 19; Horizon Medical Products, Manchester, GA). Of all untunneled jugular 
catheters, 140 consisted of a precurved Duoflow (Medcomp) inserted in the low jugular 
site. This type is known to have relatively low infection rates compared with other types 
of jugular catheters (8).
Catheter Patency Rates
The percentage of catheters that had to be removed prematurely was 61% lower in 
the TSC-locked catheters compared with the heparin-locked catheters 
(28 versus 46%; relative risk [RR] 0.57; 95% confidence interval [CI] 0.38 to 0.85; P = 0.005; 
Table 2, Figure 1). The total number of catheters removed prematurely was reduced from 
8.1 to 5.0 per 1000 catheter-days in the TSC group. Patency rates for tunneled catheters 
were much better with TSC versus heparin (RR 0.38, P = 0.015). However, in the 
TSC-treated group, the survival rates of untunneled catheters did not significantly differ 
from heparin group (RR 0.69, P = 0.11). Predictors of premature removal 
were hospitalization (RR 1.78; 95% CI 1.21 to 2.62; P = 0.006) and having an untunneled 
uncuffed catheter (RR 3.18; 95% CI 2.04 to 4.94; P < 0.0001; Table 2).
Infectious Complications
A total of 33 episodes of CRB occurred in the patients who were randomized to heparin 
locking compared with nine patients who were assigned to TSC (P < 0.001). CRB rates 
per 1000 catheter-days were reduced from 4.1 in the heparin group to 1.1 for TSC. 
The RR for CRB was 75% lower in patients with a TSC-locked catheter
(95% CI 49 to 88%; P = 0.0002). The only other independent predictors of CRB were 
age > 65 yr (RR 2.99; 95% CI 1.48 to 6.03; P = 0.002) and male gender 
(RR 2.24; 95% CI 1.15 to 4.35; P = 0.017). Both patients with a tunneled cuffed catheter 
(RR 0.13; 95% CI 0.04 to 0.39; P < 0.001) and patients with an untunneled uncuffed 
catheter (RR 0.36; 95% CI 0.13 to 1.00; P = 0.05) had lower CRB rates with TSC 
(Figure 2, Table 2).  There were 32 episodes of exit-site infections in the heparin group 
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Thrombotic Complications
Twenty-nine of the 143 catheters assigned to heparin locking had to be removed because 
of persistent flow problems (3.6 per 1000 catheter-days), and 27 of 148 catheters assigned 
to TSC had to be removed (3.2 per 1000 catheter-days; RR 0.92; 95% CI 0.54 to 1.55; 
P = 0.75). The need for locally installed urokinase or systemic urokinase administration 
was not significantly different in the treatment groups (Table 2). During the period 
that the catheter was in place, 80 of 143 catheters assigned to heparin did not need  
thrombolytic treatment of any kind (56%), and 79 of 143 assigned to TSC did not need 
thrombolytic treatment (53%; Table 2). Having an untunneled catheter was the only 
independent risk factor for premature removal 
Figure 1. Kaplan-Meier analysis of catheter survival for the locking solutions. 
The P value was calculated with use of the log-rank test.
because of flow problems (adjusted RR 6.82; 95% CI 3.05 to 15.25; P < 0.001). 
Excluding patients with a femoral catheter provided similar results for tunneled and 
untunneled catheters. 
Safety, Adverse Events, and Bleeding Episodes
A total number of 12,624 locking procedures were registered (Table 3). No serious adverse 
events that could be contributed to the locking solution were reported in both groups. 
Eighteen patients in the heparin group and 13 patients in the TSC group died while 
having a catheter in place (P = 0.20; Table 2). Nine patients immediately after locking with 
TSC and four patients after heparin locking reported symptoms, mostly perioral 
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versus 11 in the TSC group (P = 0.012). In seven of 42 periods of CRB, a concurrent 
exit-site infection was apparent, equally divided between the treatment groups. 
All-cause mortality did not differ significantly, but the number of deaths from CRB was 
lower in the patients with TSC-locked catheters compared with heparin 
(0 versus 5 patients; RR 0.96; 95% CI 0.93 to 0.99; P = 0.028). Also, the number 
of admissions for CRB decreased from 21 to six (P = 0.002).
Table 3.  Adverse and Bleeding events.
Trisodium Citrate Heparin P
Group Group Value
Locking procedures N=6208 N=6416
Adverse event no. of events
Parasthesia, “metallic taste”, tingling in
fingers immediately after locking 9 4 0.26
Thrombopenia of unknown origin 2 4 0.44
Withdrawal for medical reasons
(persistent bleeding disorder) 0 1 0.49
Bleeding events
Persistent bleeding after insertion 6 19 0.005
        Severe 0 2 0.24
Major bleeding episodes during follow up
        Total 5 16 0.010
        No. per 1,000 catheters days 0.60 2.0
        Gastrointestinal bleeding 1 7 0.034
        Exit-site bleeding 0 5 0.028
        Hemorrhagic ascites after peritoneal
        dialysis catheter removal 1 1 0.74
        Hematuria 0 1 0.49
        Postoperative bleeding 2 2 0.68
        Hemoptoe in pulmonary malignancy 1 0 0.51
In 71% of CRB cases, cultures yielded Gram-positive microorganisms, predominantly
S. aureus or S. epidermidis; in 10%, it concerned Gram-negative microorganisms.
The remaining cultures revealed multiple microorganisms. No yeasts were found. Cultures
in exit-site infections revealed similar results.
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d i S c u S S i o n
The results of this study show that for hemodialysis catheters, an interdialytic lock of TSC 
30% is more effective in preventing premature removal than heparin. 
TSC reduced the risk for CRB by 75% and reduced the number of patients who died from 
this serious complication of hemodialysis catheter use. The findings were consistent 
among the subgroups of patients with tunneled and untunneled catheters. 
Our results are in agreement with a previous observational catheter-lock study that used 
high concentrations of TSC. Ash et al. (24) observed an average decline in bacteremia of 
4.5 to 0% per month in all patients after switching from heparin to high concentration 
TSC for hemodialysis catheter locking. So far, only a few open-label comparative studies 
showing no clear differences between TSC and heparin have been published (25,30). 
These studies, however, accounted for only approximately 5,000 catheter-days of pooled 
data and mostly used lower concentrations of TSC. Adding antibiotics to a locking 
solution can also prevent CRB. However, widespread use cannot be recommended 
because the addition of antibiotics in solutions for interdialytic locking of catheters 
can cause severe side effects through leakage from the tip, resulting in continuous 
systemic levels of the antibiotic, especially aminoglycosides (19,20). 
Taurolidine-containing solutions have shown promising results. Their limited availability 
and high costs, however, preclude their use in clinical practice so far (31).
Our study results are likely to be valid because of the random assignment to treatment 
groups and the use of a double-blind design. In addition, our study included an average 
hemodialysis population with catheter-related complications similar to that reported in 
previous studies (5–7,9,32). Furthermore, we stratified patients for center and type 
of catheter to rule out the influence of local differences in catheter care.
All patients with suspected bacteremia had at least two sets of blood cultures drawn from 
their catheter. Peripheral blood cultures through separate venipuncture sites were not 
routinely performed. However, it is unlikely that we  overestimated the amount of CRB 
because in our definition we considered a CRB only apparent if the patient had cold chills 
with positive blood cultures and no other obvious cause of infection. This definition is also 
used in most other catheter studies because it precludes the need for more punctures for 
the patients and increases the chance to consent to the study protocol (6,7,9,33).
We could not show a reduction in premature removals because of thrombotic 
complications; neither was the use of urokinase for catheter flow problems reduced, 
suggesting that the mechanism of flow problems is not related to intraluminal biofilm 
formation. Probably, catheter tip construction and fibrin sheath formation on the outside 
of the catheter are more important in the pathogenesis of flow problems (8,34,35). 
Concerning reduction of patency rates, we could show only a trend and no significant 
difference in untunneled catheters. This is probably explained by the limited number 
of untunneled catheter-days included in this study and that many more untunneled 
catheters had to be removed prematurely because of flow problems. This study is the first 
that clearly demonstrates that locking of a catheter with heparin is an important cause 
of bleeding complications in hemodialysis patients. This is in agreement with 
the occasional observations reported in other studies (16,18). The probable explanation 
is that locking catheters with heparin leads to unintentional leakage of heparin from the 
or peripheral paresthesia or a “metallic” taste. Symptoms disappeared 
within 1 min of instillation and did not return in all patients after reduction of the volume 
used for locking. Unexplained thrombocytopenia was found in four patients on heparin 
and two on TSC. One patient in the heparin group was withdrawn from the study because 
of persistent prolonged coagulation times and bleeding complications.
Persistent bleeding from the place of insertion immediately after catheter placement 
was reported in 19 patients in the heparin group compared with six in the TSC group 
(P = 0.005). During follow-up, 16 patients in the heparin group experienced a major 
bleeding episode compared with five patients in the TSC group (P = 0.01).
Figure 2. Kaplan-Meier analysis of the probability that patients would remain free of cath-
eter-related bacteremia for all catheters (A) and for the subgroup with untunneled uncuffed 
catheters (B) and the subgroup with tunneled cuffed catheters (C). The P values were calcu-
lated with the use of the log-rank test.
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catheter, resulting in prolonged bleeding times. This makes patients vulnerable 
to bleeding complications. 
We demonstrated that TSC 30% can be used safely as catheter-lock solution. Side effects 
with TSC have been reported only immediately after locking and are not the result of 
persistent leakage from the tip during the period when the catheter is locked. 
The symptoms are probably caused by a temporary drop in Ca2+ and Mg2+. They disappear 
after 30 to 60 s because of the large buffer of Ca2+ and Mg2+ in whole blood. There is 
no solid theoretical base to suggest that prolonged use or multiple locking solutions 
needed in permanent tunneled cuffed catheters will increase the risk more than 
individual locking procedures. A total of 12,624 locking procedures were registered. 
No serious adverse events that could be contributed to the locking solution were 
reported in both groups. Recently, Stas et al. (25) confirmed this finding in a study 
that compared heparin 5,000 IU/ml and TSC 30% for the evaluation of catheter thrombus 
formation. It is clear that these potent solutions should be used only by authorized and 
skilled personnel and that the introduction must be accompanied by a thorough protocol 
(36). At present, in the majority of Dutch dialysis units, TSC is used for catheter locking 
with a strict protocol, and no serious adverse events have been reported.
We did not include a cost-effectiveness analysis in this study as TSC is relatively 
inexpensive. Prepared from raw base, it is approximately 10-fold less expensive than 
heparin. However, as was already discussed in the introduction, the reduction of 
expenditures for vascular access will be impressive when catheter-related complications 
can be prevented. 
In conclusion, the use of TSC 30% for catheter locking in hemodialysis can contribute 
importantly to the reduction of catheter-related complications in hemodialysis patients 
by prevention of premature catheter removal and catheter-related infections. 
Probably, even a reduction in bacteremia-related death can be achieved. 
In addition, bleeding complications from unintentional heparinization can be reduced.
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in patient characteristics. Compared to previous reports, this results in a more reliable 
comparison between catheter groups. We could demonstrate that even when a catheter 
is needed for only 14 days, tunneled cuffed catheters had the best survival and lowest 
infection rates. Femoral catheters had a high risk of complications when they were left 
in place for more than 7 days. We also showed that the risk for an adverse outcome 
increased linearly over time. These findings implicate that almost all catheters 
for hemodialysis treatment should be tunneled. However, earlier use of tunneled cuffed 
catheters must be weighted against the more time consuming and difficult insertion and 
removal of tunneled cuffed catheters and the higher costs. This is probably the reason 
that in current practice untunneled catheters are still widely used and left in place longer 
than guidelines recommend.
We hypothesized that one of the major reasons of the low patency rates of untunneled 
straight jugular catheters was the difficulty to fixate these catheters adequate. This leads 
to more manipulation and can easily give laceration and secondary infection of the 
exit-site, well known risk factors for subsequent catheter-related bacteraemia. In addition, 
straight jugular catheters have an upward directed exit site, a well established risk factor 
for exit-site infections and subsequent systemic infection because adequate drainage of 
debris is prohibited.
In Chapter 4 we describe the effect of the use of a novel precurved untunneled jugular 
catheter on catheter-related complications. The precurved untunneled catheter used 
in this study has improved fixation properties and the advantage of a forward 
to downwardly directed exit-site that makes adequate drainage of debris possible. 
We also addressed the time recommendations found in the previous study, including 
the question when a tunneled cuffed hemodialysis catheter should be used.
Our study demonstrated that this novel forwardly bended precurved haemodialysis 
catheter inserted in the low jugular site had a better survival and lower risk for infection 
compared to a straight jugular catheter. Infection rates for the novel designed catheter 
did not differ from the rates found in tunneled cuffed catheters. Considering 
catheter-related infections as major drawback for catheter use, our results demonstrated 
that an untunneled precurved catheter for the period of three months could be a safe 
option. Furthermore, it was more convenient for the patient, easier for the physician 
during insertion and probably cost-saving. However, compared to tunneled cuffed 
catheters, more untunneled precurved catheters had to be removed for flow problems. 
This is possibly caused by the fact that untunneled cuffed catheters have a smaller 
diameter. Most likely, the function of untunneled precurved catheters can be improved 
by increasing its diameter and tip construction. 
c l i n i c a l  i m p l i c at i o n S  o F  H e m o d i a ly S i S  c at H e t e r  c o n S t r u c t i o n
Catheters basically serve a simple purpose: “to guide the venous blood towards 
the dialysis machine and bring it into the venous system again in a safe and reliable 
way”. Therefore, it is remarkable that the geometry and tip design of catheters differ 
substantially and have been determined mainly by methods of trial and error. 
The common believe is that multiple side holes are needed to provide backup in case 
the distal or some of the side holes get obstructed by venous wall suction or a fibrin sleeve. 
summar y and future direc tions
t e m p o r a r y  v a S c u l a r  a c c e S S  F o r  H e m o d i a ly S i S  t r e at m e n t. 
For patients requiring hemodialysis treatment a reliable access to the blood stream 
is essential. Vascular access related complications are one of the most important causes 
of patient morbidity. The National Kidney Foundation – Dialysis Outcomes Quality 
(NKF-DOQI) Initiative committee recommends the use of a forearm arteriovenous (AV) 
fistula because these have demonstrated the best overall patency and lowest risk 
for complications. However, in a significant number of patients requiring hemodialysis 
treatment there is no adequate AV access available because they present with acute renal 
failure or have slow maturation of their fistula or failure of their permanent arteriovenous 
access. When hemodialysis treatment can not be postponed, these patients require 
a temporary vascular access by means of a hemodialysis catheter. Guidelines recommend 
that no more than 10% of prevalent hemodialysis patients should have a catheter for 
access. However, in current practice, the use of catheters for hemodialysis treatment is still 
substantial. Such widespread application of catheters exposes patients to an enhanced 
risk of catheter-related complications. As a consequence of these complications about 
50% of all temporary catheters have to be replaced resulting in substantial patient 
morbidity as well as additional costs.  In order to prevent the most important 
 catheter-related complications, i.e. infection and thrombosis, and to optimize the survival 
of a catheter, an appropriate estimation of the duration a catheter will be needed 
is most important. The optimal site of insertion must be chosen, the right type of catheter 
and whether the catheter should be tunneled or not. In addition, the access team must 
determine what kind of dressing should be used and whether antimicrobial ointment 
and/or antimicrobial locking solutions should be applied. Optimalization of catheter 
care remains an important issue in hemodialysis treatment as the use of catheters will 
probably only increase in the growing number of patients requiring dialysis treatment. 
Especially as the age of these patients is increasing and the duration they stay 
on hemodialysis has become longer.
c o m pa r i S o n  o F  o u t c o m e  o F  t e m p o r a r y  c at H e t e r S  at  d i F F e r e n t  S i t e S  a n d  o F 
d i F F e r e n t  c o n S t r u c t i o n
In Chapter 3 we examined the best cannulation site once the time period that 
a hemodialysis catheter is needed has been estimated. According to the NKF-DOQI 
guidelines, the subclavian vein should not be used because of a high risk of subclavian 
vein thrombosis. Untunneled femoral catheters should not be left in place for more 
than 5-7 days because of the high risk for infections. For untunneled jugular catheters, 
the recommendation is not to use these for more than 3-4 weeks and insert a tunneled 
jugular catheter when a catheter is needed for longer time periods. However, no clinical 
studies support these time limitations. 
In our first study we evaluated the outcome of untunneled straight jugular, femoral and 
subclavian catheters and tunneled cuffed catheters. To relate our results to the NKF-DOQI 
guidelines, we focused on the survival and infection rates for the time period of four 
weeks as especially untunneled jugular catheters could be a reasonable alternative 
to tunneled cuffed catheters for this period of time. The unique feature of our study is 
that we used a similar catheter care protocol for all catheters and corrected for differences 
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the silicone into its definitive shape. 
As polyurethane polymers are easier to process, have higher traction resistance and have 
less restriction which cleansing solutions. We assume that in the future, silicone will most 
likely be replaced as material for hemodialysis catheter manufacturing by these polymers.
l o c k i n g  S o l u t i o n S
The internal lumen of hemodialysis catheters has to be filled (locked) with a solution for 
the interdialytic period. Traditionally, heparin is installed but there are no studies 
to support this practice. Locally acting antimicrobial locking solutions could be 
an attractive alternative as they can prevent microbial catheter colonization, a well 
known risk factor for catheter-related bacteraemia. Furthermore, it is well known that 
locking solutions leak from the tip of the catheter. Through this phenomenon, heparin 
might be causing clinical problems because of unintentional systemic anticoagulation. 
Whether this feature has clinical implications is not clear. Trisodium citrate (TSC) has been 
proposed as locking solution because it is a locally acting anticoagulant, might have 
antimicrobial properties in high concentrations and is widely available and inexpensive. 
We hypothesized that a high concentration of TSC as locking solution could reduce 
catheter-related infections and bleeding complications. However, the optimal 
concentration of TSC remained to be determined. In Chapter 6 we describe the studies 
that evaluated the optimal concentration of TSC and the results of a large clinical trial 
using TSC as locking solution. In the first study we analysed the antimicrobial properties 
of 4 different concentrations of TSC against five different microorganisms frequently 
encountered in catheter-related infections in hemodialysis patients. As no standardized 
methods are available for testing antimicrobial activity of catheter locking solutions, 
we used two internationally standardized classical antimicrobial susceptibility tests 
modified for fluids. We demonstrated that the antimicrobial activity was dose dependent 
with the highest efficacy for TSC 30%. Although previously suggested by others, we also 
could show that the explanation for the antimicrobial properties of higher concentrations 
of TSC does not seem to be the hyperosmolality as in both tests the antimicrobial activity 
of TSC exceeded that of isoosmolal NaCl concentrations. We suggested that 
it is more likely that chelating effects of Ca2+ and Mg2+ by TSC interfere with bacterial wall 
integrity and prevent biofilm formation. We concluded from this study that the use 
of high concentrations of TSC for catheter locking could have an advantage over heparin 
but should be evaluated in a multicenter double blind randomised controlled trial before 
introduction into clinical practice. 
Results of this trial are described in the second part of Chapter 6. 
In one of the largest randomized studies on hemodialysis catheters we demonstrated that 
trisodium citrate 30% is more effective in preventing premature removal than heparin. 
TSC reduced the risk for catheter-related bacteraemia by 73%, the main reason that 
the study was terminated prematurely. Locking hemodialysis catheters with TSC 
even reduced the number of patients that died from catheter-related bacteraemia. 
The findings were consistent among subgroups of patients with tunneled and 
untunneled catheters. We could not show a reduction in premature removals because of 
thrombotic complications. Neither was the use of urokinase for catheter flow problems 
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However, side holes can also hamper catheter fluid dynamics and induce thrombosis.
In Chapter 5 we evaluated the performance of four different types of tunneled and 
untunneled dual lumen catheters in an in vitro set-up by studying their pressure-flow 
relationship. The calculated equivalent catheter diameter is a parameter that allows 
comparing the pressure-flow data of different catheters independently from the test fluid 
used and the length of the catheter. The calculated equivalent catheter diameter 
is derived from the pressure-flow relationship of catheters.  This is especially useful for 
dual lumen catheters as for some designs (co-axial, double D-shaped) there exists no clear 
definition for the diameters of the individual limbs, which makes it harder to compare 
their geometrical data with independent full round single lumen catheters. 
From the measurements and calculations we could show that the construction 
of tunneled catheters is superior to the construction of acute catheters. We also showed 
that double-D catheters perform better than catheters with a coaxial internal lumen. 
We have also investigated the influence of closing off some of the side-holes to see how 
that would impact catheter performance. It was concluded that multiple side holes 
generally and under the ideal circumstances of the presented in vitro set-up did 
not improve catheter performance. This is probably caused by the occurrence of local 
velocity changes both in direction as in magnitude during inflow to or outflow from side 
holes. Local velocity changes can also be caused by the tapered shape of catheter tips. 
We demonstrated that the recommended blood flow for effective hemodialysis treatment 
delivery, i.e. 
300 ml/min, can only be achieved in the acute catheters with pressure drops of over 
300 mmHg. These pressures can not easily be attained in modern dialysis equipment and 
can easily cause blood lysis through high shear stress. So far, only a limited number 
of small clinical studies have been published comparing different types of catheters and 
no clinical advantage has been shown of one model over an other. Therefore, 
more clinical studies are needed to estimate the implications of our findings 
for hemodialysis practice.
It is also not clear whether silicone or polymers like polyurethane should be the preferred 
material for hemodialysis catheters. Catheter fractures in small non-hemodialysis 
catheters have been reported, especially with silicone catheters. The reason for these 
fractures is unknown and it is not clear whether catheter material is relevant. 
In the second part of Chapter 5 we describe the first case of an asymptomatic 
spontaneous breakdown of a tunneled cuffed silicone catheter used for long-term 
hemodialysis treatment. An extensive scanning electron microscopy study showed 
accumulation of lumps of non-silicone material at the place of the fracture, leading 
to severe disruption of the original cross-linked elastomer structure. 
Using energy-dispersive X-ray spectral analysis, which shows all elements with an atomic 
number of 11 or greater in a material, we showed that the lumps were aggregates 
of barium sulphate particles used to visualize the catheter on fluoroscopy. We suggested 
that the use of too small or too many barium sulphate particles led to high viscosity of 
the raw silicone before polymerization, causing improper mixing of barium sulphate 
particles in the silicone matrix. This resulted in insufficient removal of admixed air bubbles 
and unequal dispersion of barium sulphate, causing weak spots after extrusion of 
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Currently, large bore precurved hemodialysis catheters for insertion in the jugular vein 
have become available and are under evaluation. Because flow-pressure curves 
of these catheters are at least comparable to tunneled cuffed catheters, catheter related 
thrombosis and flow problems will probably be reduced to an acceptable level. 
It is necessary that these new catheters, that require less skills and time from the inserting 
physician are tested in a randomized controlled trial because they can mean an important 
improvement in catheter care. From current experiences and evaluations, it can 
be expected that the results will show that untunneled precurved jugular catheters will 
be a safe alternative to tunneled cuffed catheters for the period of 3-4 months. 
This is the period that is normally needed in most patients to construct a definitive 
AV-access. In the growing number of very old patients becoming dependent on 
hemodialysis treatment, construction of an AV-access is often difficult and leads to 
substantial morbidity and hospitalization. As catheter-related complications will be 
reduced 
by recent developments, it may even be warranted to evaluate if a hemodialysis catheter 
could be an attractive alternative as definitive access in these patients as they have 
a limited life expectancy.
After introduction into clinical use, hemodialysis catheter practice has mainly been 
guided by trial and error and guidelines were based on personal opinions. In the past 
decade hemodialysis catheter-related complications have been reduced drastically 
by performing thorough multicenter clinical trials. This progress can only be continued 
with the help of enthusiastic teams of nephrologists and nurses, supported or even 
guided by scientists and academical departments, willing to collaborate in studies.
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reduced. This suggests that the mechanism of flow problems is not related to 
intra-luminal biofilm formation. More likely, catheter tip construction and fibrin sheath 
formation on the outside of the catheter are more important in the pathogenesis of flow 
problems.
This study is the first that clearly demonstrated that locking of a catheter with heparin 
is an important cause of clinically important bleeding complications in hemodialysis 
patients. The probable explanation is that locking catheters with heparin leads 
to unintentional leakage of heparin from the catheter, resulting in prolonged clotting 
times. We demonstrated that TSC 30% can be used safely as catheter lock solution 
as a total number of 12,624 locking procedures were registered without serious adverse 
events.
We concluded that the use of TSC 30% can contribute importantly to the reduction 
of catheter-related complications in hemodialysis patients and should replace heparin 
as catheter lock solution in hemodialysis catheters. 
F u t u r e  d i r e c t i o n S
Dedicated vascular access teams for hemodialysis patients will reduce the number 
of catheters by initiation of early construction of an arteriovenous fistula. According to 
the NKF-DOQI guidelines, patients with deteriorating renal function should be referred 
to and cared for by a nephrologist when their GFR has become lower than 30 ml/min. 
When the GFR has become lower than 20-25 ml/min, an evaluation of venous and arterial 
vessels of both arms should be performed to assess and decide which 
AV-access is feasible. If possible, a forearm AV-fistula should be constructed. 
However, despite maximum efforts to reduce the use of hemodialysis catheters 
for access to the blood stream, patients with acute renal failure, sudden renal graft failure, 
irreversible peritonitis during peritoneal dialysis requiring peritoneal catheter removal, 
acute failure of their chronic AV-access or simply late referral of patients with chronic 
renal failure are all reasons for persistent need for catheters in the future. Most likely, 
its use will not become less than 5-10% of all vascular access in a general hemodialysis 
ward. However, it is very likely that the number of hemodialysis catheter-related 
complications will decrease drastically because of the recent progress that has been made 
in catheter care and manufacturing. Currently, by implementing strict aseptical protocols, 
antimicrobial ointments for exit-site care and antimicrobial solutions for catheter locking, 
the risk for the most serious catheter-related complication, i.e. bacteraemia, has become 
less than 1 per 1000 catheter days. Currently, this is at a level of infection rates found 
in patients with AV-grafts. 
Promising progress is made with coating of catheters. In intensive care patients, catheters 
coated with antibiotics, silver or heparin reduce the number of infections substantially. 
A problem with bonding in hemodialysis catheters is that they are often needed 
for a longer period of time and the substance impregnated or bonded on catheters 
can disappear over time. However, new materials that improve biocompatibility,
like carbothene, are already used and the risk for fibrin sheet formation and catheter 
related thrombosis will likely reduce.
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Foto 1. Rechte katheter in de halsvene met omhoog gerichte huidpoort. 
Foto 2. Voorgebogen katheter met naar beneden gerichte huidpoort.
worden verwacht dat een katheter meer dan twee weken nodig is. Dit is voor de meeste 
katheters het geval. In tegenstelling tot het inbrengen van ongetunnelde katheters 
is echter het inbrengen en later verwijderen of vervangen van getunnelde katheters een 
lastige procedure die relatief veel tijd kost en niet door iedere chirurg of nierspecialist 
(nefroloog) wordt beheerst. Dit is de reden dat de behandelende arts in de dagelijkse 
praktijk nog te vaak een ongetunnelde katheter in brengt ondanks de voordelen 
van getunnelde katheters.
Een van de redenen van het verhoogde risico op infecties bij het gebruik van 
ongetunnelde jugularis katheters is waarschijnlijk het feit dat deze katheters lastig 
te fixeren zijn. Hierdoor kunnen eenvoudig ongewenste manipulaties aan de katheter 
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i n l e i d i n g
Patiënten met eindstadium nierfalen zijn aangewezen op nierfunctievervangende 
therapie. Omdat niertransplantatie niet voor iedereen (direct) mogelijk is, 
zijn veel patiënten tijdelijk of voorgoed aangewezen op dialysebehandeling. De meest 
gekozen behandeling is in dat geval hemodialyse. Bij een hemodialysebehandeling wordt 
gewoonlijk drie maal per week gedurende vier uur bloed van de patiënt naar 
een dialyseapparaat geleid waar afvalstoffen uit het bloed worden verwijderd. 
Het gezuiverde bloed wordt daarna teruggeleid naar de patiënt. Hiervoor is een goede 
toegang tot de bloedbaan noodzakelijk. Een verbinding tussen slagader en ader 
van eigen bloedvat of eventueel kunststof materiaal (arterioveneuze shunt) 
heeft hiervoor de voorkeur. Deze verbinding wordt meestal aangelegd op de onderarm 
en bij elke behandeling met twee naalden aangeprikt. De patiënt moet hiervoor 
echter geopereerd worden waarna het meestal nog weken duurt voordat deze shunt 
daadwerkelijk kan worden gebruikt. 
Als hemodialyse behandeling echter niet kan worden uitgesteld, is de enige mogelijkheid 
het inbrengen van een dubbellumen katheter. Deze kan worden ingebracht in een grote 
ader in de lies (vena femoralis), onder het sleutelbeen (vena subclavia) of laag in de hals 
(vena jugularis). Katheters zijn vaak maanden nodig en worden niet steeds opnieuw 
ingebracht. Een katheter in de liesvene is erg onpraktisch voor een patiënt en raakt 
snel geïnfecteerd. Een katheter in de sleutelbeenvene geeft een verhoogd risico op het 
verstopt raken van de ader die later misschien nog nodig is voor het aanleggen van een 
arterioveneuze shunt. Om die redenen gaat de voorkeur uit naar een katheter
in de halsvene. Soms worden ze eerst een stuk onderhuids getunneld voordat 
ze de bloedbaan ingaan, voornamelijk omdat verondersteld wordt dat dit infecties kan 
voorkomen. Het gebruik van katheters gaat echter gepaard met complicaties, zoals 
infecties. Hiervan is bacteriële bloedbaaninfectie de meest gevaarlijke en potentieel 
levensbedreigend. Een ander veel voorkomend probleem is dat katheters verstopt 
kunnen raken. Deze complicaties leiden ertoe dat de helft van de katheters voortijdig 
verwijderd en vervangen moeten worden.
De studies beschreven in dit proefschrift hebben tot doel de complicaties gepaard 
gaande met het gebruik van hemodialysekatheters te verminderen. 
v e r g e l i j k i n g  v a n  v e r S c H i l l e n d e  S o o r t e n  k at H e t e r S  i n g e b r a c H t  o p 
v e r S c H i l l e n d e  p l a at S e n
In hoofdstuk 3 beschrijven we de resultaten van een studie waarin de complicaties die 
gepaard gaan met het gebruik van ongetunnelde katheters ingebracht in de liesvene, 
sleutelbeenvene en halsvene met elkaar worden vergeleken en met getunnelde 
katheters. We konden aantonen dat ongetunnelde katheters in de lies al binnen een 
week meer complicaties geven dan getunnelde katheters. Voor ongetunnelde katheters 
ingebracht in de halsvene betroffen de complicaties vooral infecties. Al na twee weken 
was de kans op complicaties en infecties hoger bij het gebruik van ongetunnelde 
katheters ten opzichte van getunnelde. Volgens de bevindingen van dit onderzoek zou 
dus moeten worden gekozen voor een getunnelde hemodialyse katheter wanneer mag 
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werking van verschillende concentraties TNC geanalyseerd. We vonden dat hoge 
concentraties nodig zijn voor optimale antimicrobiële werking. Ook konden we 
aantonen dat heparine geen antimicrobiële werking heeft. Het mechanisme waardoor 
TNC antimicrobiële werking heeft, bleek niet te berusten op de hoge osmolaliteit 
(deeltjesdichtheid) zoals tot nog toe werd verondersteld. Waarschijnlijk is het wegvangen 
van calcium en magnesium verantwoordelijk voor de antimicrobiële werking van TNC. 
In het tweede deel van hoofdstuk 6 beschrijven we de resultaten van een 
gerandomiseerde klinische studie in meerdere ziekenhuizen in Nederland en België 
waarin TNC 30% werd vergeleken met heparine als opvulvloeistof. In totaal 291 patiënten 
met katheters werden hiervoor onderzocht. We konden aantonen dat katheters langer 
gebruikt konden worden als TNC 30% als opvulvloeistof werd gebruikt. Het aantal 
bloedbaan infecties werd met 73% gereduceerd en er bleken zelfs minder patiënten aan 
deze gevreesde complicatie te zijn overleden als TNC als opvulvloeistof werd gebruikt. 
Tevens bleek dat er belangrijk minder bloedingen, zoals maagdarmbloedingen, optraden 
bij patiënten bij wie TNC 30% als opvulvloeistof was gebruikt. De resultaten van 
deze studie hebben ertoe geleid dat in meer dan 80% van de hemodialysecentra in 
Nederland heparine vervangen is door TNC.
c o n c l u S i e
Dit proefschrift beschrijft de belangrijkste problemen waar patiënten,
dialyseverpleegkundigen en nefrologen ondervinden als een katheter noodzakelijk 
is om toegang tot de bloedbaan te krijgen voor hemodialyse behandeling. Katheters 
zullen voorlopig noodzakelijk blijven. Het is daarom belangrijk dat door zorgvuldig 
uitgevoerd wetenschappelijk onderzoek wordt gekeken hoe complicaties kunnen worden 
gereduceerd. Wij hebben geprobeerd hieraan een bijdrage te leveren. In de afgelopen 
jaren is door dit soort onderzoek en de toegenomen aandacht voor katheter gerelateerde 
problemen de zorg dusdanig verbeterd dat het aantal infecties in veel hemodialysecentra 
drastisch verminderd is.
Nieuwe veelbelovende ontwikkelingen dienen zich al weer aan. Ook voor 
deze ontwikkelingen geldt dat zorgvuldig gekeken moet worden of ze daadwerkelijk 
een verbetering betekenen voor de zorg aan de hemodialyse patiënt. Daartoe zijn 
meer wetenschappelijke studies nodig die gezamenlijke inspanning vragen van 
patiënten, dialyseverpleegkundigen, nefrologen en wetenschappers van universitaire 
afdelingen en hemodialysecentra. Alleen dan zal de kwaliteit van de zorg voor 
deze kwetsbare groep patiënten kunnen groeien.
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plaatsvinden met beschadiging van de plaats waar de katheter het lichaam ingaat, 
de huidpoort. De kans op infecties wordt ook verhoogd doordat door de rechte vorm 
van de katheter de huidpoort omhoog gericht is waardoor zich vuil kan ophopen rondom 
de insteekplaats van de katheter (foto 1).
In hoofdstuk 4 beschrijven we resultaten van een studie naar een nieuw model 
voorgebogen ongetunnelde jugularis katheter die als voordeel heeft dat de fixatie 
beter is en de huidpoort naar beneden is gericht (foto 2). We konden aantonen dat deze 
katheter tot aanmerkelijk minder katheter gerelateerde infecties leidt. Gedurende 
de eerste drie maanden dat deze katheter in de patiënt blijft, blijkt de kans op een infectie 
even groot als bij gebruik van een getunnelde katheter. Ten opzichte van getunnelde 
katheters zijn ongetunnelde katheters relatief dun en heeft het uiteinde (tip) vaak een 
andere vorm.  Dit is waarschijnlijk de reden dat in deze studie ongetunnelde katheters 
sneller gedeeltelijk of geheel verstopt raakten.
S t u d i e S  n a a r  d e  i n v l o e d  v a n  d e  c o n S t r u c t i e  o p  d e  F u n c t i e  v a n  e e n 
H e m o d i a ly S e  k at H e t e r
Met als doel de zojuist beschreven verschillen in constructie verder te analyseren 
beschrijven we in hoofdstuk 5 een onderzoek waarbij we met behulp van 
een laboratoriumopstelling de verhouding tussen druk en stroomsnelheid van 
vier verschillende soorten getunnelde en ongetunnelde katheters hebben bestudeerd. 
We konden concluderen dat de constructie van getunnelde katheters tot veel betere 
prestaties leidt dan de constructie van ongetunnelde katheters. De combinatie van 
de relatief dunne diameter en taps toelopende tipconstructie van de onderzochte 
ongetunnelde katheters leidt ertoe dat zeer hoge drukken nodig zijn om voldoende 
stroomsnelheid voor effectieve dialysebehandeling te genereren. Vaak is dit hoger dan 
een normaal hemodialyse apparaat kan leveren. Ook vonden we dat zijgaten, 
hoewel in vrijwel alle katheters aangebracht door de fabrikanten, vanuit het perspectief 
van doorgankelijkheid en stroomsnelheid ongewenst zijn. In het eerste deel van 
hoofdstuk 5 beschrijven we een uitgebreide speurtocht naar de oorzaak van een 
spontaan in een patiënt afgebroken hemodialysekatheter. Hieruit wordt duidelijk dat 
het verwerken van siliconen tot een dialyse katheter een delicaat proces is.
o p v u l v l o e i S t o F F e n
Tussen de hemodialysebehandelingen wordt in het lumen van een katheter een vloeistof 
achtergelaten om verstopping van de katheter te voorkomen. Tot voor kort werd hiervoor 
het antistollingsmiddel heparine gebruikt. Lekkage van dit middel uit de tip van 
de katheter zou echter mogelijk bloedingen kunnen veroorzaken als gevolg 
van ongewenste systemische antistolling van een patiënt. Mogelijk hebben 
antistollingsmiddelen die alleen lokaal werken dat nadeel niet. Van enkele van deze 
oplossingen wordt gesuggereerd dat ze ook een antimicrobiële werking hebben. 
Dit zou katheter gerelateerde infecties kunnen voorkomen. Ons onderzoek heeft 
zich gericht op trinatrium citraat (TNC) oplossingen omdat deze al voor andere medische 
toepassingen beschikbaar waren en goedkoop zijn. In het eerste deel van
hoofdstuk 6 hebben we met behulp van een laboratoriumstudie de antimicrobiële 
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stand komen van de microbiologische onderzoeken. Jullie konden mijn ideeën gelukkig 
altijd weer kanaliseren en reduceren tot uitvoerbare. 
Saskia Kars van de faculteit van aardwetenschappen wil ik bedanken voor de gastvrijheid, 
creatieve hulp en het beschikbaar stellen van de electronenmicroscoop bij de speurtocht 
naar de oorzaak van een gebroken katheter. Dit ondanks het feit dat je geen enkele 
affiniteit had met de medische wereld.
Prof.dr. J. van der Meer, beste Jan, ik ben je veel dank verschuldigd voor het vertrouwen 
dat je altijd in me hebt gesteld. In 1991 steunde je me in mijn ambitie internist 
 te worden, stelde mij daarna aan als chef de clinique op je afdeling en uiteindelijk 
beoordeelde je mijn proefschrift. Je oog voor het detail en klinische vaardigheden 
hebben mij gevormd. Ik ben dan ook vereerd dat je plaats hebt willen nemen in mijn 
promotiecommissie. Prof.dr. A.J.M. Donker dank ik voor het feit dat ik de opleiding tot 
nefroloog op zijn afdeling kon volgen. Prof.dr. J. Verrips, Jojade, prof.dr. B. Meyer, Birgit, 
dank voor de aandacht aan mijn proefschrift, jullie stimulans, grammaticale correcties en 
avondjes vol filosofische uitstapjes. Ik ben vereerd dat jullie er zo duidelijk bij willen zijn.
Mijn collega internisten en maag-, darm- en leverartsen van het Sint Lucas Andreas 
ziekenhuis bedank ik voor de tijd en het vertrouwen dat ze in mijn hebben gesteld 
bij mijn aanstelling dat het allemaal wel goed zou komen met dat proefschrift. 
Ze hebben er te lang op moeten wachten. Vooral mijn collega-nefrologen Carl Siegert, 
Harald Brulez en Bert-Jan Potter van Loon ben ik in deze dank verschuldigd voor hun 
flexibiliteit. De leden van mijn promotiecommissie wil ik bedanken voor de tijd die 
ze hebben willen besteden aan het lezen van mijn proefschrift.
Mijn vrienden en vriendinnen bedank ik voor hun steun, stimulans en enthousiasme 
als het weer eens eventjes niet mee zat. Wolbert, zoals beloofd, het is eindelijk af. 
Mijn watersportvrienden en vriendinnen bedank ik voor de o zo noodzakelijke 
stresslozende uurtjes samen in, op en boven het water. Jack, Marc, Sylvia, Wolbert, Sergio, 
het wordt tijd weer eens samen een vliegertje op te laten.
Mars, dank voor de jaren samen en de steun die je was bij de poging een rijpend gezin 
te combineren met het bevredigen van een wetenschappelijke ambitie en persoonlijke 
carrière. De prijs was te hoog maar op dit proefschrift ben ik trots.
Mijn ouders, die mijn studie mogelijk hebben gemaakt en altijd zijn blijven geloven 
in mijn ambities. Ik dank jullie voor het warme nest van waaruit ik mij kon ontwikkelen 
en waarop ik altijd kon terugvallen. Broertjes, ik kon mij geen betere wensen.
Lieve Agnes, hoewel je het begin niet hebt meegemaakt is jouw steun tijdens de laatste 
loodjes onmisbaar geweest. Altijd kon ik op je rekenen en klagen hoorde niet 
in je vocabulaire ondanks de nachtjes doorwerken. Ik dank je voor alles. 
De komende tijd eindelijk weer eens samen op tijd onder de wol.
Bram, Zim en Jo, jullie liefde en glimlach is er altijd, no matter what, een heerlijk idee dat 
ik koester en dat mij door de donkere uurtjes hielp.  Zim, en eh……………..
Dit proefschrift is daarom aan jullie opgedragen.
dankwoord
d a n k W o o r d
Een dankwoord hoort mijns inziens in eerste instantie gericht te zijn aan de patiënten 
die ondanks de vaak zorgelijke gezondheidstoestand waarin ze terecht waren gekomen 
de tijd namen om na te denken over deelname aan één van studies. Ik wil hun met name 
danken voor de bereidwilligheid en het gestelde vertrouwen. 
Mijn promotor prof.dr. P.M. ter Wee, Piet, het is nauwelijks te geloven maar het is dan 
eindelijk klaar. Ik vraag me af hoe vaak je hebt gedacht dat het er allemaal wel nooit meer 
van zou komen na mijn vertrek naar de periferie. Met je nimmer aflatende telefoontjes, 
mailtjes en opmerkingen in de wandelgangen als vriend en collega ben 
je de belangrijkste motor geweest bij het tot stand komen van dit proefschrift. 
Je commentaren en het weer terugbrengen van mijn soms eindeloze zinnen tot leesbare 
tekst waren onmisbaar. Hoewel je nooit hebt gepushed hield je ook niet op mij 
er regelmatig op te wijzen dat dit toch eigenlijk ook nog af moest. Je geduld is beloond 
en ik ben er trots op bij je te mogen promoveren. Dank voor je vertrouwen, 
tijd en middelen die je ter beschikking hebt gesteld.
Mijn collega’s van de afdeling nefrologie in het VU medisch centrum moet ik bedanken 
voor hun hulp bij het verzamelen van gegevens en bedenken van nieuwe oplossingen, 
in het bijzonder Han Groeneveld en Mark Vervloet. Han, jij bent mijn belangrijkste 
leermeester geweest met betrekking tot het inbrengen van katheters. 
Met jou enthousiasme zo vaak gelardeerd met een gezonde dosis cynisme 
is mijn belangstelling voor dit onderwerp tot bloei gekomen. 
Mark, jou wetenschappelijk benadering van problemen en bereidheid om altijd weer 
kritisch naar manuscripten en protocollen te kijken waren erg waardevol en ik ben blij 
dat jullie me willen flankeren tijdens mijn verdediging. Frans van Ittersum, dank voor 
je geautomatiseerde oplossingen, soms scheelde dat veel werk. Muriel, Carola, Anita, 
Roeland, Nynke, Azam, dank voor jullie gezelligheid en collegialiteit als dat weer 
eens nodig was wegens mijn ritjes langs één van de dialysecentra.
De multicenter studie kon alleen maar slagen door de hulp en inzet van vele collega, 
dialyseverpleegkundigen en secretaresses van 10 dialysecentra in Nederland en België. 
Hoewel ik jullie eigenlijk allemaal bij naam wil noemen neem ik niet het risico iemand 
te vergeten en wil jullie als collectief bedanken. Jullie bijdrage aan deze studie is een 
voorbeeld voor de resultaten die samenwerking in nefrologisch Nederland kan opleveren. 
Marjon van Vliet, research nurse in het VU medisch centrum, verdient hierbij toch een 
aparte vermelding voor haar hulp bij het tot stand komen van deze studie.
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